Program Book - American Society of Hypertension

Transcription

American Society of Hypertension, Inc.
2011 Annual Scientific Meeting
and Exposition
Program Book
Hilton New York
Saturday, May 21, 2011 – Tuesday, May 24, 2011
8
More than
References: 1. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al; INVEST Investigators. A calcium
antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery
disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA.
2003;290(21):2805-2816. 2. Dahlöf B, Sever PS, Poulter NR, et al; ASCOT Investigators. Prevention
of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required
versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes
Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet.
2005;366(9489):895-906. 3. Black HR, Elliott WJ, Grandits G, et al; CONVINCE Research Group. Principal
results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA.
2003;289(16):2073-2082. 4. Dahlöf B, Devereux RB, Kjeldsen SE, et al; LIFE Study Group. Cardiovascular
morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a
randomised trial against atenolol. Lancet. 2002;359(9311):995-1003.
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936
©2011 Novartis
1
8
Visit booth
#1100
to find out more
10
out of
patients may need more than
1 agent to get to BP goal1-4
Printed in USA
4/11
DIO-1052602
About the American Society of
Hypertension, Inc.
The American Society of Hypertension, Inc., (ASH) is the largest
organization of hypertension researchers and health care providers
in the United States committed to eliminating hypertension and its
consequences. ASH has a domestic and international membership of
basic science and clinical investigators, physicians, physician assistants, nurse practitioners and pharmacists, as well as other individuals
with a scientific interest in hypertension.
The Society was founded in 1985 in order to provide a forum for the
exchange of information among basic scientists, clinical investigators
and others involved in the study or management of high blood pressure. The specific focus of the Society is to translate current research
findings in hypertension into effective treatment strategies, in order
to better address the needs of hypertensive patients. The primary mission of the Society is to improve the care of patients with hypertension
and associated disorders by:
• Enhancing the education and treatment of patients with hypertension
• Educating health care professionals regarding hypertension and
current prevention and treatment strategies
• Assisting health care professionals in addressing the challenges of
the modern-day care of patients with hypertension
• Advocating public policy that ensures patient access to high
quality hypertension care and supports increased hypertension
research
• Facilitating communication and collaboration among providers,
investigators, policymakers, and patients in areas relating to hypertension and vascular health
• Promoting the career development of researchers in hypertension
and associated disorders, including research in the pathobiology,
prevention, diagnosis, treatment, and psychosocial aspects of
hypertension
The American Society of Hypertension, Inc. is an accredited provider
of Continuing Medical Education (CME) by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.
For more information contact the American Society of Hypertension,
Inc. at:
148 Madison Avenue
Fifth Floor
New York, NY 10016
Telephone: 212-696-9099
Fax:
212-696-0711
E-mail:
ash@ash-us.org
Website: www.ash-us.org
Past Presidents of the American
Society of Hypertension, Inc.
John H. Laragh, MD
Edward G. Biglieri, MD
Jay N. Cohn, MD
Louis Tobian, MD
Barry M. Brenner, MD
Lawrence R. Krakoff, MD
Michael H. Alderman, MD
Michael A. Weber, MD
Theodore W. Kurtz, MD
Haralambos Gavras, MD
Thomas D. Giles, MD
Jean E. Sealey, DSC
Suzanne Oparil, MD
Henry R. Black, MD
First President
President 1988 – 1990
President May 19, 2006
Table of Contents
General Information.................................................................... 9
Continuing Education................................................................ 9
Hilton New York Floor Layout................................................ 10
Corporate Members.................................................................... 16
Meeting Sponsors......................................................................... 17
ASH Leadership............................................................................... 18
2011 Program Committee....................................................... 19
Robert Tigerstedt Award Lecture........................................ 20
Young Scholar Award Lectures............................................. 22
Marvin Moser Clinical Hypertension
Award Lecture................................................................................. 24
2011 Abstract Reviewers........................................................... 26
Poster Category Presentation by Day............................... 30
ASH Faculty....................................................................................... 32
Program at a Glance.................................................................... 35
Hypertension Highlights 2011, May 21........................... 40
ASH Program, May 21................................................................. 41
Primary Care Clinician Program, May 22......................... 49
ASH Program, May 22................................................................. 51
ASH Program, May 23................................................................. 64
ASH Program, May 24................................................................. 78
ASH Program Posters, May 21................................................ 86
ASH Program Late-Breaking Posters, May 23............... 144
Faculty Disclosure Listing......................................................... 145
ASH Exhibitor Floor Plan........................................................... 154
ASH Innovations Theater.......................................................... 157
ASH Exhibitors................................................................................. 158
Author Index..................................................................................... 168
Hilton New York Floor Plans.................................................... 181
5
Program Color Key
The pages of this Program Book are color-coded to match the
Program at a Glance (pages 35–36) and serve as a quick, identifiable
reference of the type of educational activity or event taking place.
Scientific Sessions*
1 Pathobiology Track 2 Translational Track 3 Therapy Track
Hypertension Highlights 2011
Special Event
Meet the Professor Sessions
Hypertension for the Primary Care Clinician
Debates
Poster Sessions
Satellite Symposia
Hypertension Resource Pavilion
The ASH Twenth-Sixth Annual Scientific Meeting is
organized around three (3) concurrent themes:
• Pathobiology of Hypertension
• Translational Issues in Hypertension
• Therapy of Hypertension
Sessions in each of the three (3) themes (or tracks) are labeled
throughout the Program Book to be easily identifiable.
Future Meeting Dates
Saturday, May 19, 2012 to Tuesday, May 22, 2012
Hilton New York, New York, NY
Wednesday, May 15, 2013 to Saturday, May 18, 2013
San Francisco Marriott, San Francisco, CA
Letter from the President
and Program Committee Chair
Dear Colleague,
On behalf of the Board of Directors of the
(ASH), we are pleased to welcome you to
the Twenty-Sixth Annual Scientific Meeting and Exposition of ASH. The theme of
this year’s Scientific Meeting is Adolescent
Obesity and Cardiovascular Risk Reduction: The Expanding Epidemic.
The 2011 Annual Scientific meeting topics
are organized around three (3) concurrent
themes:
George L. Bakris, MD, FASH
— Pathobiology of Hypertension
— Translational Issues in Hypertension
— Therapy of Hypertension
The Scientific Sessions feature several innovative components designed to enhance the
translation of basic and applied research
into effective hypertension prevention and
treatment strategies.
• Hypertension Highlights 2011 – Saturday, May 21, 2011
William B. White, MD, FASH
Hypertension Highlights is a full-day
program dedicated to educating clinicians and scientists about some of the most interesting, controversial and evolving topics in the field. It is an ideal update for
Hypertension Specialists and those wishing to become specialists
in the field.
• Plenary Session I – Sunday, May 22, 2011
The Keynote speaker for the opening session will be F. Xavier
Pi-Sunyer, MD, MPH, Professor of Medicine, Chief of Endocrinology, Diabetes, and Nutrition, Director of the New York Obesity
Research Center, St. Luke’s/Roosevelt Hospital Center, New York,
New York. Dr. Pi-Sunyer will speak on “Blood Pressure in Obesity.”
Following Dr. Pi-Sunyer’s lecture will be Dr. Rae-Ellen Kavey
presenting a lecture on “Cardiovascular Risk and Risk Reduction
in Children and Adolescents,” Dr. Sadaf Farooqi, PhD, presenting a
lecture on “Mechanisms from Studies of Human Obesity” and Dr.
Joseph Flynn addressing the topic of “Evaluation and Treatment of
Hypertension in Childhood.”
• Plenary Session II – Monday, May 23, 2011
This session will include the Awards Session as well as state-of-theart topics. Dr. Oscar Carretero will present the Robert Tigerstedt
Award Lecture on “Acetyl-Ser-Asp-Lys-Pro, an Endogenous Tetrapeptide: Role in Target Organ Damage in Hypertension, and Autoimmune Myocarditis.” Young Scholar Awards will be presented to
Drs. Michael Ryan and Alessandro Cataliotti. Dr. Murray Epstein
will receive the Marvin Moser Clinical Hypertension Award.
7
Letter continued
Following the Awards Session, Dr. Abraham Aviv will present a
lecture on the “Leukocyte Telomere Length Genetics and Cardiovascular Disease” and Dr. Joseph Hill will discuss “Development of
Cardiac Hypertrophy.”
• Young Investigator-in-Training Abstract Competition Saturday, May 21, 2011
Trainees submitting the highest ranking abstracts to the meeting
will present their work orally in a special session and compete for
cash prizes. This highlighted session is consistent with ASH’s goal
to foster and facilitate the training of young and new investigators
in hypertension.
• Hypertension for the Primary Care Clinician – Sunday, May 22, 2011
This program will address commonplace questions that face clinicians in day-to-day care of hypertension including peri-operative
hypertension management, clinical partners in ambulatory care
management of hypertension and the resistant hypertensive
patient.
• Debates – Saturday, May 21 – Sunday, May 22, 2011
This year there are five debates on controversial topics of relevance
to Hypertension Specialists.
• Joint Society Symposia
Interactions with other societies, both national and international,
focused on the topic of hypertension and cardiovascular and
kidney disease risk as it relates to obesity will be covered. This year
we have a record number of joint society sessions that include:
AHA Council for High Blood Pressure Research (HBPR), the
Association for Research into Arterial Structure and Physiology
(ARTERY), the China Social Worker’s Association Vascular Protection Committee, the European Society of Hypertension (ESH),
Hypertension Canada, the International Pediatric Hypertension
Association (IPHA), the International Society on Hypertension
in Blacks (ISHIB), the Inter-American Society of Hypertension (IASH), the National Lipid Association/American Society
for Preventive Cardiology (NLA/ASPC), the National Kidney
Foundation (NKF) and the Preventive Cardiovascular Nurses
Association (PCNA).
The Society will also sponsor a small number of industry-supported
Satellite Symposia which will introduce novel approaches to antihypertensive therapy. The Pavilion will host many informative scientific,
technical, periodical and book exhibits designed to support you in
your mission of providing the latest in care for your hypertensive
patients.
We look forward to seeing you in New York.
Sincerely,
President, 2010 – 2012
Chair, 2011 Scientific Program
Committee
8
General Information
This program book has been underwritten by Novartis
Pharmaceuticals Corporation.
Education
Program Objectives
In keeping with the purpose of the American Society of Hypertension,
Inc. (ASH), the Twenty-Sixth Annual Scientific Meeting is designed to
encourage and promote the development, advancement, and exchange
of fair and balanced and evidence-based information regarding the
research, diagnosis and treatment of hypertension and related cardiovascular diseases, with the goal of improved patient care and health.
The sessions will:
• Present and examine new findings on the physiology, pathophysiology, epidemiology, diagnosis, and management of hypertension
and related conditions.
• Review current state-of-the-art advances in managing particular
groups of patients.
• Evaluate specific treatment modalities and pharmacological
agents.
Target Audience
Physicians, scientists, pharmacists, physician assistants, nurses and
other health care professionals with an interest in the mechanisms or
management of hypertension and related diseases will benefit from
attending Scientific Sessions, Satellite Symposia, Embedded Symposia,
Meet the Professor Sessions, Case Discussions, Poster Sessions and
the Scientific Exposition.
Continuing Education Credit
The American Society of Hypertension, Inc. is accredited by the
Accreditation Council for Continuing Medical Education to provide
continuing medical education for physicians. The American Society of
Hypertension, Inc. designates this educational activity for a maximum
of 30 AMA PRA Category 1 Credits™. Each physician should claim
credit commensurate with the extent of their participation in the
activity.
Conflict of Interest Disclosure
The American Society of Hypertension, Inc. strives to ensure balance,
independence, objectivity, and scientific rigor in all of its educational
programs. All faculty members participating in this program have
been required to disclose any real or apparent conflict(s) of interest
that may have a direct bearing on the subject matter of the session in
which they are participating. This includes relationships in place at
the time of the meeting or in the twelve (12) months preceding the
meeting, with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related
to the subject matter of the presentation topic.
The intent of the policy is to identify openly any conflict of interest so
that the listeners may form their own judgments about the presentations with the full disclosure of the facts. All Conflict of Interest Disclosure Statements are available to meeting attendees in the program
book on pages 145–153 and at the ASH Information/Membership
Booth located at the entrance of the Hypertension Resource Pavilion
on the third Floor.
9
General Information continued
Disclosures not available at the time the program book was printed
are included as a separate listing in the registrant bags.
Dagger (†) denotes that the abstract presenting author has related
disclosure information. Please reference the full Disclosure Index at
the ASH Information /Membership Booth, located at the entrance
of the Hypertension Resource Pavilion on the third Floor and in the
Author Index of The Journal of Clinical Hypertension 2011 Abstract
Supplement.
Hilton New York Floor Layout
For detailed floor plans of Exhibition and Poster Areas, see pages 154 & 155.
For detailed floor plans of Hilton New York, see pages 181 – 183.
10
Meeting Venue/Headquarters Hotel
Hilton NY
1335 Avenue of the Americas
New York, NY 10019
Phone: 1-212-586-7000
Fax:
1-212-315-1374
Meeting Registration
Registration for the Meeting will be held on the
Third Floor Promenade.
Registration Desk Hours
Groups
Friday, May 20
4:00 PMto 6:00 PM
Individuals
Friday, May 20
Saturday, May 21
Sunday, May 22
Monday, May 23
Tuesday, May 24
6:00 PMto
7:00 AMto
7:00 AMto
5:30 AMto
7:00 AMto
9:00 PM
7:00 PM
6:00 PM
5:00 PM
9:30 AM
ASH Information/Membership Booth
The ASH Information/Membership booth will be located at the
entrance of the Hypertension Resource Pavilion on the Third Floor.
Information/Membership Booth Hours
Friday, May 20
Saturday, May 21
Sunday, May 22
Monday, May 23
Tuesday, May 24
4:00 PMto 9:00 PM
8:30 AMto 5:00 PM
8:30 AMto 5:00 PM
8:30 AMto 5:00 PM
8:30 AMto 12:00 PM
Program Information
Hypertension Highlights is a full-day program dedicated to educating clinicians and scientists about some of the most interesting,
controversial and evolving topics in the field. It is an ideal update for
Hypertension Specialists and those wishing to become specialists in
the field.
Saturday, May 21, 2011
8:30 AMto 3:00 PM
ASH Plenary Sessions
Plenary Sessions feature engaging lectures by keynote speakers. The
topics are of broad general interest.
Sunday, May 22, 2011
Monday, May 23, 2011
1:15 PMto 3:00 PM
1:30 PMto 4:00 PM
11
ASH Scientific Sessions
The Scientific Sessions will address basic and clinical science issues
over a wide range of topics.
Tuesday, May 24, 2011
4:30 PMto 6:00 PM
3:30 PMto 5:15 PM
8:00 AMto10:00 AM
10:30 AMto 12:00 PM
8:15 AMto 9:30 AM
10:00 AMto11:30 AM
The Hypertension for the Primary Care Clinician program will address commonplace questions that face clinicians in day-to-day care
of hypertension.
8:00 AMto 12:30 PM
Joint Sessions
Special Sessions jointly sponsored by Society-related organizations
will enrich the knowledge base and foster new interactions between
attendees.
4:30 PMto 6:00 PM
9:00 AMto10:30 AM
3:30 PMto 5:15 PM
8:30 AMto10:00 AM
10:30 AMto 12:00 PM
Distinguished faculty will provide valuable instructions on (1) writing
a grant; (2) developing an abstract and lecture and (3) understanding
statistics in clinical research.
Attendees will be admitted on a first-come, first-served basis.
11:00 AMto 12:00 PM
Clinical Debates
Clinical Debates will provide for lively discussion on controversial
topics.
11:00 AMto 12:00 PM
11:45 AMto 12:15 PM
4:30 PMto 5:00 PM
Abstract Presentations
Authors will showcase their research in oral or poster format.
6:00 PMto 7:00 PM
5:30 PMto 6:30 PM
4:30 PMto 5:30 PM
12
Satellite Symposia
The latest information regarding new concepts, treatments, devices
and techniques will be addressed in Satellite Symposia supported by
educational grants.
6:00 AMto 7:30 AM
ASH Hypertension Resource Pavilion - Technical Exhibits
Technical Exhibits will be located in the Hypertension Resource
Pavilion at the Hilton NY. ASH will host a welcome reception,
lunches, and high teas in the exhibit hall.
Opening Reception
4:30 PMto 7:30 PM
6:00 PMto 7:30 PM
High Tea
10:00 AMto 1:00 PM
and 3:30 PMto 6:30 PM
5:30 PMto 6:30 PM
High Tea
10:00 AMto 1:30 PM
and 4:00 PMto 5:30 PM
4:30 PMto 5:30 PM
Innovations Theater – Rhinelander Gallery
6:30 PMto 7:30 PM
12:00 PMto 1:00 PM
5:30 PMto 6:30 PM
2011 ASH Hypertension Community Outreach
ASH is proud to present its 4th Annual Hypertension Community
Outreach Initiative in conjunction with the Twenty-Sixth Annual
Scientific Meeting & Exposition. In 2008, ASH began the
Hypertension Community Outreach Initiative in New Orleans with
great success. We continued the Outreach Initiative in San Francisco
in 2009 and in New York once again, in 2010.
In 2011, the Outreach Initiative will provide hypertension screening
and education targeting local New York underinsured and uninsured
population segments. ASH will educate the residents of the New York
City, Long Island and New Jersey about hypertension and provide
them with products and tools to take home.
Visit the ASH Hypertension Community Outreach Booth #1600 in
the Pavilion, learn more about the Outreach program and check your
blood pressure.
Multimedia CD-ROM of Scientific Meeting
Audio recordings on CD-ROM including select speaker presentations
in PDF format of the Scientific Sessions and Satellite Symposium will
be for sale through AVMG in the Second Flood Promenade. You may
also download the individual sessions in MP3 format to your computer post-conference. Visit our e-commerce store at www.ash-us.org.
13
ASH Policy Regarding Videotaping, Photography and
Audio Taping
No individual is permitted to film, videotape, photograph and/or
audiotape meeting symposia, scientific sessions, posters or exhibits without prior written approval from the American Society of
Hypertension, Inc.
ASH Information/Membership Booth
The On-Site ASH Information/Membership Booth will be located
at the entrance of the Hypertension Resource Pavilion on the Third
Floor.
ASH Staff Members
Executive Office
Torry Mark Sansone, Executive Director
Mary Trifault, Executive Associate
Scientific Meetings & Professional Affairs
Melissa Levine, Associate Executive Director
Ashley Buron, Program Coordinator
Meeting and Exhibit Services, Hypertension Community Outreach Services
Gilda C. Caputo Hansen, Director
Education Services
Kathleen Sheridan, Director of Education
Nicole Rabin, Associate Manager, Continuing Education (CE)
Services
Olivia Carr, Program Manager, Educational Services
Membership & Marketing Services
Angel Loayza, Manager
Barbara E. Escobar, Associate Manager
Financial Services
Kevin Lee, Manager
Kereyne A. Bishop, Associate Accounting Manager
Journal of the American Society of Hypertension (JASH)
Ashley Buron, Managing Editor
14
ASH EDUCATION AND RESEARCH FOUNDATION announces its ASH EDUCATION AND RESEARCH FOUNDATION announces its [New Logo] [New Logo] Inaugural ASH Foundation Inaugural ASH Foundation 5K & 10K Run/Walk 5K & 10K Run/Walk Monday, May 23 , 2011 rd
NYC Central Park 7:00 AM rd
Monday, May 23
, 2011 NYC Central Park 7:00 AM Registration: Daiichi Sankyo, Inc. Booth # 1200 Hypertension Resource Pavilion Running Shirt, Water bottle, and Course Maps Registration: Daiichi Sankyo, Inc. will be provided upon registration. Booth # 1200 Hypertension Resource Please consider supporting the Foundation with a registration donation. Pavilion Running Shirt, Water bottle, and Course Maps
will be provided upon registration. Please consider supporting the Foundation with a
registration donation. The Foundation thanks Daiichi Sankyo, Inc. for their generous supporting donation. 2011 ASH Corporate Members
Boehringer Ingelheim Pharmaceuticals, Inc.
Daiichi Sankyo, Inc.
Forest Laboratories, Inc.
Merck & Co., Inc.
Pfizer Inc
Takeda Pharmaceuticals North America, Inc.
16
ASH Sponsors
The American Society of Hypertension, Inc. wishes
to acknowledge the following Corporate Sponsors
for their generous support of the ASH Twenty-Sixth
Annual Scientific Meeting.
2011 Annual Scientific Meeting
Sponsors
SERVIER
2011 Hypertension Community
Outreach
The American Society of Hypertension, Inc. wishes
to acknowledge and thank our Community Partners
for their generous support of this program.
American Kidney Fund
Association of Black Cardiologists, Spirit of the Heart
AVMG, Inc.
Boomer Esiason Foundation
Forest Pharmacueticals, Inc.
Foundation of National Lipid Association Hilton NY
HoMedics, Inc.
Institute for Health Equity at Nassau University Medical Center
Metropolitan Exposition, Inc.
MR CHAMMPS at St. Joseph’s Regional Medical Center
Omron Healthcare, Inc.
PepsiCo, Inc.
Society for Cardiovascular Angiography and Interventions (SCAI)
17
ASH Leadership
2010-2011 Board of Directors
Officers
President: George L. Bakris, MD, FASH
President-Elect: William B. White, MD, FASH
Vice President: Sandra J. Taler, MD, FASH
Secretary: John D. Bisognano, MD, PhD, FASH
Treasurer: Franz H. Messerli, MD, FASH
Immediate Past President: Henry R. Black, MD, FASH
Directors-At-Large
Keith C. Ferdinand, MD, FASH
Alan H. Gradman, MD, FASH
Daniel T. Lackland, DrPH, FASH
Robert A. Phillips, MD, PhD, FASH
Addison A. Taylor, MD, PhD, FASH
Mattew R. Weir, MD, FASH
Ex Officio Non-Voting Members
Thomas D. Giles, MD, FASH, Chair, ASH Specialists Program Inc.
Michael A. Weber, MD, FASH, Editor-In-Chief,
The Journal of Clinical Hypertension (JCH)
Myron H. Weinberger, MD, Editor-In-Chief,
Journal of the American Society of Hypertension (JASH)
Torry Mark Sansone, Executive Director
18
2011 Scientific Program
Committee
George L. Bakris, MD, FASH, President
William B. White, MD, FASH, Chair
Pathobiology of Hypertension
David G. Harrison, MD, Co-Chair
Nancy J. Brown, MD
Michael W. Brands, PhD
Joey P. Granger, PhD
Allyn L. Mark, MD
Susanne B. Nicholas, MD, PhD, MPH
J. Howard Pratt, MD
Translational Issues in Hypertension
Brent M. Egan, MD, FASH, Co-Chair
Donald L. Batisky, MD
John D. Bisognano, MD, PhD, FASH
Stephen R. Daniels, MD, PhD, FASH
Daniel Duprez, MD, PhD, FASH
Joel Handler, MD
Nancy Houston Miller, RN, BSN
Therapy of Hypertension
Robert A. Phillips, MD, PhD, FASH, Co-Chair
Jan N. Basile, MD, FASH*
Michael J. Bloch, MD, FASH*
Lynne T. Braun, PhD, CNP
Barry L. Carter, PharmD
Joseph A. Diamond, MD, FASH
F. Wilford Germino, MD, FASH*
David S. Kountz, MD
Louis Kuritzky, MD*
Gbenga Ogedegbe, MD, MPH, MS, FASH*
Aldo J. Peixoto, MD, FASH
C. Venkata S. Ram, MD, FASH
Scott D. Solomon, MD
*Indicates Primary Care
19
Special Lecture
Monday, May 23, 2011, 1:30 PM – 4:00 PM • East Ballroom • Third Floor
Robert Tigerstedt Award Lecture
Oscar A. Carretero, MD, FASH
Oscar A. Carretero, MD was born in
Mendoza, Argentina and received his
degree from the School of Medicine at the
University of Cuyo, Mendoza, Argentina.
Dr. Carretero has contributed greatly to
our understanding of the role of vasoactive hormones in the regulation of blood
pressure and renal function, as well as the
pathogenesis of hypertension and target
organ damage (TOD). His research has
resulted in over 360 publications. His
fundamental contributions began with
his initial hypothesis in 1972 that renal
kinins may be involved in the regulation
of sodium and water excretion, acting as natriuretic and diuretic hormones. His work has contributed uniquely to the understanding of the
role of the renal kallikrein-kinin system, ranging from the development
of methods to measure the components of the system and its localization
to demonstrating that the renal kallikrein-kinin system is natriuretic and
diuretic not only in high mineralocorticoid situations but also in the basal
state. This work culminated with the demonstration that animals lacking
the main kinin receptor (B2) develop hypertension when they are fed a
high sodium diet. As a pioneer in the field of kinin research, where his
contributions have been fundamental, numerous, and of high quality,
we now understand that kinins act as paracrine hormones, regulating
organ blood flow and renal function, and also participate on the chronic
cardiovascular protective effect of angiotensin-converting enzyme (ACE)
and angiotensin resector blockers. He and his colleagues demonstrated
that kallikrein in the kidney is produced mainly in the connecting tubule
(CNT) and in collaboration with Luciano Barajas they demonstrated that
the CNT returns to the glomerulus and makes contact with the afferent
arteriole. Recently he demonstrated that there is a crosstalk between the
CNT and the afferent arteriole, showing that when sodium is increased
in the perfusate of the CNT, the afferent arteriole dilates. They call this
cross talk between the CNT and the afferent arteriole connecting tubuloglomerular feedback. This seminal contribution explains why during
a sodium load, renal blood flow increases.
Recently he has made another seminal contribution by demonstrating
that the endogenous tetrapeptide N-Acetyl-Ser-Asp-Lys-Pro (Ac-SDKP);
that is destroyed mainly by ACE; has anti-inflammatory and anti-fibrotic
effects, and also contributes to the cardiovascular and renal protective effect of ACE inhibitors. Furthermore, he discovered that the enzyme prolyl
oligopeptidase is involved in the release of Ac-SDKP from the protein
thymosin β-4. He has shown that inhibition of this enzyme promotes
vascular and renal fibrosis. He and his group have demonstrated that
this peptide inhibits fibrosis by a) decreasing inflammation, b) fibroblast
proliferation and collagen synthesis, c) TGF expression and d) its TGF
signaling (Smad phosphorylation).
continued…
20
Special Lecture continued
In addition, Dr. Carretero has trained numerous investigators in the
field of hypertension. Among his distinguished and well-known students
are Alberto Nasjletti, Professor of Pharmacology at the Medical College
of New York; A Guillermo Scicli, Professor of Medicine Henry Ford
Health Sciences, Wayne State University; and Sadayoshi Ito, Chairman
and Professor of Medicine, Tohoku University; Luis Juncos, Division
Director, Nephrology, University of Mississippi. These are among many
who have become important investigators in the field of cardiovascular
or renal physiology and medicine.
Dr. Carretero is an active invited international lecturer, and has received
many awards including a Lifetime Achievement Award from the InterAmerican Society of Hypertension and the Novartis award from the
Council of High Blood Pressure Research, American Heart Association.
He also received a Dr. Honoris Causa from University of Cordoba and a
Professor Honoris Causa from the University of Mendoza. He has been
Chairman, Council for High Blood Pressure Research of the AHA, and
President of the Inter-American Society of Hypertension. He also serves
in various NIH study sections and committees and serves on the editorial
boards of several scientific journals.
21
Young Scholar Award*
Alessandro Cataliotti, MD, PhD
Alessandro Cataliotti, MD, PhD, is an
associate consultant in the Division of
Cardiovascular Diseases and Internal
Medicine at Mayo Clinic Rochester. He
holds the academic rank of associate
professor of medicine.
Dr. Cataliotti obtained his medical degree
with the highest score cum laude from
the University of Catania, Italy where he
also pursued residency and fellowship
in internal medicine, as well as a PhD
program in cardiovascular science. Dr.
Cataliotti began a research fellowship at
Mayo Clinic under the supervision of Dr. Burnett in 1998. Throughout
his research career, Dr. Cataliotti has been the recipient of numerous
awards, including competitive travel awards from the American Society
of Hypertension in 2000 and 2003; Heart Failure Society of America in
1999, 2000, 2001 and 2003; European Society of Hypertension in 2001;
and International Society of Hypertension in 2002; and many more in
the following years. Of note, Dr. Cataliotti received a two-year grant
from Bristol-Myers Squibb in 1999 in support for his research here at
Mayo Clinic. Dr. Cataliotti was also a recipient of a Beginning Grant in
Aid from the American Heart Association in 2003-2004. From 2005 to
2009, he was awarded a Ministry of Education, University and Research of
Italy (MIUR), Rientro dei Cervelli Project. Underscoring Dr. Cataliotti’s
outstanding research achievements and again recognition by his scientific
peers was the awarding of one of twelve 2006 Doris Duke Clinical Scientist
Development Grants. He has been funded by the National Institutes of
Health and currently is the principal investigator of two RO1s.
Dr. Cataliotti’s research has focused on humoral integration of the heart
and kidney in heart failure and hypertension with a special emphasis
upon the natriuretic peptide system. He has published over 70 publications in leading peer-reviewed journals, including the Circulation,
Lancet, Proceedings of The National Academy of Science, American
Journal of Physiology, Kidney International, Journal of American Society
of Nephrology, American Journal of Kidney Disease, Peptide, Journal of
Hypertension, Regulatory Peptides, European Journal of Heart Failure,
Hypertension, Circulation Research, American Journal of Hypertension
and the Mayo Clinic Proceedings.
Dr. Cataliotti has been active in the discovery of novel drug delivery
strategies for cardiac peptides in cardiovascular disease and in hypertension. He was the first to report feasibility of oral delivery of human
B-type natriuretic peptide in experimental hypertension, and has
pioneered the cardiac gene delivery strategy for natriuretic peptides in
hypertensive heart disease.
*Supported by an educational grant from SERVIER.
22
Young Scholar Award*
Michael J. Ryan, PhD
Dr. Ryan is an Associate Professor of
Physiology & Biophysics at the University
of Mississippi Medical Center in Jackson,
MS. He earned his doctorate from the
State University of New York at Buffalo
in 1999 and received his post-doctoral
training at the University of Iowa from
1999-2004. In 2004, he was recruited as
an Assistant Professor of Physiology &
Biophysics at the University of Mississippi
Medical Center where he rose to his current rank of Associate Professor in 2009.
Dr. Ryan’s research focuses on the
mechanistic role that chronic inflammation has in the development of
hypertension. In order to examine this link, he studies an animal model
that develops the chronic autoimmune inflammatory disorder systemic
lupus erythematosus (SLE). Hypertension is prevalent and cardiovascular
disease is a leading cause of death in individuals with SLE. Dr. Ryan is
specifically interested in the effect of immune and inflammatory mediators
on renal function, renal injury and vascular physiology as it pertains to
the development of hypertension. His work has been continuously funded
by the American Heart Association and National Institutes of Health.
Dr. Ryan currently sits on the editorial board of Hypertension, the American
Journal of Physiology: Regulatory, Integrative and Comparative Physiology, the Journal of Hypertension and Frontiers in Vascular Physiology.
He is an active member of the American Heart Association peer review
system serving as a co-chair of the Vascular Biology & Blood Pressure
II peer review committee. Dr. Ryan is a Fellow of the American Heart
Association and serves on the Leadership Committee of the Council
for High Blood Pressure as well as on the Greater Southeast Affiliate
Research Committee. Ryan is also an active member of the American
Physiological Society. He has served on the Porter Physiology Development Committee and currently serves on the Education Committee of
the American Physiological Society where he actively contributes to the
educational missions of the society.
23
Special Lecture
Marvin Moser Clinical Hypertension Award Lecture
Murray Epstein, MD
Dr. Murray Epstein is Professor of Medicine at the University of Miami, School
of Medicine. He was a recipient of the
1990 Distinguished Scientist Award of the
National Kidney Foundation. He served
as a member of the National High Blood
Pressure Education Program Coordinating
Committee and is a contributor to the 6th
Report of the Joint National Committee.
Dr. Epstein is listed in Who’s Who in
America (59th, 60th and 61st edition) and
Who’s Who in Medicine.
Dr. Epstein has authored over 400 journal
articles and book chapters. Many of these have related to 1) the pathogenesis and management of hypertension, 2) renal function in diseases
characterized by abnormal volume regulation, and 3) the role of the
renin angiotensin aldosterone system. He has also written extensively
on head out water immersion, a unique clinical investigational model
that he has defined and applied to the study of a wide range of disease
states. The unique attributes of this clinical investigative model include
a prompt redistribution of circulating blood volume with a consequent
relative central hypervolemia, in the absence of concomitant changes in
plasma composition. Dr. Epstein has successfully applied the immersion
model as a clinical investigative tool to characterize the determinants
of deranged volume homeostasis and renin-aldosterone, eicosanoid,
kallikrein, vasopressin and ANF responsiveness in diverse edematous
disorders including advanced liver diseases, chronic renal failure and
hypertension. He has also utilized the immersion model to define the
relative roles of volume and the renin-angiotensin axis as determinants
of aldosterone responsiveness in anephric humans.
Dr. Epstein has also defined the effects of calcium antagonists on renal
hemodynamics and renal function At the preclinical level Dr. Epstein,
in collaboration with his co-investigator Dr. Rodger Loutzenhiser, developed and used the isolated perfused hydronephrotic kidney model to
visualize the renal microvasculature and define the effect of interventions
with calcium antagonists and a wide array of vasoconstrictors including
angiotensin II and endothelin on the afferent and efferent arterioles. He
extended these studies to the clinical arena in order to define the effect of
calcium antagonists on renal hemodynamics and as prophylactic agents
to obviate acute renal failure in diverse clinical settings. Most recently
Dr. Epstein has focused his clinical and investigative attention on the
role of aldosterone as a pivotal determinant of cardiovascular and renal
injury, and the use of aldosterone blockade to reverse these adverse
effects. Currently his major investigative focus is on mineralocorticoid
receptor blockade as an intervention to abrogate progressive kidney disease, and as an intervention to confer cardiovascular and renal benefits
in patients with chronic kidney disease, and in ESRD patients who are
being treated by hemodialysis.
continued…
24
Special Lecture continued
A member of several editorial boards, Dr. Epstein also serves as a
reviewer for numerous prominent journals and for study sections for
granting agencies.
Dr. Epstein has served as the editor of 4 editions of THE KIDNEY IN
LIVER DISEASE (Hanley & Belfus, Philadelphia, 1996), the premier
book in the field, which surveys the wide spectrum of renal functional
abnormalities in liver disease. Dr. Epstein has also co authored HYPERTENSION: PRACTICAL MANAGEMENT (1988), which has subsequently
been published in Spanish and Portuguese editions. He has also edited
CALCIUM ANTAGONISTS AND THE KIDNEY (Hanley & Belfus, 1990),
the first comprehensive book to survey the diverse effects of calcium
antagonists on renal function, and the clinical applicability of these findings, including renal protection. Most recently, Dr. Epstein has edited
3 editions of CALCIUM ANTAGONISTS IN CLINICAL MEDICINE
(Hanley and Belfus, 1992, 1997, and 2002), the first comprehensive book
to survey the effects of calcium antagonists on both cardiovascular and
renal function. In addition, this book considers the effects of calcium
antagonists on other organ systems including the management of gastrointestinal disorders, and disorders of the cerebral circulation.
Dr. Epstein has also co-edited ANGIOTENSIN II RECEPTOR ANTAGONISTS (Hanley & Belfus 2001), the first comprehensive book to survey
the effects of AT1 receptor antagonists on both cardiovascular and renal
function. In addition, this book considers the effects of these novel agents
in elucidating the profound physiological effects of angiotensin II.
Dr. Epstein, who is a 1963 graduate of Columbia University College of
Physicians and Surgeons, did his postgraduate medical training at University Hospital in Madison, Wisconsin and at the Cleveland MetroHealth
Medical Center of Western Reserve University from 1966 to 1968, he
was a Research Fellow in Nephrology in the Kidney Laboratory of Peter
Bent Brigham Hospital in Boston, under Professor John P. Merrill. Dr.
Epstein was also an Established Investigator of the Howard Hughes
Medical Institute. He is ABIM-certified in internal medicine and nephrology, and is a Fellow of both the American College of Physicians and the
American Society of Nephrology. Dr Epstein has also been designated
a Hypertension Specialist by the American Society of Hypertension.
25
2011 Abstract Reviewers
Gilbert M. Eisner, MD, FASH
Washington, DC
William J. Elliott, MD, PhD,
FASH
Yakima, WA
Michael Ernst, PharmD
Iowa City, IA
Bonita Falkner, MD, FASH
Philadelphia, PA
Pamela J. Fall, MD, FASH
Augusta, GA
Daniel I. Feig, MD, PhD
Houston, TX
John M. Flack, MD, MPH
Detroit, MI
Joseph T. Flynn, MD, FASH
Seattle, WA
Philip B. Gorelick, MD, MPH
Lincoln, IL
Pittsburgh, PA
Jackson, MS
Richard H. Grimm, Jr., MD, PhD
Minneapolis, MN
John E. Hall, PhD
Jackson, MS
Joel Handler, MD
Anaheim, CA
Willa A. Hsueh, MD
Houston, TX
David J. Hyman, MD, MPH
Houston, TX
Kenneth A. Jamerson, MD, FASH
Ann Arbor, MI
Richard J. Johnson, MD
Denver, CO
John B. Kostis, MD, FASH
New Brunswick, NJ
David S. Kountz, MD
Neptune, NJ
Louis Kuritzky, MD
Gainesville, FL
San Francisco, CA
Daniel T. Lackland, DrPH, FASH
Charleston, SC
Lewis Landsberg, MD
Chicago, IL
Lawrence J. Appel, MD, MPH,
FASH
Baltimore, MD
Steven A. Atlas, MD, FASH
Bronx, NY
Chicago, IL
Jan N. Basile, MD, FASH
Charleston, SC
Atlanta, GA
Dan R. Berlowitz, MD, MPH
Bedford, MA
John D. Bisognano, MD, PhD,
FASH
Rochester, NY
Henry R. Black, MD, FASH
New York, NY
Michael J. Bloch, MD, FASH
Reno, NV
Augusta, GA
Chicago, IL
Robert D. Brook, MD, FASH
Ann Arbor, MI
Angela L. Brown, MD
St. Louis, MO
David A. Calhoun, MD
Birmingham, AL
Oscar A. Carretero, MD, FASH
Detroit, MI
Iowa City, IA
John R. Cockcroft, MD
Cardiff, United Kingdom
Stephen R. Daniels, MD, PhD,
FASH
Aurora, CO
Prakash C. Deedwania, MD,
FASH
Fresno, CA
Joseph A. Diamond, MD, FASH
New Hyde Park, NY
Daniel Duprez, MD, PhD,
FASH
Minneapolis, MN
Brent M. Egan, MD, FASH
Charleston, SC
26
2011 Abstract Reviewers continued
Friedrich C. Luft, MD
Berlin, Germany
Giuseppe Mancia, MD
Milan, Italy
Samuel J. Mann, MD
New York, NY
Allyn L. Mark, MD
Iowa City, IA
Nancy Houston Miller, RN,
BSN
Palo Alto, CA
Gary Mitchell, MD
Norwood, MA
Michael A. Moore, MD, FASH
Winston Salem, NC
L. Gabriel Navar, PhD
New Orleans, LA
Shawna D. Nesbitt, MD, MS,
FASH
Dallas, TX
Susanne B. Nicholas, MD, PhD,
MPH
Los Angeles, CA
Daniel T. O’Connor, MD
San Diego, CA
Gbenga Ogedegbe, MD, MPH,
MS, FASH
New York, NY
Suzanne Oparil, MD, FASH
Birmingham, AL
Vasilios Papademetriou, MD,
FASH
Washington, DC
West Haven, CT
Robert A. Phillips, MD, PhD,
FASH
Worcester, MA
Bertram Pitt, MD
Ann Arbor, MI
J. Howard Pratt, MD
Indianapolis, IN
L. Michael Prisant, MD, FASH
Augusta, GA
Clive Rosendorff, MD, PhD,
FASH
Bronx, NY
Gary E. Sander, MD, PhD,
FASH
Metairie, LA
Ernesto L. Schiffrin, MD, PhD
Montreal, Canada
Alan B. Schwartz, MD, FASH
Philadelphia, PA
Scott D. Solomon, MD
Boston, MA
James R. Sowers, MD, FASH
Columbia, MO
Jan A. Staessen, MD, PhD
Leuven, Belgium
Sandra J. Taler, MD, FASH
Rochester, MN
Addison A. Taylor, MD, PhD,
FASH
Houston, TX
Sheldon W. Tobe, MD, FASH
Toronto, Canada
Peter P. Toth, MD, PhD
Sterling, IL
Rhian M. Touyz, MD, PhD
Ottawa, Canada
Raymond R. Townsend, MD
Philadelphia, PA
Jason G. Umans, MD, PhD
Bethesda, MD
Alan B. Weder, MD
Ann Arbor, MI
Myron H. Weinberger, MD
Indianapolis, IN
Howard Weintraub, MD
New York, NY
Matthew R. Weir, MD, FASH
Baltimore, MD
Farmington, CT
Peter W. F. Wilson, MD
Atlanta, GA
Nathan D. Wong, PhD, MPH
Irvine, CA
Jackson T. Wright, Jr., MD,
PhD, FASH
Cleveland, OH
Steven A. Yarows, MD, FASH
Chelsea, MI
27
3
More than half of
hypertensive patients need
3 or more
agents
to help them get to BP GOAL1-4
References: 1. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al; INVEST Investigators. A calcium antagonist vs
a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International
Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):2805-2816. 2. Wright
JT Jr, Bakris G, Greene T, et al; African American Study of Kidney Disease and Hypertension Study Group. Effect of
blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from
the AASK trial. JAMA. 2002;288(19):2421-2431. 3. Cushman WC, Ford CE, Cutler JA, et al; ALLHAT Collaborative
Research Group. Success and predictors of blood pressure control in diverse North American settings: the
Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack trial (ALLHAT). J Clin Hypertens. 2002;4(6):393404. 4. Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or
hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-2428. 5. Flack JM,
Calhoun DA, Satlin L, Barbier M, Hilkat R, Brunel P. Efficacy and safety of initial combination therapy with amlodipine/
valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study.
J Hum Hypertens. 2009;23(7):479-489. 6. Flack JM, Sica DA, Bakris G, et al. Management of high blood pressure
in blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension.
2010;56(5):780-800.
©2011 Novartis
?
Looking for
antihypertensive
EFFICACY
in African American
patients?5,6,*
Visit booth
#1100
to find out more
*Patients with stage 2/severe hypertension, including African American patients with moderate-to-severe
hypertension. Stage 2 hypertension is defined as ≥160/100 mm Hg.
Printed in USA
4/11
EXR-1052006
Poster Category Presentation
Posters will be displayed in the Second Floor Promenade.
Posters on Display: 4:30 PM – 7:30 PM • Poster Viewing: 6:00 PM – 7:00 PM
Adolescent Hypertension and Obesity.............................. (PO-1 – PO-5)
Antiatherosclerotic Drugs................................................... (PO-6 – PO-7)
Cardiac Structure and Function/Imaging....................... (PO-8 – PO-10)
Comprehensive Multi-Level Interventions for
Hypertension Management in High-Risk Groups....... (PO-11 – PO-30)
Endothelial Function....................................................... (PO-31 – PO-45)
Epidemiology/Special Populations................................ (PO-46 – PO-78)
Immune Mechanisms in Hypertension......................... (PO-79 – PO-82)
Metabolic Syndrome (Diabetes/Glycemic Control;
Dysglycemic Drugs; Insulin Resistance).....................(PO-83 – PO-102)
New Insights into the Role of Uric Acid
in Hypertension............................................................(PO-103 – PO-104)
Pediatric Hypertension................................................(PO-105 – PO-111)
Risk Factors (Lipids)....................................................(PO-112 – PO-115)
Stroke.............................................................................(PO-117 – PO-119)
Vascular Injury/Inflammation and Remodeling......(PO-120 – PO-123)
Posters on Display: 10:00 AM – 6:30 PM • Poster Viewing: 5:30 PM – 6:30 PM
Featured Posters
Blood Pressure Measurement/Monitoring......................(FP-1 – FP-4)
Adolescent Hypertension...................................................(FP-5 – FP-8)
Aldosterone and Anti-Aldosterone Agents..............(PO-124 – PO-130)
Antihypertensive Drugs and Pharmacology............(PO-131 – PO-157)
Clinical Trials................................................................(PO-158 – PO-184)
Coronary Artery Disease.............................................(PO-185 – PO-191)
Genetics/Gene Therapy/Proteomics..........................(PO-192 – PO-198)
Heart Failure/Hypertrophy
(Diastolic Dysfunction)...............................................(PO-199 – PO-216)
Hypertension in Patients with Chronic
Kidney Disease.............................................................(PO-217 – PO-226)
Kidney and Hypertension...........................................(PO-227 – PO-242)
Off-Target Cardiovascular Effects of
Non-Cardiovascular Drugs.........................................(PO-243 – PO-244)
Dagger (†) denotes that the presenting author has related disclosure
information.
30
Poster Category Presentation
Featured Posters
Cardiac Structure and Function..................................... (FP-9 – FP-13)
Arterial Structure and Compliance............................(PO-245 – PO-259)
Blood Pressure Measurement/Monitoring............(PO-260 – PO-305A)
Cellular Mechanisms (Cell Biology;
Cell Membrane Transport/Ion Channels;
Coagulation/Thrombosis; Growth Factors)..............(PO-306 – PO-308)
Lipid Metabolism...........................................................................(PO-309)
Neural Hormonal Mechanisms (Renin; Neural Control; Vasoactive
Autacoids).....................................................................(PO-310 – PO-312)
Non – Pharmacological Therapy (Alternative
Medicine; Diet; Physical Activity)..............................(PO-313 – PO-322)
Nutrition and Cardiovascular Prevention.................(PO-323 – PO-330)
Obesity...........................................................................(PO-331 – PO-339)
Patient – Provider-Healthcare System Issues............(PO-340 – PO-355)
Preclinical Models/Experimental Hypertension......(PO-357 – PO-358)
Pregnancy......................................................................(PO-359 – PO-361)
Salt-Sensitive Mechanisms of Hypertension.............(PO-362 – PO-364)
Secondary Hypertension.............................................(PO-365 – PO-367)
Late-Breaking Posters......................................... (LB-PO-01 – LB-PO-03)
information.
31
2011 ASH Faculty
Rajiv Agarwal, MD
Indianapolis, IN
Lawrence J. Appel, MD, MPH,
FASH
Baltimore, MD
Nancy Artinian, PhD, RN
Detroit, MI
Phyllis August, MD, MPH
New York, NY
Abraham Aviv, MD
Newark, NJ
Chicago, IL
Jan N. Basile, MD, FASH
Charleston, SC
Atlanta, GA
John D. Bisognano, MD, PhD,
FASH
Rochester, NY
Henry R. Black, MD, FASH
New York, NY
Michael J. Bloch, MD, FASH
Reno, NV
William E. Boden, MD
Buffalo, NY
Augusta, GA
Chicago, IL
Emmanuel Bravo, MD
Cleveland, OH
Angela L. Brown, MD
St. Louis, MO
Nancy J. Brown, MD
Nashville, TN
David A. Bushinsky, MD
Rochester, NY
Norman R. C. Campbell, MD
Calgary, Canada
Oscar A. Carretero, MD
Detroit, MI
Iowa City, IA
Rochester, MN
Cardiff, United Kingdom
Jay N. Cohn, MD
Minneapolis, MN
Steven D. Crowley, PhD
Durham, NC
William C. Cushman, MD,
FASH
Memphis, TN
Stephen R. Daniels, MD, PhD,
FASH
Aurora, CO
Michael H. Davidson, MD
Chicago, IL
Daniel Duprez, MD, PhD,
FASH
Minneapolis, MN
Lance D. Dworkin, MD
Providence, RI
Brent M. Egan, MD, FASH
Charleston, SC
Paula T. Einhorn, MD, MS
Bethesda, MD
William J. Elliott, MD, PhD,
FASH
Yakima, WA
Murray Epstein, MD
Miami, FL
Murray D. Esler, MBBS, PhD
Melbourne, Australia
Bonita Falkner, MD, FASH
Philadelphia, PA
Sadaf Farooqi, PhD
Cambridge, United Kingdom
Houston, TX
Ross Feldman, MD
London, Canada
Atlanta, GA
Detroit, MI
Joseph T. Flynn, MD, FASH
Seattle, WA
Stanley S. Franklin, MD, FASH
Los Angeles, CA
William H. Frishman, MD
Valhalla, NY
James B. Froehlich, MD, MPH
Ann Arbor, MI
Leonard M. Fromer, MD
Los Angeles, CA
Jeffrey L. Garvin, PhD
Detroit, MI
32
2011 ASH Faculty continued
Rae-Ellen W. Kavey, MD, MPH
Rochester, NY
Donald E. Kohan, MD, PhD
Salt Lake City, UT
David S. Kountz, MD
Neptune, NJ
New York, NY
Henry Krum, MBBS, PhD
Melbourne, Australia
Louis Kuritzky, MD
Gainesville, FL
San Francisco, CA
Robert F. Kushner, MD
Chicago, IL
Daniel T. Lackland, DrPH,
FASH
Charleston, SC
Edward G. Lakatta, MD
Baltimore, MD
Babbette LaMarca, PhD
Jackson, MS
Marc B. Lande, MD, MPH
Rochester, NY
Daniel Levy, MD
Framingham, MA
Nita A. Limdi, PharmD, PhD,
MSPH
Birmingham, AL
Tianhu Liu, MD
Chengdu, China
Charles J. Lowenstein, MD
Rochester, NY
Jianfang Luo, MD
Guangzhou, China
James M. Luther, MD
Nashville, TN
Guiseppe Mancia, MD
Milan, Italy
Samuel J. Mann, MD
New York, NY
Athanasios J. Manolis, MD,
PhD
Athens, Greece
Allyn L. Mark, MD
Iowa City, IA
Barry J. Materson, MD, MBA,
FASH
Miami, FL
Boston, MA
F. Wilford Germino, MD, FASH
Orland Park, IL
Ali G. Gharavi, MD
New York, NY
Thomas D. Giles, MD, FASH
New Orleans, LA
Alan S. Go, MD
Oakland, CA
Pittsburgh, PA
Jackson, MS
Richard H. Grimm, Jr., MD,
PhD
Minneapolis, MN
Yuan Guo, MD, MS
Beijing, China
John E. Hall, PhD
Jackson, MS
Joel Handler, MD
Anaheim, CA
David Harder, MD, PhD
Milwaukee, WI
Raymond C. Harris, MD
Nashville, TN
David G. Harrison, MD
Atlanta, GA
Joseph A. Hill, MD, PhD
Dallas, TX
Norman K. Hollenberg, MD,
PhD
Boston, MA
Suzanne Hughes, RN, MSN
Akron, OH
Joseph L. Izzo, Jr., MD, FASH
Buffalo, NY
Edgar A. Jaimes, MD
Birmingham, AL
Kenneth A. Jamerson, MD,
FASH
Ann Arbor, MI
Julie A. Johnson, PharmD
Gainesville, FL
Denver, CO
Pedro A. Jose, MD
Washington, DC
Luis Juncos, MD
Córdoba, Argentina
33
David L. Mattson, PhD
Milwaukee, WI
Richard J. McManus, MD
Birmingham, United Kingdom
John Merenich, MD
Denver, CO
Franz H. Messerli, MD, FASH
New York, NY
Nancy Houston Miller, RN,
BSN
Palo Alto, CA
Mark E. Molitch, MD
Chicago, IL
Krzysztof Narkiewicz, MD,
PhD
Gdánsk, Poland
New Orleans, LA
Shawna D. Nesbitt, MD, MS,
FASH
Dallas, TX
Joel M. Neutel, MD, FASH
Tustin, CA
Susanne B. Nicholas, MD, PhD,
MPH
Los Angeles, CA
Eoin O’Brien, MD
Dublin, Ireland
Gbenga Ogedegbe, MD, MPH,
MS, FASH
New York, NY
Suzanne Oparil, MD, FASH
Birmingham, AL
Julio A. Panza, MD
Washington, DC
Vasilios Papademetriou, MD,
FASH
Washington, DC
Gianfranco Parati, MD
Milan, Italy
West Haven, CT
Robert A. Phillips, MD, PhD,
FASH
Worcester, MA
Thomas A. Pearson, MD, PhD,
MPH
Rochester, NY
F. Xavier Pi-Sunyer, MD, MPH
New York, NY
Bertram Pitt, MD
Ann Arbor, MI
Velvie A. Pogue, MD
New York, NY
David M. Pollock, PhD
Augusta, GA
J. Howard Pratt, MD
Indianapolis, IN
Henry A. Punzi, MD
Carrollton, TX
Leopoldo Raij, MD, FASH
Miami, FL
C. Venkata S. Ram, MD, FASH
Dallas, TX
James Rippe, MD
Shrewsbury, MA
Talma Rosenthal, MD
Tel Aviv, Israel
Peter M. Rothwell, MD
Oxford, United Kingdom
Luis M. Ruilope, MD
Madrid, Spain
Jackson, MS
Elijah Saunders, MD, FASH
Baltimore, MD
Montreal, Canada
Roland E. Schmieder, MD
Erlangen, Germany
Antoinette Schoenthaler, EdD
New York, NY
Domenic A. Sica, MD
Richmond, VA
Sidney Smith, Jr., MD
Chapel Hill, NC
Matthew Sorrentino, MD
Chicago, IL
Thomas A. Sos, MD
New York, NY
James R. Sowers, MD, FASH
Columbia, MO
Lesley A. Stevens, MD, MS
Boston, MA
Allan D. Struthers, MD
Dundee, United Kingdom
Laura P. Svetkey, MD
Durham, NC
Sandra J. Taler, MD, FASH
Rochester, MN
Ting Tao, MD
Shanghai, China
34
2011 American Society of Hypertension Annual Meeting & Expostion – Program at a Glance
Day – Date – Time
Pathobiology
Translational
Therapy
Special Sessions
Joint Sessions
Debates/Meet the Professor
Innovations Theater
Satellite Symposia
Saturday, May 21, 2011 Pavilion Hours – Open 4:30 PM to 7:30 PM Posters on Display – 4:30 PM to 7:30 PM; Poster Viewing – 6:00 PM to 7:00 PM
Americas Hall, 3rd Floor
Hypertension
Highlights 2011
8:30 AM to 3:00 PM
East Ballroom, 3rd Floor
Membership Meeting
ASH Members Only
3:15 PM to 4:15 PM
Trianon Rendezvous, 3rd Floor
4:30 PM to 6:00 PM
Young Investigator
Competition Award
Joint Session – American
Heart Association’s Council for
High Blood Pressure Research
Sutton North, 2nd Floor
Genomics and Hypertension
Joint Session – Preventive
Cardiovascular Nurses
Association
Beekman Parlor, 2nd Floor
Sutton South, 2nd Floor
Joint Session – Association for
Research into Atterial Structure
and Physiology and North
American Artery
Regent Parlor, 2nd Floor
Joint Session – National Lipid
Association/American Society
of Preventive Cardiology
Sutton Center, 2nd Floor
Innovations Theater
6:30 PM to 7:30 PM
Rhinelander Gallery, 2nd Floor
Saturday, May 21, 2011 6:00 PM to 7:30 PM Opening Reception – Hypertension Resource Pavilion
Sunday, May 22, 2011 10:00 AM to 1:00 PM Hypertension Resource Pavilion Opens – 11:30 AM to 1:00 PM Brunch
Hypertension for the
Primary Care Clinician 2011
8:00 AM to 12:30 PM
Joint Session – International
Pediatric Hypertension
Association
9:30 AM to 11:00 AM
Joint Session – China Social
Worker’s Association Vascular
Protection Committee
Joint Session –
Hypertension Canada
Joint Session –
Inter-American Society of
Hypertension
Meet the Professor –
How to Write a 12 Page Grant
11:00 AM to 12:00 PM
Understanding Statistics in
Clinical Research
How to Develop an Abstract/
Lecture
Debate –
Is it Blood Pressure Variablility
or Average Daily Blood
Pressure that Best Predicts
Stroke?
Debate –
Surgical Intervention for Renal
Artery Stenosis is Indicated
12:00 PM to 1:00 PM
West Ballroom, 3rd Floor
1:15 PM to 3:00 PM
Plenary Session I
Innovations Theater
3:30 PM to 5:15 PM
Aldosterone
Hypertension in Patients
With Chronic Kidney
Disease
Comprehensive MultiLevel Interventions for
Hypertension Management
in High-Risk Groups
Mercury Ballroom, 3rd Floor
Control of Hypertension is
Leaving the Office: The Role
of Home Blood Pressure and
Telemedicine
Joint Session –
International Society of
Hypertension in Blacks
Trianon Ballroom, 3rd Floor
Sunday, May 22, 2011 5:30 PM to 6:30 PM High Tea and Poster Viewing
Innovations Theater
5:30 PM to 6:30 PM
Monday, May 23, 2011 10:00 AM to 1:30 PM Hypertension Resource Pavilion Opens – Lunch in Pavilion 12:00 PM to 1:15 PM
Symposia
6:00 AM to 7:30 AM
8:00 AM to 10:00 AM
10:30 AM to 12:00 PM
Off-Target Cardiovascular
Effects of NonCardiovascular Drugs
New Insights into the Role
of Uric Acid in Hypertension
Devices and Surgical
Ablation for Refractory
Hypertension
Immune Mechanisms in
Hypertension
Management of Elevated
Blood Pressure in the
Hospital Setting
Management of
Hypertension in Diabetics
and Chronic Kidney Disease
Joint Session –
National Kidney Foundation
Hyperkalemia Management
in High Risk Patients: New
Evidence-Based Approaches
Joint Session –
European Society of
Hypertension
Debate
Are Elevated Potassium Levels
Really a Concern?
11:45 AM to 12:15 PM
Plenary Session II
1:30 PM to 4:00 PM
Monday, May 23, 2011 4:00 PM to 5:30 PM Hypertension Resource Pavilion Opens – High Tea and Poster Viewing 4:30 PM to 5:30 PM
Debate
The Dominant Contributor
to Systemic Hypertension is:
Sympathetic Nervous System
not the RAAS; or Activation
of the Intrarenal RAAS not
the SNS
4:30 PM to 5:00 PM
Debate
Hypertension is a Disorder of
the Kidney
Late-Breaking Clinical Trials
8:15 AM to 9:30 AM
10:00 AM to 11:30 AM
Salt-Sensitive Mechanisms
of Hypertension
Integrated Cardiovascular
Disease Guidelines and
Implementation
Nutrition and
Cardiovascular Prevention
2011 Annual Scientific Meeting and Exposition
2011 Program
at a Glance
Hilton New York
Saturday, May 21, 2011 – Tuesday, May 24, 2011
Addison A. Taylor, MD, PhD,
FASH
Houston, TX
Jens Titze, MD
Erlangen, Germany
Sheldon W. Tobe, MD, FASH
Toronto, Canada
Robert D. Toto, MD
Dallas, TX
Ottawa, Canada
Philadelphia, PA
Joseph A. Vassalotti, MD
New York, NY
Ronald G. Victor, MD
Los Angeles, CA
Hongyu Wang, MD, PhD
Beijing, China
R. Clinton Webb, PhD
Augusta, GA
David J. Webb, MD
Edinburgh, United Kingdom
Michael A. Weber, MD, FASH
New York, NY
Alan B. Weder, MD
Ann Arbor, MI
Indianapolis, IN
Matthew R. Weir, MD, FASH
Baltimore, MD
Adam Whaley-Connell, DO,
FASH
Columbia, MO
Andrew Whelton, MD
Baltimore, MD
Farmington, CT
Ian B. Wilkinson, MD
Cambridge, United Kingdom
Bryan Williams, MD
Leicester, United Kingdom
Gordon H. Williams, MD
Boston, MA
Atlanta, GA
Nathan D. Wong, PhD, MPH
Irvine, CA
Martin S. Zand, MD
Rochester, NY
37
Program Color Key
The pages of this Program Book are color-coded to match the
Program at a Glance (pages 35–36) and serve as a quick, identifiable
reference of the type of educational activity or event taking place.
Scientific Sessions*
Special Event
Debates
Poster Sessions
Satellite Symposia
Hypertension Resource Pavilion
The ASH Twenth-Sixth Annual Scientific Meeting is
organized around three (3) concurrent themes:
• Pathobiology of Hypertension
• Translational Issues in Hypertension
• Therapy of Hypertension
Sessions in each of the three (3) themes (or tracks) are labeled
throughout the Program Book to be easily identifiable.
2011
American Society
of Hypertension
Program
May 21
Saturday Morning
8:00 AM – 3:00 PM • East Ballroom • Third Floor
Part I:
Co-Chairs:
8:00 AM
8:30 AM
9:00 AM
9:30 AM
10:00 AM
Henry R. Black, MD, FASH, New York, NY and
Michael A. Weber, MD, FASH, New York, NY
Breakfast
Cardiovascular Effects of Anti-Diabetic Drugs
Nancy J. Brown, MD, Nashville, TN
Role of the Kidney in Angiotensin II Hypertension
Steven D. Crowley, PhD, Durham, NC
Neurohormonal Assessment in the Diagnosis and
Management of Hypertension
Ronald G. Victor, MD, Los Angeles, CA
Break
Part II:
10:30 AM
11:15 AM
12:15 PM
Panel Discussion: Hypertension and Obesity in
Adolescence: Epidemiology, Nutritional Aspects,
Evaluation and Management
Moderator: Bonita Falkner, MD, FASH, Philadelphia,
PA
Panel Discussion Participants:
Donald L. Batisky, MD, Atlanta, GA
Joseph T. Flynn, MD, FASH, Seattle, WA and
Robert F. Kushner, MD, Chicago, IL
Partnership with the Patient to Improve Blood
Pressure Control and the Role of the Hypertension
Specialist in the “Medical Home”
Moderator: Elijah Saunders, MD, FASH, Baltimore,
MD
Joel Handler, MD, Anaheim, CA and
Nancy Houston Miller, RN, BSN, Palo Alto, CA
Lunch
Part III:
1:00 PM
2:15 PM
Panel Discussion: Resistant Hypertension:
Pathophysiology, Evaluation, and New/Old
Treatment Considerations
Moderator: C. Venkata S. Ram, MD, FASH, Dallas, TX
Michael W. Brands, PhD, Augusta, GA
John D. Bisognano, MD, PhD, FASH, Rochester, NY
Domenic A. Sica, MD, Richmond, VA and
Gordon H. Williams, MD, Boston, MA
Complementary and Alternative Therapies in
Hypertension
Moderator: Robert A. Phillips, MD, PhD, FASH,
Worcester, MA
Brent M. Egan, MD, FASH, Charleston, SC and
Matthew Sorrentino, MD, Chicago, IL
40
Saturday Afternoon
ASH Membership Meeting
3:15 PM – 4:15 PM • Trianon Rendezvous • Third Floor
ASH Annual Membership Meeting
41
May 21
May 21
Saturday Afternoon
Sessions
4:30 PM – 6:00 PM • Beekman Parlor • Second Floor
Genomics and Hypertension
Co-Chairs:
4:30 PM
5:00 PM
5:30 PM
Theodore W. Kurtz, MD, San Francisco, CA and
Alan B. Weder, MD, Ann Arbor, MI
Pharmacogenetics and Cardiovascular Disease
Nita A. Limdi, PharmD, PhD, MSPH, Birmingham, AL
Genomics of Experimental Hypertension:
Translation to Humans
Antihypertensive Drug Pharmacogenomics
Julie A. Johnson, PharmD, Gainesville, FL
42
Saturday Afternoon
May 21
Sessions
4:30 PM – 6:00 PM • Sutton North • Second Floor
Advancements in the Pathophysiology of
Hypertension: Some Novel Concepts
Held in Partnership with the American Heart Association’s Council
for High Blood Pressure Research (HBPR)
Co-Chairs:
4:30 PM
4:40 PM
5:06 PM
5:32 PM
Phyllis August, MD, MPH, New York, NY and
Rhian M. Touyz, MD, PhD, Ottawa, Canada
Overview
Pathophysiology of Hypertension in Preeclampsia:
Novel Concepts
Joey P. Granger, PhD, Jackson, MS
Vascular Function, Hypertension and Erectile
Dysfunction: Novel Mechanisms
R. Clinton Webb, PhD, Augusta, GA
Obesity-Related Hypertension: Basic Concepts and
Clinical Implications
John E. Hall, PhD, Jackson, MS
43
May 21
Saturday Afternoon
Sessions
4:30 PM – 6:00 PM • Sutton Center • Second Floor
Cardiovascular Risk Prevention
Held in Partnership with the American Society of Preventive
Cardiology (ASPC) and the National Lipid Association (NLA)
Co-Chairs:
4:30 PM 4:40 PM
5:00 PM
5:20 PM
5:40 PM
George L. Bakris, MD, FASH, Chicago, IL and
Peter W. F. Wilson, MD, Atlanta, GA
Welcoming Remarks
Prevention Strategy and National Healthcare
Thomas A. Pearson, MD, PhD, MPH, Rochester, NY
National Health Forum Initiatives: Dollars and
Cents
Keith C. Ferdinand, MD, FASH, Atlanta, GA
Aggressive Medical Management versus
Intervention: An Uphill Road to Policy Change
William E. Boden, MD, Buffalo, NY
Leadership Panel Discussion
George L. Bakris, MD, FASH, Chicago, IL, Michael H.
Davidson, MD, Chicago, IL and Nathan D. Wong, PhD,
MPH, Irvine, CA
Questions and Answers
44
Saturday Afternoon
May 21
Sessions
4:30 PM – 6:00 PM • Sutton South • Second Floor
Advocating for Adherence to Better Control
Hypertension
Held in Partnership with the Preventive Cardiovascular Nurses
Association (PCNA)
Co-Chairs: 4:30 PM
4:52 PM
5:14 PM 5:36 PM
Nancy Artinian, PhD, RN, Detroit, MI and
Barry L. Carter, PharmD, Iowa City, IA
Enhancing Adherence in Ethically-Diverse
Populations
Gbenga Ogedegbe, MD, MPH, MS, FASH, New York,
NY and Antoinette Schoenthaler, EdD, New York, NY
From Adherence to Advocacy: The Need to Reduce
Sodium
Suzanne Hughes, RN, MSN, Akron, OH
Adherence and Persistence with Medications:
The ASH Position
Nancy Houston Miller, RN, BSN, Palo Alto, CA
Practical Tips to Assess and Promote Adherence in
Clinical Practice
Lynne T. Braun, PhD, CNP, Chicago, IL
45
May 21
Saturday Afternoon
Sessions
4:30 PM – 6:00 PM • Regent Parlor • Second Floor
Arterial Stiffness: A Paradigm Shift in
Understanding the Increased Cardiovascular Risk
Associated with Aging and Chronic Disease
Held in Partnership with the Association for Research into Arterial
Structure and Physiology (ARTERY) and North American Artery
(NAA)
Co-Chairs:
4:30 PM
4:52 PM
5:14 PM
5:36 PM
John R. Cockcroft, MD, Cardiff, United Kingdom and
Stanley S. Franklin, MD, FASH, Los Angeles, CA
Chronic Obstructive Pulmonary Disease Arterial
Stiffness and Cardiovascular Disease
Vasculitides Arterial Stiffness and Cardiovascular
Disease
Ian B. Wilkinson, MD, Cambridge, United Kingdom
Is Vascular Aging Inevitable?
Edward G. Lakatta, MD, Baltimore, MD
Pulse Wave Analysis in Subjects with Chronic
Kidney Disease
Raymond R. Townsend, MD, Philadelphia, PA
46
Saturday Afternoon
May 21
Sessions
Young Investigator-in-Training Abstract
Competition
Moderator:
Judges:
4:30 PM
4:42 PM
4:54 PM
5:06 PM
5:18 PM
Addison A. Taylor, MD, PhD, FASH, Houston, TX
Stephen R. Daniels, MD, PhD, FASH, Aurora, CO,
Thomas D. Giles, MD, FASH, New Orleans, LA,
Lawrence R. Krakoff, MD, New York, NY,
Susanne B. Nicholas, MD, PhD, MPH, Los Angeles, CA,
and Myron H. Weinberger, MD, Indianapolis, IN
OR-1: Waist Hip Ratio vs Body Mass Index as
Predictors of Endothelial Dysfunction
Arantxa Rodriguez, Rosa Fabregate, Martin Fabregate,
Susana Tello, Angelica Fernandez, Asuncion Guerri,
Nuria De la Torre, Jose Saban‑Ruiz. Ramon y Cajal
Hospital, Madrid, ES.
OR-2: M-Atrial Natriuretic Peptide, a Novel AntiHypertensive Therapeutic Peptide, Is Markedly
Resistant to In Vitro Degradation
Paul M. McKie, Alessandro Cataliotti, Tomoko Ichiki,
S. Jeson Sangaralingham, Valentina Cannone, John C.
Burnett, Jr. Mayo Clinic, Rochester, MN, US.
OR-3: Outcomes with Atenolol or Other β-Blockers:
Network and Bayesian Meta-Analyses of Clinical
Trials in Hypertension
W. Kurtis Childers†,1 William J. Elliott,1 Sanjib Basu,2
Peter M. Meyer.2 1Pacific Northwest University of
Health Sciences, Yakima, WA, US; 2RUSH Medical
College, Chicago, IL, US.
OR-4: Role of Renal DJ-1 in the Regulation of
Oxidative Stress
Santiago Cuevas Gonzalez, Yanrong Zhang, Yu Yang,
Laureano D. Asico, Pedro A. Jose, Ines Armando.
Children’s National Medical Center, George
Washington University, Washington, DC, US.
OR-5: Adiposity, Metabolic and Dietary Risk Factors
Associated with Prehypertension in Black and White
Adolescent Males: A Cross-Sectional Study
Samip J. Parikh, Haidong Zhu, Norman K. Pollock,
Inger Stallmann-Jorgensen, Gutin Bernard, Yanbin
Dong. Medical College of Georgia, Augusta, GA, US.
47
May 21
Saturday Evening
Posters
Stroke.............................................................................(PO-117 – PO-119)
information.
48
Sunday Morning
May 22
Sessions
8:00 AM – 12:30 PM • West Ballroom • Third Floor
Hypertension for the Primary Care Clinician 2011
7:30 AM
Breakfast
8:00 AM to 9:00 AM
The Management of the Hypertensive Patient
Before and After Surgery
Co-Chairs:
8:00 AM
8:10 AM
8:35 AM
Jan N. Basile, MD, FASH, Charleston, SC and
F. Wilford Germino, MD, FASH, Orland Park, IL
Case Presentation
F. Wilford Germino, MD, FASH
Pre-operative Evaluation of the Patient with
Hypertension
James B. Froehlich, MD, MPH, Ann Arbor, MI
Peri-operative Management of the Hospitalized
Patient with Hypertension
9:00 AM to 10:00 AM
A Systems Approach to Optimize Blood Pressure
Control
Co-Chairs:
9:00 AM
9:20 AM
9:40 AM
10:00 AM
Paula T. Einhorn, MD, MS, Bethesda, MD and Gbenga
Ogedegbe, MD, MPH, MS, FASH, New York, NY
Exporting Lifestyle Modification into Your Practice
Laura P. Svetkey, MD, Durham, NC
Electronic Medical Records and the Hypertension
Initiative in the Carolinas
Brent M. Egan, MD, FASH, Charleston, SC
A Team Based Approach to Blood Pressure Control
Barry L. Carter, PharmD, Iowa City, IA
Break
10:15 AM to 11:15 AM
Evaluation of Resistant Hypertension
Co-Chairs:
10:15 AM
Louis Kuritzky, MD, Gainesville, FL and
Samuel J. Mann, MD, New York, NY
Out of Office Monitoring to Rule Out Resistant
Hypertension
Angela L. Brown, MD, St. Louis, MO
continued…
49
May 22
Sunday morning
Sessions continued
10:30 AM
10:55 AM
11:15 AM
Outpatient Evaluation for Secondary Causes of
Resistant Hypertension
Emmanuel Bravo, MD, Cleveland, OH
Treatment of Resistant Hypertension:
Tricks of the Trade
William J. Elliott, MD, PhD, FASH, Yakima, WA
Panel Discussion:
How Has the Management of Hypertension in
Primary Care Changed Since JNC 7?
Chair: Michael J. Bloch, MD, FASH, Reno, NV
George L. Bakris, MD, FASH, Chicago, IL,
Jan N. Basile, MD, FASH, Charleston, SC,
Angela L. Brown, MD, St. Louis, MO and
Leonard M. Fromer, MD, Los Angeles, CA
This Live activity, Hypertension for the Primary Care Clinician 2011,
has been reviewed and is acceptable for up to 4.25 Prescriptive credits by
the American Academy of Family Physicians. Physicians should claim
only the credit commensurate with the extent of their participation in
the activity.
50
Sunday Morning
May 22
Sessions
9:00 AM – 10:30 AM • Sutton North • Second Floor
The Role of Neurohumoral and Vasoactive
Substances in Hypertension
Held in Partnership with the International Pediatric Hypertension
Association (IPHA)
Co-Chairs: 9:00 AM
9:30 AM
10:00 AM
Donald L. Batisky, MD, Atlanta, GA and
Jay N. Cohn, MD, Minneapolis, MN
Effects of Endothelin Blockade on Blood Pressure:
Pro and Con
David M. Pollock, PhD, Augusta, GA
The Interplay of Race/Ethnicity, Inflammation
and Elevated Blood Pressure in Children and
Adolescents
Marc B. Lande, MD, MPH, Rochester, NY
Dopamine, the Kidney and Hypertension
Pedro A. Jose, MD, Washington, DC
51
May 22
Sunday Morning
Sessions
9:00 AM – 10:30 AM • Regent Parlor • Second Floor
Renin-Angiotensin System in Hypertension:
Regulation and Consequences
Held in Partnership with the Inter-American Society of Hypertension
(IASH)
Co-Chairs:
9:00 AM
9:22 AM
9:44 AM
10:06 AM
Haralambos Gavras, MD, Boston, MA and
L. Gabriel Navar, PhD, New Orleans, LA
Introduction: The Intratubular RAS in Hypertension
Role of the Transcription Factor ETS-1 as Mediator
of Angiotensin II Induced End-Organ Injury
Edgar A. Jaimes, MD, Birmingham, AL
Hypertension, Insulin Resistance and Oxidative
Stress
Leopoldo Raij, MD, FASH, Miami, FL
Therapeutic Efficacy of New Renin Inhibitors
Luis Juncos, MD, Córdoba, Argentina
52
Sunday Morning
May 22
Sessions
9:00 AM – 10:40 AM • Sutton Center • Second Floor
The 3rd American Society of Hypertension/China
Social Worker’s Association Vascular Protection
Committee Session on Early Vascular Disease
Detection and Management: Experience from China
Co-Chairs:
9:00 AM
9:20 AM
9:40 AM
10:00 AM
10:20 AM
Suzanne Oparil, MD, FASH, Birmingham, AL and
Hongyu Wang, MD, PhD, Beijing, China
Chinese Guidelines for Early Vascular Disease
Detection 2011: Experience from China Hongyu Wang, MD, PhD
Role of Cardiometabolic Syndrome and Related
Vascular Disease in Chinese Elderly
Ting Tao, MD, Shanghai, China
Epidemiology of Hypertension and Peripheral
Vascular Disease in China Jianfang Luo, MD, Guangzhou, China
Carotid IMT Examination for Atherosclerosis
Screening in Diabetes Yuan Guo, MD, MS, Beijing, China
Arterial Stiffness Parameters Integrated for Vascular
Health Evaluation in Hypertensive Patients
Tianhu Liu, MD, Chengdu, China
53
May 22
Sunday Morning
Sessions
9:00 AM – 10:30 AM • Sutton South • Second Floor
Overcoming Clinical Inertia: Changing Practice
Paradigms on Both Sides of the 49th Parallel
Held in Partnership with Hypertension Canada
Co-Chairs:
9:00 AM
9:10 AM
9:35 AM
10:00 AM
10:10 AM
10:20 AM
Ross Feldman, MD, London, Canada and
Alan H. Gradman, MD, FASH, Pittsburgh, PA
Introduction: Definitions and Scope of the Issue
Joel M. Neutel, MD, FASH, Tustin, CA
Clinic Focused Educational Interventions to
Improve Blood Pressure Control: Using the Heart
and Stroke Hypertension Clinic Model as the
Paradigm
Sheldon W. Tobe, MD, FASH, Toronto, Canada
Simplifying Treatment Algorithms as a Means of
Reducing Clinical Inertia
Ross Feldman, MD
US Approaches for Guidelines Implementation
William C. Cushman, MD, FASH, Memphis, TN
Implementation and Impact of the Canadian
Hypertension Education Program
Norman R.C. Campbell, MD, Calgary, Canada
54
Sunday Morning
May 22
Posters
Featured Posters
information.
55
May 22
Sunday Morning
Debates
11:00 AM – 12:00 PM
Sutton South • Second Floor
Debate: Is it Blood Pressure Variability or Average
Daily Blood Pressure that Best Predicts Stroke?
Moderator:
11:00 AM
11:20 AM
11:40 AM
11:55 AM
William B. White, MD, FASH, Farmington, CT
Blood Pressure Variability
Peter M. Rothwell, MD, Oxford, United Kingdom
Average Daily Blood Pressure
Eoin O’Brien, MD, Dublin, Ireland
Rebuttal
Regent Parlor • Second Floor
Debate: Surgical Intervention for Renal Artery
Stenosis is Indicated
Moderator:
11:00 AM
11:20 AM
11:40 AM
11:55 AM
Bryan Williams, MD, Leicester, United Kingdom
Yes: Thomas A. Sos, MD, New York, NY
No: Lance D. Dworkin, MD, Providence, RI
Rebuttal
56
Sunday Morning
May 22
Special Sessions
11:00 AM – 12:00 PM
Beekman Parlor • Second Floor
How to Write a 12 Page Grant
David Harder, MD, PhD, Milwaukee, WI
Sutton North • Second Floor
Understanding Statistics in Clinical Research
Richard H. Grimm, Jr., MD, PhD, Minneapolis, MN
Sutton Center • Second Floor
How to Develop an Abstract/Lecture
David G. Harrison, MD, Atlanta, GA
57
May 22
Sunday Afternoon
Plenary Session I
1:15 PM – 3:00 PM • East Ballroom • Third Floor
Plenary Session I
Co-Chairs:
1:15 PM
1:30 PM
2:00 PM
2:20 PM
2:40 PM
President’s Opening Address
Keynote Lecture: Blood Pressure in Obesity
F. Xavier Pi‑Sunyer, MD, MPH, New York, NY
Cardiovascular Risk and Risk Reduction in Children
and Adolescents
Rae‑Ellen W. Kavey, MD, MPH, Rochester, NY
Mechanisms from Studies of Human Obesity
Sadaf Farooqi, PhD, Cambridge, United Kingdom
Evaluation and Treatment of Hypertension in
Childhood
Joseph T. Flynn, MD, FASH, Seattle, WA
58
Sunday Afternoon
May 22
Sessions
3:30 PM – 5:15 PM • Mercury Ballroom • Third Floor
1 Aldosterone
J. Howard Pratt, MD, Indianapolis, IN and
Gordon H. Williams, MD, Boston, MA
3:30 PM
Non-Renal Effects of Aldosterone
James M. Luther, MD, Nashville, TN
3:50 PM
Interactions Between Aldosterone and
Nitric Oxide
Charles J. Lowenstein, MD, Rochester, NY
4:10 PM
Role of Aldosterone and Mineralocorticoid Receptor
Activation in Obesity Related Hypertension
John E. Hall, PhD, Jackson, MS
Original Communications
4:30 PM
OR-6: Spironolactone Reverses ChlorthalidoneInduced Sympathetic Activation in Hypertensive
Patients
Prafull Raheja, Debbie Arbique, Zhijun Wang, Wanpen
Vongpatanasin. UT Southwestern Medical Center,
Dallas, TX, US.
4:45 PM
OR-7: Plasma Aldosterone Levels Affect Calcium
Metabolism in Patients with Essential Hypertension
Gian Luca Colussi, Cristiana Catena, GianLuca Colussi,
Leonardo A. Sechi. University of Udine, Udine, IT.
5:00 PM
OR-8: Inappropriately Intense Salt Restriction,
Which Causes Elevation of Plasma Aldosterone
Level, Might Augment Myocardial Fibrosis in
Animal Model of Renal Tubular Injury
Tatsuhiko Mori,1 Kenichi Hasegawa,2 Hirohisa
Matsuda,1 Yasuo Matsumura,2 Nobukazu Ishizaka.1
1Osaka Medical College, Takatsuki, JP; 2Osaka
University of Pharmaceutical Sciences, Takatsuki, JP.
Co-Chairs:
59
May 22
Sunday Afternoon
Special Sessions
2 Hypertension in Patients with Chronic Kidney
Disease
Rajiv Agarwal, MD, Indianapolis, IN and
Aldo J. Peixoto, MD, FASH, West Haven, CT
3:30 PM
Clinical Epidemiology of Hypertension and Chronic
Kidney Disease
Rajiv Agarwal, MD
3:50 PM
Hypertension in Advanced Kidney Disease
Luis M. Ruilope, MD, Madrid, Spain
4:10 PM
Hypertension in Renal Transplant Patients
Martin S. Zand, MD, Rochester, NY
4:30 PM
OR-9: Administration-Time-Dependent Effects of
Angiotensin Receptor Blockers in Hypertensive
Patients with Chronic Kidney Disease
Ramon C. Hermida, Diana E. Ayala, Artemio Mojon,
Maria J. Fontao, Luisa Chayan, Jose R. Fernandez.
University of Vigo, Vigo, ES.
4:45 PM
OR-10: Carvedilol for the Treatment of Intradialytic
Hypertension: The Mechanisms and Treatment of
Intradialytic Hypertension (MATCH) Study
Jula K. Inrig, Peter Van Buren, Catherine Kim, Robert
Toto. UT Southwestern, Dallas, TX, US.
5:00 PM
OR-11: Cardiovascular Risk Assessment – Addition
of CKD and Race to the Framingham Equation
Paul E. Drawz,1,2 Sarah Baraniuk,3 Barry R. Davis,3
Mahboob Rahman.2,4 1MetroHealth Medical Center,
Cleveland, OH, US; 2Case Western Reserve University,
Cleveland, OH, US; 3University of Texas School of
Public Health, Houston, TX, US; 4University Hospitals
Case Medical Center, Cleveland, OH, US.
Co-Chairs:
60
Sunday Afternoon
May 22
Sessions
3:30 PM – 5:15 PM • West Ballroom • Third Floor
3 Comprehensive Multi-Level Interventions for
Hypertension Management in High-Risk Groups
Daniel Levy, MD, Framingham, MA and
Robert A. Phillips, MD, PhD, FASH, Worcester, MA
3:30 PM
Hypertension in Minorities: A New York State
Clinical Guidance Statement
Joseph L. Izzo, Jr., MD, FASH, Buffalo, NY
3:50 PM
Clinical Trial Interventions: Where Have We Gone
Right or Wrong?
4:10 PM
Integrated and Alternate Approaches to Treatment
William J. Elliott, MD, PhD, FASH, Yakima, WA
4:30 PM
OR-12: Influence of Inflammatory and
Prothrombotic Factors in Left Ventricular Structure
and Function in Essential Hypertensive Patients
Gregory Vyssoulis,1 Eva Karpanou,2 Stella Maria
Kyvelou,1 I. Barbetseas,1 C. Stefanadis.1 11st Cardiology
Clinic Athens University Hippokration Hospital, GR;
21st Cardiology Clinic Onassis Cardiosurgery Center,
GR.
4:45 PM
OR-13: The Kaiser Permanente Northern California
Hypertension Project 2001-2009: How an Integrated
Care Delivery System Increased Blood Pressure
Control Rates from 44% to 80% in 8 Years
Marc G. Jaffe, Joseph D. Young. The Permanente
Medical Group, Oakland, CA, US.
5:00 PM
OR-14: Intensive Blood Pressure Control Does Not
Increase Falls and Fractures in Patients with Type 2
Diabetes:The ACCORD Trial
Karen Margolis,1 Lisa Palermo,2 Eric Vittinghoff,2 Hal
Atkinson,3 Gregory Evans,3 Bruce Hamilton,4 Robert
Josse,5 Patrick O’Connor,1 Debra Simmons,6 Margaret
Tiktin,7 Ann Schwartz.2 1HealthPartners Research
Foundation, US; 2U of CA-SF, US; 3Wake Forest SOM,
US; 4Baltimore VAMC, US; 5University of Toronto,
CA; 6Central Arkansas Veterans Healthcare System,
US; 7Case Western Research University, US.
Co-Chairs:
61
May 22
Sunday Afternoon
Sessions
New Perspectives in ISHIB Consensus Statement:
Is Clinical Judgment Medically Appropriate?
Held in Partnership with the International Society on Hypertension
in Blacks (ISHIB)
Co-Chairs:
3:30 PM
3:45 PM
4:00 PM
4:20 PM
4:40 PM
Kenneth A. Jamerson, MD, FASH, Ann Arbor, MI and
Daniel T. Lackland, DrPH, FASH, Charleston, SC
Is There a Role for Opinion in Guidelines or
Consensus Reports? A Perspective
Keith C. Ferdinand, MD, FASH, Atlanta, GA
Highlights of the New Consensus Statement
Shawna D. Nesbitt, MD, MS, FASH, Dallas, TX
Debate
Supporting Perspective
John M. Flack MD, MPH, Detroit, MI
Opposing Perspective
William C. Cushman, MD, FASH, Memphis, TN
Rebuttal
62
Sunday Afternoon
May 22
Sessions
3:30 PM – 5:00 PM • Trianon Ballroom • Third Floor
Control of Hypertension is Leaving the Office:
The Role of Home Blood Pressure and Telemedicine
Co-Chairs:
3:30 PM
3:52 PM
4:14 PM
4:36 PM
Lawrence R. Krakoff, MD, New York, NY and
Home Blood Pressure and Cardiovascular Risk
Gianfranco Parati, MD, Milan, Italy
Using Home Blood Pressure in Clinical Practice
Gbenga Ogedegbe, MD, MPH, MS, FASH, New York,
NY
Home Blood Pressure and Telemetry to Improve
Hypertension Control
Richard J. McManus, MD, Birmingham, United
Kingdom
The Future of Telemedicine in the Management of
Hypertension
Supported by an educational grant from Omron Healthcare, Inc.
63
May 23
Monday morning
Satellite Symposium
6:00 AM – 7:30 AM • Trianon Ballroom • Third Floor
The Role of Beta-Blockers in Hypertension:
A Healthy Debate
Chairman: Jan N. Basile, MD, FASH, Charleston, SC
Learning Objectives:
• Describe the differences and similarities
among agents within the beta-blocker class of
antihypertensive agents
• Summarize the results of key clinical trials
investigating beta blockade in African American,
Hispanic, and Asian patient populations
• List reasons why beta-blockers should or should
not be used as first line or second step therapy for
hypertension
Program Agenda:
6:00 AM
Welcome
Overview of Program Learning Objectives
Audience Response System (ARS)
Jan N. Basile, MD, FASH, Chairman
6:05 AM
The Class Effect With Beta-Blockers: Does One Size
Fit All?
Addison A. Taylor, MD, PhD, FASH,
Houston, TX
6:25 AM
Beta-Blockers and Ethnicity: What Do We Really
Know?
Henry A. Punzi, MD, Dallas, TX
6:45 AM
Debate: Beta-Blockers Are Appropriate for First
Line or Second Step Therapy in Patients With
Hypertension
AGREE: William H. Frishman, MD,
Valhalla, NY
DISAGREE: Franz H. Messerli, MD, FASH,
New York, NY
7:15 AM
Faculty Panel Discussion With Questions From the
Audience
Jan N. Basile, MD, FASH, Moderator
Review of Program Learning Objectives and Closing
7:30 AM
Remarks
Jan N. Basile, MD, FASH, Moderator
A Breakfast will be held at 5:30 AM in the
Trianon Ballroom.
Supported by an educational grant from Forest Laboratories, Inc.
64
Monday Morning
May 23
Sessions
8:00 AM – 10:05 AM • Mercury Ballroom • Third Floor
1 Off-Target Cardiovascular Effects of NonCardiovascular Drugs
Franz H. Messerli, MD, FASH, New York, NY and
Suzanne Oparil, MD, FASH, Birmingham, AL
8:00 AM
Anti-VEGF and Other Chemotherapeutic Agents
Rhian M. Touyz, MD, PhD, Ottawa, Canada
8:20 AM
Non-Steroidal Anti-Inflammatory Drugs
Raymond C. Harris, MD, Nashville, TN
8:40 AM
PDE5 Inhibitors and Organic Nitrates
David J. Webb, MD, Edinburgh, United Kingdom
9:00 AM
PPAR Agents
Julio A. Panza, MD, Washington, DC
9:20 AM
OR-15: Effects on Ambulatory Blood Pressure of
Adding Low-Dose Aspirin at Bedtime in Subjects
with Treated Hypertension
Ramon C. Hermida, University of Vigo, Vigo, ES.
9:35 AM
OR-16: Cardio-Metabolic Effects of Acute and
Sub-Acute Exposures to Ambient Levels of Fine
Particulate Matter Air Pollution
Robert D. Brook,1 Robert L. Bard,1 J. Timothy
Dvonch,1 Masako Morishita,1 Niko Kaciroti,1 Sanjay
Rajagopalan.2 1University of Michigan, US; 2Ohio State
University, US.
9:50 AM
OR-17: Impact of Nonsteroidal Anti-Inflammatory
Drugs on Nocturnal Blood Pressure
W. B. White†,1 L. Lavange,2 A. Marquis.2 1University of
Connecticut School of Medicine, Farmington, CT, US;
2University of North Carolina at Chapel Hill, Chapel
Hill, NC, US.
Co-Chairs:
65
May 23
Monday morning
Sessions
8:00 AM – 10:00 AM • East Ballroom • Third Floor
2 New Insights into the Role of Uric Acid in
Hypertension
Co-Chairs: Richard J. Johnson, MD, Denver, CO and
Andrew Whelton, MD, Baltimore, MD
8:00 AM
Fructose-Obesity-Uric Acid Link
8:25 AM
Oxidative Stress and Impact of Uric Acid
Allan D. Struthers, MD, Dundee, United Kingdom
8:40 AM
Urate-Lowering and Blood Pressure Response
Daniel I. Feig, MD, PhD, Houston, TX
9:00 AM
OR-18: Associations of Uric Acid with Asymmetric
Dimethylarginine, L-arginine and Arterial Stiffening
in Hypertension
K. Dimitriadis, C. Tsioufis, A. Aggelis, S. Kyvelou,
E. Stefanadi, L. Lioni, D. Flessas, C. Stefanadis.
Hippokration Hospital, Athens, GR.
9:15 AM
OR-19: Epoxyeicosatrienoic Acid Agonist Attenuates
Adipogenesis Derived from Mesenchymal Stem Cells
Via Heme Oxygenase-PPARg Pathways
DongHyun Kim,1 Luca Vanella,1 Nitin Puri,1 Michal L.
Schwartzman,2 John R. Falck,3 Komal Sodhi,1 Nader G.
Abraham.1 1University of Toledo College of Medicine,
Toledo, OH, US; 2New York Medical College, Valhalla,
NY, US; 3University of Texas Southwestern Medical
Center, Dallas, TX, US.
9:30 AM
OR-20: Effect of Allopurinol on Blood Pressure:
A Systematic Review
Vikram Agarwal,1 Nidhi Hans,2 Franz Messerli.1 1St.
Luke’s-Roosevelt Hospital Center, NY, US; 2Harvard
School of Public Health, MA, US.
66
Monday Morning
May 23
Sessions
8:00 AM – 10:00 AM • West Ballroom • Third Floor
3 Devices and Surgical Ablation for Refractory
Hypertension
Domenic A. Sica, MD, Richmond, VA and
Ronald G. Victor, MD, Los Angeles, CA
8:00 AM
How to Evaluate and Choose the Appropriate
Patient?
Henry Krum, MBBS, PhD, Melbourne, Australia
8:20 AM
Renal Nerve Ablation
Roland E. Schmieder, MD, Erlangen, Germany
8:40 AM
Carotid Baroreceptor Manipulation
9:00 AM
OR-21: True Resistant Hypertension: Optimal CutOff Ambulatory Blood Pressure Level for Diagnosis
and Effect of Spironolactone
Jose A. Garcia‑Donaire, Julian Segura, Cesar Cerezo,
Luis M. Ruilope. Hospital 12 de Octubre, Madrid, ES.
9:15 AM
OR-22: Individualized Programming Demonstrates
Feasibility of Unilateral Approach to Delivery of
Baroreflex Activation Therapy®
Domenic Sica†,1 John Bisognano,2 Mitra Nadim,3 Luis
Sanchez,4 George Bakris.5 1Virginia Commonwealth
University, Richmond, VA, US; 2University of
Rochester, Rochester, NY, US; 3University of Southern
California, Los Angeles, CA, US; 4Washington
University, St. Louis, MO, US; 5University of Chicago,
Chicago, IL, US.
9:30 AM
OR-23: The Efficacy of Adding the Direct Renin
Inhibitor Aliskiren on the Patients with Resistant
Hypertension (55% Had Chronic Kidney Disease)
– Subgroup Analysis on Different Levels of Plasma
Renin Activity
Fumitoshi Satoh, Ryo Morimoto, Masataka Kudo,
Yoshitugu Iwakura, Yoshikiyo Ono, Sadayoshi Ito.
Tohoku University Hospital, Sendai, JP
9:45 AM
OR-24: Exploring the Prevalence of Resistant
Hypertension in a Large Ethnically Diverse
Hypertensive Population
Simran Bhandari, In Lu Liu, Jiaxiao Shi, Federico
Calara, Scott Rasgon, John Sim. Kaiser Permanente
Los Angeles Medical Center, Los Angeles, CA, US.
Co-Chairs:
67
May 23
Monday morning
Sessions
8:30 AM – 10:00 AM • Trianon Rendezvous • Third Floor
The Kidney Early Evaluation Program (KEEP):
A New Longitudinal Dimension for a New Decade
Held in Partnership with the National Kidney Foundation (NKF)
Co-Chairs:
8:30 AM
8:52 AM
9:14 AM
9:36 AM
Joseph A. Vassalotti, MD, New York, NY
KEEP: CKD Screening Program Overview
KEEP: Longitudinal Preliminary Results
KEEP: Experience with the CKD-EPI Equation
Lesley A. Stevens, MD, MS Boston, MA
Where Do We Stand on Blood Pressure Control
in KEEP?
Adam Whaley‑Connell, DO, FASH, Columbia, MO
68
Monday Morning
Afternoon
May 23
21
Posters
Featured Posters
Neural Hormonal Mechanisms (Renin; Neural Control; Vasoactive
Autacoids).....................................................................(PO-310 – PO-312)
Obesity...........................................................................(PO-331 – PO-339)
Pregnancy......................................................................(PO-359 – PO-361)
information.
69
May 23
Monday morning
Sessions
10:05 AM – 11:35 AM • Trianon Ballroom • Third Floor
Hyperkalemia Management in High Risk Patients:
New Evidence-Based Approaches
Co-Chairs:
10:05 AM
10:35 AM
11:05 AM
Murray Epstein, MD, Miami, FL and
Luis M. Ruilope, MD, Madrid, Spain
The Spectrum of Cardiovascular Risk Associated
with Potassium Abnormalities
Domenic A. Sica, MD, Richmond, VA
Use of RAAS Inhibitors for Cardio-Renal Risk
Reduction and Potassium Management
Luis M. Ruilope, MD
Conventional versus Novel Approaches to the
Management of Hyperkalemia
David A. Bushinsky, MD, Rochester, NY
Supported by an educational grant from Relypsa, Inc.
70
Monday Morning
May 23
Debate
11:45 AM – 12:15 PM • Trianon Ballroom • Third Floor
Debate: Are Elevated Potassium Levels Really a
Concern?
Moderator:
11:35 AM
11:45 AM
11:55 AM
Barry J. Materson, MD, MBA, FASH, Miami, FL
Yes: Vasilios Papademetriou, MD, FASH,
Washington, DC
No: Bertram Pitt, MD, Ann Arbor, MI
Rebuttal
71
May 23
Monday morning
Sessions
10:30 AM – 12:00 PM • Mercury Ballroom • Third Floor
1 Immune Mechanisms in Hypertension
Co-Chairs:
10:30 AM
10:52 AM
11:14 AM
11:36 AM
Michael W. Brands, PhD, Augusta, GA and
The Role of Inflammatory Cytokines in PregnancyInduced Hypertension
Babbette LaMarca, PhD, Jackson, MS
T-Regulatory Cells in Hypertension
Ernesto L. Schiffrin, MD, PhD, Montreal, Canada
Novel Mechanisms of Renal Injury in Hypertension
David L. Mattson, PhD, Milwaukee, WI
Adaptive Immune Response in Hypertension
72
Monday Morning
May 23
Sessions
10:30 AM – 12:00 PM • East Ballroom • Third Floor
2 Management of Elevated Blood Pressure in the
Hospital Setting
Co-Chairs:
10:30 AM
10:52 AM
11:14 AM
11:36 AM
William J. Elliott, MD, PhD, FASH, Yakima, WA and
Sandra J. Taler, MD, FASH, Rochester, MN
Hypertension in the Emergency Department
C. Venkata S. Ram, MD, FASH, Dallas, TX
Hypertension in the Inpatient Unit
Alan B. Weder, MD, Ann Arbor, MI
Hypertension in the Peri-operative Period
Daniel Duprez, MD, PhD, FASH, Minneapolis, MN
Hypertension in the Dialysis Unit
Aldo J. Peixoto, MD, FASH, West Haven, CT
73
May 23
Monday morning
Sessions
10:30 AM – 12:00 PM • West Ballroom • Third Floor
3 Management of Hypertension in Diabetics and
Chronic Kidney Disease
Co-Chairs:
10:30 AM
10:52 AM
11:14 AM
11:36 AM
James R. Sowers, MD, FASH, Columbia, MO and
Is There an Optimal Blood Pressure Goal in the
Patient with Type-2 Diabetes?
Matthew R. Weir, MD, FASH, Baltimore, MD
Prevention of Renal Disease in the Hypertensive,
Type-2 Diabetic
Robert D. Toto, MD, Dallas, TX
Prevention of Renal Disease in the AfricanAmerican Patient with Hypertension
Velvie A. Pogue, MD, New York, NY
Management of Metabolic Co-Morbidities in the
Hypertensive Patient
Mark E. Molitch, MD, Chicago, IL
74
Monday Morning
May 23
Sessions
10:30 AM – 12:00 PM • Trianon Rendezvous • Third Floor
Blood Pressure Variability and Treatment Goals
Held in Partnership with the European Society of Hypertension
(ESH)
Co-Chairs:
10:30 AM
10:52 AM
11:14 AM
11:36 AM
Krzysztof Narkiewicz, MD, PhD, Gdánsk, Poland
Short and Long-Term Blood Pressure Variability
Giuseppe Mancia, MD, Milan, Italy
J-Curve Revisited
Athanasios J. Manolis, MD, PhD, Athens, Greece
Target Blood Pressure in Nephropatic Patients
Ambulatory and Home Blood Pressure Targets
75
May 23
Monday Afternoon
Plenary Session II
Award Presentations
Co-Chairs:
Norman K. Hollenberg, MD, PhD, Boston, MA
1:30 PM
Robert Tigerstedt Award Lecture
Acetyl-Ser-Asp-Lys-Pro, an Endogenous
Tetrapeptide: Role in Target Organ Damage in
Hypertension, and Autoimmune Myocarditis
Oscar A. Carretero, MD, FASH, Detroit, MI
2:00 PM
Young Scholar Award Lecture*
Novel Mechanisms Linking Chronic Inflammation
and Hypertension in Systemic Lupus Erythematosus
Michael J. Ryan, PhD, Jackson, MS
2:20 PM
Young Scholar Award Lecture*
State Rescued with Innovative BNP Based
Technologies
Alessandro Cataliotti, MD, PhD, Rochester, MN
2:40 PM
Marvin Moser Clinical Award Lecture
Water Immersion: A Model of Volume Expansion for Assessing Renin-Aldosterone Responsiveness
and Renal Sodium Handling in Humans
Murray Epstein, MD, Miami, FL
State-of-the-Art Lectures
Co-Chairs:
3:00 PM
3:30 PM
Leukocyte Telomere Length Genetics and
Cardiovascular Disease
Abraham Aviv, MD, Newark, NJ
Development of Cardiac Hypertrophy
Joseph A. Hill, MD, PhD, Dallas, TX
76
Monday Afternoon
May 23
Debates
4:30 PM – 5:00 PM
Beekman Parlor • Second Floor
Debate: The Dominant Contributor to Systemic
Hypertension is
Moderator:
4:30 PM
4:40 PM
4:50 PM
Murray Epstein, MD, Miami, FL
Sympathetic Nervous System not the RAAS
Murray D. Esler, MBBS, PhD, Melbourne, Australia
Activation of the Intrarenal RAAS not the SNS
L. Gabriel Navar, PhD, New Orleans, LA
Rebuttal
Sutton North • Second Floor
Debate: Hypertension is a Disorder of the Kidney
Moderator:
4:30 PM
4:40 PM
4:50 PM
Jens Titze, MD, Erlangen, Germany
Yes: Joey P. Granger, PhD, Jackson, MS
No: Allyn L. Mark, MD, Iowa City, IA
Rebuttal
77
May 24
Tuesday MORNING
Sessions
8:15 AM – 9:30 AM • West Ballroom • Third Floor
Late-Breaking Clinical Trials
Co-Chairs:
8:15 AM
8:30 AM
8:45 AM
9:00 AM
LB-OR-01: Evaluation of Cardiovascular Effects in
Three Double-Blind, Placebo-Controlled Clinical
Trials with Controlled-Release Phentermine/
Topiramate
Suzanne Oparil†,1 Wesley Day,2 Charles Bowden.2
1University of Alabama, Birmingham, AL, US; 2Vivus,
Mountain View, CA, US.
LB-OR-02: Longterm (3 – 5 Months) Spaceflight
Promotes a Sustained Decrease in Blood Pressure
and Systemic Vascular Resistance in Astronauts
Peter Norsk,1 Ali Asmar,1 Niels Juel Christensen.2
1University of Copenhagen, Copenhagen, DK; 2Herlev
University Hospital, Herlev, DK.
LB-OR-03: Azilsartan Medoxomil Plus
Chlorthalidone Reduces BP More Effectively
Than Olmesartan Plus HCTZ in Stage 2 Systolic
Hypertension
William C. Cushman†,1 George Bakris,2 William B.
White,3 Michael Weber,4 Domenic Sica,5 Andrew
Roberts,6 Eric Lloyd,6 Stuart Kupfer.6 1University of
TN College of Medicine, US; 2U of Chicago Pritzker
School of Medicine, US; 3U of CT School of Medicine,
US; 4New York, NY, US; 5VA Commonwealth U Health
System, US; 6Takeda Global Research & Development,
US.
LB-OR-04: Common Blood Pressure Genetic
Variants and Their Relations to Hypertension,
Target-Organ Damage, and Cardiovascular Disease
Risk: The International Collaboration for Blood
Pressure Genome-Wide Association Studies (ICBP)
Georg Ehret,1 Patricia Munroe,4 Christopher NewtonCheh,5 Kenneth Rice,3 Cornelia van Duin,6 Aravinda
Chakravarti,1 Daniel Levy,2 Mark Caulfield,4 Toby
Johnson.4 1Johns Hopkins, Baltimore, MD, US;
2NHLBI, Framingham, MA, US; 3University of
Washington, Seattle, WA, US; 4London School of
Medicine, London, GB; 5Broad Institute, Cambridge,
MA, US; 6The Rotterdam Study, Rotterdam, NL.
continued…
78
Tuesday Morning
May 24
Sessions continued
9:15 AM
LB-OR-05: Sixteen Novel Loci Influence Blood
Pressure in Diverse Populations
Georg B. Ehret,1 Patricia B. Munroe,2 Kenneth M.
Rice,3 Murielle Bochud,4 Andrew D. Johnson,5
Daniel I. Chasman,6 Albert V. Smith,7 Bruce M.
Pstay,3 Goncalo R. Abecasis,8 Aravinda Chakravarti,1
Paul Elliott,9 Cornelia M. van Duijn,10 Christopher
Newton Cheh,11 Daniel Levy,5 Mark J. Caulfield,2
Toby Johnson.2 1Johns Hopkins University School of
Medicine, US; 2Queen Mary University of London,
GB; 3University of Washington, Seattle, US; 4University
of Lausanne, CH; 5National Heart Lung, and Blood
Institute, Bethesda, US; 6Brigham and Women’s
Hospital, Boston, US; 7University of Iceland, Reykajvik,
IS; 8University of Michigan School of Public Health,
Ann Arbor, US; 9Imperial College, GB; 10Erasmus
Medical Center, NL; 11Massachusetts General Hospital,
US.
79
May 24
Tuesday MORNING
Sessions
10:00 AM – 11:30 AM • Sutton North • Second Floor
1 Salt-Sensitive Mechanisms of Hypertension
Co-Chairs:
10:00 AM
10:30 AM
11:00 AM
Allyn L. Mark, MD, Iowa City, IA and
Jens Titze, MD, Erlangen, Germany
Renal Sodium Handling, Endothelin, and
Genetic Models
Donald E. Kohan, MD, PhD, Salt Lake City, UT
Significance of Non-Osmotic Sodium
Jens Titze, MD
Nitric Oxide, Superoxide and Renal Sodium
Handling
Jeffrey L. Garvin, PhD, Detroit, MI
80
Tuesday Morning
May 24
Sessions
10:00 AM – 11:30 AM • Sutton Center • Second Floor
2 Integrated Cardiovascular Disease Guidelines
and Implementation
Co-Chairs:
10:00 AM
10:30 AM
11:00 AM
Henry R. Black, MD, FASH, New York, NY and
Sidney Smith, Jr., MD, Chapel Hill, NC
Rationale for the NHLBI Integrated Cardiovascular
Risk Reduction Guidelines
Sidney Smith, Jr., MD
Implementation of the Integrated Cardiovascular
Risk Reduction Guidelines
John Merenich, MD, Denver, CO
Results of the Integrated Cardiovascular Risk
Reduction Guidelines Implementation in Northern
California
Alan S. Go, MD, Oakland, CA
81
May 24
Tuesday MORNING
Sessions
10:00 AM – 11:30 AM • Beekman Parlor • Second Floor
3 Nutrition and Cardiovascular Prevention
Co-Chairs:
10:00 AM
10:30 AM
11:00 AM
Lawrence J. Appel, MD, MPH, FASH, Baltimore, MD
and David S. Kountz, MD, Neptune, NJ
High Fructose Corn Syrup, Sucrose and Fructose:
What Do We Really Know?
James Rippe, MD, Shrewsbury, MA
Cations and Blood Pressure Control
Lawrence J. Appel, MD, MPH, FASH
Low Protein and Renal Protection
Robert D. Toto, MD, Dallas, TX
82
Hypertension Awareness Campaign for Your Patients
ARE YOU 1 IN 3?
GET THE FACTS. KNOW YOUR RISKS.
Help spread the word by visiting 1in3people.com.
As per the American Heart Association, 1 in 3 US adults has high blood pressure.1
1. Roger VL, Go AS, Lloyd-Jones DM, et al; for the American Heart Association Statistics Committee and Stroke
Statistics Subcommittee. Heart disease and stroke statistics—2011 update: a report from the American
Heart Association. Circulation. 2011;123;e18-e209.
© 2011 Novartis
Printed in USA
4/11
CVF-1058015
Printed on Recycled Paper
2011
American Society
of Hypertension
Program
Posters
May 21
Saturday Afternoon
Posters
Stroke.............................................................................(PO-117 – PO-119)
information.
86
Saturday Afternoon
May 21
Posters
4:30 PM – 7:30 PM • Second Floor Promenade
Adolescent hypertension and obesity
PO-1:
PO-2:
PO-3:
PO-5:
Common Carotid Artery Intima-Media Thickness
in Patients with Abdominal Obesity and Essential
Hypertension
Evgeny V. Shlyakhto,1 Olga D. Belyaeva,2 Olga O.
Bolshakova,1 Aelita V. Berezina,2 Olga O. Berkovich,2
Elena I. Baranova.2 1Almazov Federal Heart, Blood
and Endocrinology Centre, Saint-Petersburg, RU;
2Saint-Petersburg State Medical University, SaintPetersburg, RU.
Prevalence of Hypertension in Pediatric Oncology
Survivors
Kathy K. Y. Lee‑Son,1 Sheila L. Pritchard,2 Douglas
G. Matsell,1 Josephine X. Chow,1 Janis M. Dionne.1
1BC Children’s Hospital, Vancouver, BC, CA; 2BC
Children’s Hospital, Vancouver, BC, CA.
Blood Pressure Variability in White Coat
Hypertensive Adolescents
Egle R. Silva, Jose J. Villasmil, Greily A. Bermudez,
Mayela J. Bracho, Carlos E. Esis, Gustavo E. Calmon,
Alicex C. Gonzalez. Instituto de Enfermedades
Cardiovasculares, Universidad del Zulia, Maracaibo,
VE.
Pharmacologic Management of Primary
Hypertension in Adolescents
Esther Yoon, Lisa Cohn, Albert Rocchini, David
Kershaw, Gary Freed, Frank Ascione, Sarah Clark.
University of Michigan, US.
Antiatherosclerotic Drugs
PO-6:
PO-7:
Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A
Reductase Inhibitors on Blood Pressure
Vikram V. Agarwal, Alexandros Briasoulis, Franz H.
Messerli. St. Luke’s-Roosevelt Hospital, Columbia
University College of Physicians and Surgeons, New
York, NY, US.
Statin Effect on the Blood Pressure in Young and
Elderly Adults: Meta-Analysis
Camila Hartmann, Manuela S. Baldo, Talita R.
Strano, Tariane F. Foiato, Emilton Lima, Jr.. Pontifícia
Universidade Católica do Paraná, Curitiba, PR, BR.
Cardiac Structure and Function/Imaging
PO-8:
Effect of Telmisartan on Paroxymal Atrial
Fibrillation in Hypertensive Patients with Different
Left Atrial Size
Roberto Fogari, Amedeo Mugellini, Annalisa Zoppi,
Gianluigi Marasi, Pierangelo Lazzari. University of
Pavia, Pavia, IT.
87
May 21
Saturday Afternoon
Posters
PO-9:
PO-10:
Effect of Aliskiren on QT Dispersion in Diabetic and
Non Diabetic Hypertensive Patients
Roberto Fogari, Amedeo Mugellini, Annalisa Zoppi,
Gianluigi Marasi, Pierangelo Lazzari. University of
Pavia, IT.
Impact of Antihypertensive Therapy on
Dyssynchrony in Patients with Never-Treated
Hypertension
Beom‑June Kwon, Sung‑Won Jang, Kyu‑Young Choi,
Dong‑Bin Kim, Eun‑Joo Cho, Ho‑Joong Youn, Tae‑Ho
Rho, Jae‑Hyung Kim. The Catholic University of
Korea, Seoul, KR.
Comprehensive multi-level interventions
for hypertension management in highrisk groups
PO-11:
PO-12:
PO-13:
PO-14:
PO-15:
Refractory Hypertension Characterized by
Heightened Sympathetic Tone
Maria Czarina Acelajado,1 Roberto Pisoni,2 Tanja
Dudenbostel,3 Suzanne Oparil,3 David A. Calhoun.3
1Philippine General Hospital, Manila, PH; 2Medical
University of South Carolina, Charleston, SC, US;
3University of Alabama at Birmingham, Birmingham,
AL, US.
Prehypertension has Increased Peripheral Resistance
in Patients with Obesity
Ricardo M. Cabrera Sole,1 Caridad Turpin Lucas,1 Erik
Luepke,2 Santiago Garcia Ruiz,1 Santos J. Martinez.1
1University General Hospital of Albacete, Albacete, ES;
2University General Hospital “La Paz”, Madrid, ES.
Some Fixed Combinations are Better Reducing
Central Blood Pressure and Hypertensive Time than
Others
Ricardo M. Cabrera Sole,1 Caridad Turpin Lucas,1
Santiago Garcia Ruiz,1 Ana Galdamez Nuñez,2 Erik
Luepke,3 Manuel Aguilera Saldaña.1 1University
General Hospital of Albacete, Albacete, ES; 2Health
Center of Villacerrada, Albacete, ES; 3University
General Hospital “La Paz”, Madrid, ES.
Prevalence of Orthostatic Hypotension among Very
Elderly Persons with Hypertension
Elaine Ku,1 Yee Lu,1 Edward Schneider,1 Rick Smith,2
Vito M. Campese.1 1USC/Keck School of Medicine, Los
Angeles, CA, US; 2Los Angeles Jewish Home for the
Aging, Reseda, CA, US.
Effects of Renal Stenting on Renal and Cardiac
Outcomes in Patients with Resistant Hypertension
Cristiana Catena, GianLuca Colussi, Frine Capobianco,
Stefania Fedrizzi, Leonardo A. Sechi. University of
Udine, Udine, IT.
88
Saturday Afternoon
May 21
Posters
PO-16:
PO-17:
PO-18:
PO-19:
PO-20:
PO-21:
PO-22:
Evaluation of a Treatment Algorithm Using
Combination Therapy for the Management
of Patients with Hypertension and
Hypercholesterolemia (STITCH2)
G. K. Dresser†, S. A. E. Nelson, J. L. Mahon, G. Y. Zou,
M. K. Vandervoort, C. J. Wong, B. G. Feagan, R. D.
Feldman. Robarts Research Institute, London, CA.
Sex Differences Impact the Hemodynamics of
Untreated Essential Hypertensive Subjects
Carlos M. Ferrario,1,2 Ronald D. Smith.1 1Consortium
Southeastern Hypertension Control, Winston Salem,
NC, US; 2Wake Forest University School of Medicine,
Winston Salem, NC, US.
Improving Global Vascular Risk Management Using
the COSEHC™ Cardiovascular Risk Assessment Tool
Carlos M. Ferrario†,1,2 Michael A. Moore,1 Debra
Simmons,1,2 Chris Colby,3 Alex Exuzides,3 Sumeet
Panjabi.4 1Consortium for Southeastern Hypertension
Control, Winston Salem, NC, US; 2Wake Forest
University School of Medicine, Winston Salem, NC,
US; 3ICON Clinical Research, San Francisco, CA, US;
4Daiichi Sankyo, Inc., Parsippany, NJ, US.
A COSEHC Sponsored Quality Improvement
Initiative Enriches Chronic Disease Practice and
Performance of North Carolina Diabetic Patients
Mazen Hamad,1 Brian Forrest,2 Michael Moore,2
Debra Simmons,2 JaNae Joyner.2 1Cary Healthcare
Associates, Cary, NC, US; 2The Consortium for
Southeastern Hypertension Control (COSEHC),
Winston Salem, NC, US.
Cardiovascular Care Disparities in a South Carolina
Primary Care Site Participating in the COSEHC
Customized Model of Intervention and Care
(COSMIC) Project
JaNae Joyner,1 Brian Forrest,1 Kristina Yu‑Isenberg,2
Debra Simmons,1 Daniel Lackland.1 1The Consortium
for Southeastern Hypertension Control (COSEHC),
Winston Salem, NC, US; 2Novartis Pharmaceuticals
Corporation, US.
Adherence to Comprehensive Interventions for
Management of Uncontrolled Hypertension
Tessa J. Kerby, Stephen E. Asche, Michael V. Maciosek,
JoAnn M. SperlHillen, Simrandeep K. Tiawana,
Patrick J. O’Connor, Karen L. Margolis. HealthPartners
Research Foundation, Minneapolis, MN, US.
Blood Pressure Control in Spanish Speaking
Patients with Type II Diabetes Mellitus Using a
Group Visit Model
Mateo Levine Ledezma, Marie F. Martinez, Scott A.
Rasgon. Kaiser Permanente, Los Angeles, CA, US.
89
May 21
Saturday Afternoon
Posters
PO-23:
PO-25:
PO-26:
PO-27:
PO-28:
PO-29:
PO-30:
A Multi-Level Intervention to Control Hypertension
in African Americans
Gbenga Ogedegbe,1 Jonathan Tobin,2 Joseph Schwartz,3
Thomas Pickering.3 1NYU School of Medicine, NY,
NY, US; 2Clinical Directors Network, NY, NY, US;
3Columbia University, NY, NY, US.
Physical Characteristics of Salt in the Treatment and
Prevention of Hypertension
Maithri Reddy,1 Podduturu S. Reddy,2 Sushma Reddy.1
1Endocrinology & Diabetes Center, Fort Gratiot, MI,
US; 2St.Clair Pulmonary & Critical Care, Port Huron,
MI, US.
Relation between Cardiovascular Risk Score,
Asymptomatic Peripheral Disease and Left
Ventricular Hypertrophy
Juan José Tamarit‑García,1 Belén Roig‑Espert,2 Vicente
Navarro‑Ibáñez.2 1Dr. Peset Universitary Hospital,
Valencia, ES; 2Manises Hospital, Manises, Valencia, ES.
A Computer-Mediated Intervention and DASH Diet,
WHEELS-I Program, Sustains Improved Blood
Pressure over 8 Weeks in Women from Diverse
Ethnic Backgrounds
Margaret Scisney‑Matlock,1 Susan Steigerwalt,2
Kenneth Jamerson,1 Stephanie Lucas,3 Susan Pressler,1
Amanda Sen,1 Elizabeth Brough.1 1University of
Michigan, Ann Arbor, MI, US; 2St. John Health
System, Detroit, MI, US; 3Center Preventative
Medicine, St Clair Shores, MI, US.
Relationships between Aggressive Systolic BP Goals,
Nocturnal BP Dipping, and Carotid Atherosclerosis
in Type 2 Diabetes: The SANDS Study
Angela Silverman,3 Mihriye Mete,3 Jerome L. Fleg,2
Marie Russell,1 Robert E. Ratner,3 Mary J. Roman,4
Mario Stylianou,2 Jason G. Umans,3 Matthew R.
Weir,5 Barbara V. Howard.3 1Phoenix Indian Medical
Center, US; 2National Heart, Lung, and Blood Institute,
US; 3MedStar Health Research Institute, US; 4Weill
Medical College of Cornell University, US; 5University
of Maryland School of Medicine, US.
Improved Hypertension Control Rates through a
Multidisciplinary Regional Approach
Ann M. Wells, Stephanie C. Schneider, Jennifer Bajaj,
Susan Schreiner, Beverly Kroner. Kaiser Permanente
Colorado, Denver, CO, US.
Clinical Pharmacist-Physician Team Approach in
Treating Resistant Hypertension Cases
Sandra A. Yoo, Joel Handler, Alec V. Does. Kaiser
Permanente, Anaheim, CA, US.
90
Saturday Afternoon
May 21
Posters
Endothelial Function
PO-31:
PO-32:
PO-33:
PO-34:
PO-35:
PO-37:
PO-38:
PO-39:
A Novel ANP-Like Peptide, ANP1-28RR, Revealed
by a Single Nucleotide Polymorphism of the ANP
Gene, rs5065 Codes for a Peptide with Increased
Permeability Properties In Vitro
Valentina Cannone, Brenda K. Huntley, Guido
Boerrigter, Alessandro Cataliotti, Denise M. Heublein,
John C. Burnett. Mayo Clinic, Rochester, MN, US.
Exaggerated Exercise Blood Pressure Response
is Associated with Arterial Stiffness, Asymmetric
Dimethylarginine and Osteoprotegerin in Essential
Hypertension
K. Dimitriadis, C. Tsioufis, A. Aggelis, A. Michaelides,
S. Aslam, C. Wilcox, V. Papademetriou, C. Stefanadis.
Endothelial Impact of Blood Pressure above the
Goals in Hypertensive Patients
Jose Saban‑Ruiz, Martin Fabregate, Rosa Fabregate,
Olivia Sanchez, Susana Tello, Angelica Fernandez,
Nuria De la Torre, Arantxa Rodriguez. Ramon y Cajal
Plasma Sodium but Not Sodium to Potassium Ratio
Could be a Simple and Low-Cost Technique to
Predict Vascular Inflammation. Correlation with
Resistin Levels
Martin Fabregate, Rosa Fabregate, Nuria De la Torre,
Cristina Martinez, Arantxa Rodriguez, Ana Alonso,
Carlos Moreno, Jose Saban‑Ruiz. Ramon y Cajal
Time for Action. Correlation between Plasma Renin
Activity and Biomarkers. A Mandatory Study as
Result of a Recent Heart Outcomes Prevention
Evaluation Analysis
Jose Saban‑Ruiz, Martin Fabregate, Rosa Fabregate,
Elena Tutor, Elena Castresana, Nuria De la Torre,
Juanjo Villafruela, Susana Tello, Arantxa Rodriguez.
Ramon y Cajal Hospital, Madrid, ES.
Variability of Flow Mediated Dilation Technique: A
Multicentre Italian Study
Francesco Faita, Lorenzo Ghiadoni, Vincenzo
Gemignani, Elisabetta Bianchini, Almerina Biggi,
Giuseppe Ambrosio, Gaetano A. Lanza, Maria Lorenza
Muiesan, Francesco Cosentino, Stefano Taddei.
Working Group on Endothelium of the Italian Society
of Hypertension, IT.
Endothelial Dysfunction in Hypertensive Patients
with Metabolic Syndrome
Olga Gonzalez‑Albarran, Sara Calvo, Marta Carrasco,
Marta Cano, Berniza Calderon, Ana Maria Matei.
Hospital Ramón y Cajal, Madrid, ES.
Normative Brachial Artery Diameter Dilatation
Following Reactive Hyperemia
Martha A. Kaeser, Daniel W. Haun, Norman W.
Kettner. Logan College of Chiropractic, Chesterfield,
MO, US.
91
May 21
Saturday Afternoon
Posters
PO-40:
PO-41:
PO-42:
PO-43:
PO-44:
PO-45:
Severity of Obstructive Sleep Apnea and
Atherosclerosis: Multiple Associations in the Setting
of Hypertension
A. Kasiakogias, C. Tsioufis, C. Thomopoulos, I.
Andrikou, M. Almiroudi, I. Mpafakis, K. Kintis, C.
Stefanadis. Hippokration Hospital, Athens, GR.
Modulation of Vascular Function and Oxidative
Stress in Type II Diabetes Mellitus: Effects of AlphaLipoic Acid
Bobby V. Khan†,1 Tahir Haque,1 Desikan Rajagopal,1
Nadya Merchant,1 Barry Connell,2 Tarek M. Saleh.2
1Atlanta Vascular Research Foundation, Atlanta,
GA, US; 2University of Prince Edward Island,
Charlottetown, PE, CA.
Atherogenic Index of the Plasma as Marker of
Oxidative Stress and Endothelial Dysfunction
Rosa Fabregate, Arantxa Rodriguez, Martin Fabregate,
Elena Marin, Andres Reyes, Cristina Martinez, Susana
Tello, Nuria De la Torre, Jose Saban‑Ruiz. Ramon y
Cajal Hospital, Madrid, ES.
The Effect of Angiotensin Converting Enzyme
Inhibitors and Angiotensin-II Receptor Antagonists
on the Endothelial Dysfunction in Patients
with Chronic Pulmonary Heart with Arterial
Hypertension
Nestor M. Seredyuk, Igor P. Vakalyuk, Vitaliy N.
Seredyuk, Sergiy V. Fedorov. Ivano-Frankivsk National
Medical University, Ivano-Frankivsk, UA.
Associations of Renal Flow Reserve with Endothelial
Dysfunction in Essential Hypertensives
C. Tsioufis, D. Tsiachris, I. Tatsis, K. Dimitriadis, D.
Syrseloudis, I. Kallikazaros, V. Papademetriou, C.
Increased Endothelin-1 Vasoconstrictor Tone with
Prehypertension
Brian R. Weil,1 Michael L. Mestek,1 Jared J. Greiner,1
Brian L. Stauffer,2 Christopher A. DeSouza.1
1University of Colorado at Boulder, Boulder, CO,
US; 2University of Colorado Denver and the Health
Sciences Center, Aurora, CO, US.
Epidemiology/Special Populations
PO-46:
Management of Hypertensive Patients in France
as a Function of Gender and Cardiovascular Risk:
PARITE Study
Simon Tabassome,1 Claire Mounier‑Vehier,2
Dominique Guedj,3 Assya Achouba,4 Emmanuel
Ghannad,5 Stéphane Quéré,4 Maxime Guenoun.6
1CHU Saint-Antoine, Paris, FR; 2Cardiologic Hospital,
Lille, FR; 3Cardiologist, Paris, FR; 4Novartis Pharma
SAS, Paris, FR; 5Cardiologist, Gif sur Yvette, FR;
6Cardiologist, Marseille, FR.
92
Saturday Afternoon
May 21
Posters
PO-47:
PO-48:
PO-49:
PO-50:
PO-51:
PO-52:
PO-53:
PO-54:
The Relationship of Resistant Hypertension and
Treatment Outcomes with Total Compliance and
Brain Natriuretic Peptide in an African American
Hypertensive Cohort
Omid Bakhtar, Brian A. Ference, Phillip D. Levy,
Samar A. Nasser, Lowell Hedquist, John M. Flack.
Division of Translational Research and Clinical
Epidemiology, Wayne State University, Detroit Medical
Center, Detroit, MI, US.
Which Ambulatory Blood Pressure Monitoring
Parameters Predict Mortality in Elderly Subjects?
Iddo Z. Ben‑Dov,1 Michael Bursztyn.2 1The Rockefeller
University, New York, NY, US; 2Hadassah – Hebrew
University Medical Center, Jerusalem, IL.
Birth Weight, Stimulus Response and Hemodynamic
Variability Implicates Ethnic Contrasts of
Autonomic Control of Heart Rate and Blood
Pressure and an Effect on CV Disease
Wei Chen, Pronabesh DasMahapatra, Camilo
Fernandez, Gerald S. Berenson. Tulane University
Health Sciences Center, New Orleans, LA, US.
Changes in Levels of Serum Cholesterol and
Development of Hypertension in the Brisighella
Heart Study
Claudio Borghi, Ada Dormi, Sergio d’Addato, Arrigo
Cicero, Luca Laghi, Eugenio Roberto Cosentino,
Maddalena Veronesi. St. Orsola-Malpighi Hospital,
Bologna, IT.
Alcohol Consumption and the Risk of Hypertension:
A Systematic Review and Meta-Analysis
Alex Briasoulis, Vikram Agarwal, Manpreet S.
Sabharwal, George Syros, Girish N. Nadkarni, Franz
H. Messerli. St. Luke’s-Roosevelt Hospital Center,
Columbia University College of Physicians and
Surgeons, New York, NY, US.
Trends in Albuminuria under RAS Suppression and
Relationship with Cardiovascular Disease
Cesar Cerezo,1 Julian Segura,1 Jose R. Banegas,2 Juan
J. de la Cruz,2 Ton J. Rabelink,3 Luis M. Ruilope.1
1Hospital 12 de Octubre, Madrid, ES; 2Universidad
Autónoma, Madrid, ES; 3Leiden University Medical
Center, Leiden, NL.
Large Change in the Opinon on Antihypertensive
Drug Treatment among General Practioners in
Sweden between 2002 and 2009
John K. F. Dahlström, Mats Persson, Bo Carlberg,
Lars‑Hjalmar Lindholm. Family Medicine, Umeå, SE.
Novel Method for Assessing the Prevalence of
Hypertension and Cardiovascular Disease Risk in
a Community Screening Program in a South East
Region of US
Mahfouz El Shahawy,1 Miglena Entcheva,1 Susan
Gaida,1 Joshua Grant.2 1Sarasota Memorial Hospital,
Sarasota, FL, US; 2Lake Erie College of Osteopathic
Medicine, US.
93
May 21
Saturday Afternoon
Posters
PO-55:
PO-56:
PO-57:
PO-58:
PO-59:
PO-60:
PO-61:
Pre-Hypertension: Is it a Disease?
Mahfouz El Shahawy,1 Miglena Entcheva,1 Susan
Gaida,1 Joshua Grant.2 1Sarasota Memorial Hospital,
Sarasota, FL, US; 2Lake Erie College of Osteopathic
Medicine, US.
Exercise Capacity Predicts Progression from PreHypertension to Hypertension in African American
Men
Charles Faselis,1,2 Raya Kheirbek,1 Michael Doumas,1,2
Ross Fletcher,1 Vasilios Papademetriou,1,3 Peter
Kokkinos.1,2,3 1Veterans Affairs Medical Center,
Washington, DC, US; 2George Washington University,
Washington, DC, US; 3Georgetown University,
Washington, DC, US.
Biracial (Black-White) Divergence and Correlates
of Augmentation Index among Younger Adults: The
Bogalusa Heart Study
Camilo Fernandez, Pronabesh DasMahapatra, Wei
Chen, Sathanur R. Srinivasan, Gerald S. Berenson.
Tulane University Health Sciences Center, New
Orleans, LA, US.
Use of Electronic Health Records to Evaluate
Hypertension Pharmacoepidemiology in a Primary
Care Practice Network
Christopher Hebert†, Rustam Kudyakov, Yahya Daoud,
Dunlei Cheng, Andrew Masica. Baylor Health Care
System, Dallas, TX, US.
Cardiovascular Risk Factors Prevalence in Greek
Hypertensives Stratified by Gender and Age
Gregory Vyssoulis,1 Eva Karpanou,2 Stella Maria
Kyvelou,1 M. Liakos,1 C. Stefanadis.1 11st Cardiology
Clinic Athens University Hippokration Hospital, GR;
21st Cardiology Clinic Onassis Cardiosurgery Center,
GR.
ABO and Rhesus Blood Groups and Cardiovascular
Risk in Essential Hypertensive Patients
Stella Maria Kyvelou,1 Gregory Vyssoulis,1 Eva
Karpanou,2 T. Gialernios,1 C. Stefanadis.1 11st
Cardology Clinic Athens University Hippokration
Hospital, GR; 21st Cardiology Clinic Onassis
Cardiosurgery Center, GR.
Efficacy, Safety and Tolerability of Valsartan/
Hydrochlorothiazide Single Pill Combination in
Asian Patients with Essential Hypertension: An
Observational Study
Wen‑Ter Lai†,1 Jeong‑Euy Park,2 Neelesh Dongre,3
Jackson Wang.3 1Kaohsiung Medical University
Hospital, Kaohsiung, TW; 2Samsung Medical Center,
Irwon-dong, Gangnam-gu, Seoul, KR; 3Novartis
Pharma AG, Basel, CH.
94
Saturday Afternoon
May 21
Posters
PO-62:
PO-63:
PO-64:
PO-65:
PO-66:
PO-67:
PO-68:
PO-69:
PO-70:
Trends in Serum Lipids, Hypertension, Physician
Advice and Compliance among ReproductiveAged Women: United States National Health and
Nutrition Examination Survey 1999-2008
Tabassum H. Laz, Mahbubur Rahman, Abbey B.
Berenson. University of Texas Medical Branch,
Galveston, TX, US.
Excessive Blood Pressure Elevation during Exercise
Correlates with Low Fitness among Normotensive
Firefighters
Adi Leiba,1,2 Dorothee M. Baur,1,3 Stefanos N. Kales.1,3
1Harvard School of Public Health, Boston, MA, US;
2Sheba Medical Center, Tel Hashomer, IL; 3Cambridge
Health Alliance, Cambridge, MA, US.
Smoking and Hypertension: Do They Follow the
Same Trend?
Aurelio Leone. City Hospital, Massa, Ms, IT.
Arterial Hypertension and Liver Cirrhosis: The
Experience of a Single Liver Unit
Simona Leoni, Serena Flori, Barbara Stagni, Ilaria
Serio, Luigi Bolondi. Malpighi Hospital, Division of
Internal Medicine Prof. Bolondi, Bologna, IT.
Blood Pressure Control and Age: The Experience of
a Single Centre
Serena Flori, Simona Leoni, Barbara Stagni, Ilaria
Serio, Luigi Bolondi. Malpighi Hospital, Division of
Internal Medicine, Bologna, IT.
The Effect of Coffee on Blood Pressure and
Cardiovascular Disease among Hypertensive
Individuals: Meta-Analysis
Arthur E. Mesas, Luz Leon‑Muñoz, Fernando
Rodriguez‑Artalejo, Esther Lopez‑Garcia. Autonoma
University of Madrid, Madrid, ES.
Mechanisms Underlying Increased Aortic BP in
Black Versus White Young Adults: The ENIGMA
Study
Carmel M. McEniery,1 Andrew T. Garrett,2 Nigel
Baber,2 John R. Cockcroft,3 Ian B. Wilkinson.1
1University of Cambridge, Cambridge, GB; 2University
of Hertfordshire, GB; 3Cardiff University, GB.
Diabetes Type 2 and Other Cardiovascular Risk
Factors in an Adult Mediterranean Population
Javier Nieto,1 Patricio Giralt,2 Maria Jose Ballesteros,1
G. Gutierrez,3 Carmen Mora,1 Agustin Carreño.1
1Hospital General, Ciudad Real, ES; 2Fundacion
Sociosanitaria, Ciudad Real, Castilla La Mancha, ES;
3Consejería de Salud, Toledo, ES.
Serum Uric Acid is an Independent Risk Factor for
Cardiovascular Diseases Mortality in Hypertensive
Patients
Mitsuru Ohishi, Yasushi Takeya, Miyuki Onishi, Yuji
Tatara, Kei Kamide, Hiromi Rakugi. Osaka University,
Suita, Osaka, JP.
95
May 21
Saturday Afternoon
Posters
PO-71:
PO-72:
PO-73:
PO-74:
PO-75:
PO-76:
PO-77:
Blood Pressure Control and All Cause Mortality in
Old and Very Old Patients with Hypertension
Vasilios Papademetriou, Richard Amdur, Charles
Faselis, Michael Doumas, Costas Tsioufis, Peter
Kokkinos, Ross D. Fletcher. Veterans Administration
and Georgetown University Medical Centers
Washington DC, Washington, DC, US.
Ambulatory Blood Pressure Monitoring Profile in
Untreated African Blacks and Causasians Untreated
Hypertensive Patients Matched for Age and Gender
Albertino Damasceno,1 C. Mavimbe,1 Loide Barbosa,2
Jose A. Silva,2 Domingos Diogo,1 T. Madede,1 Jorge
Polonia.2 1Universidade Eduardo Mondlane, Maputo,
MZ; 2Hospital Pedro Hispano, Matosinhos, PT.
Regional Differences in Hypertensive
Cardiovascular Remodeling between Fishing and
Farming Communities in Japan
Koji Sakata,1 Yuichiro Yano,2 Takuro Imamura,1 Kazuo
Kitamura,1 Kazuomi Kario.2 1University of Miyazaki,
JP; 2Jichi Medical University School of Medicine, JP.
Relevance of Atrial Fibrillation in a Large Cohort of
Hypertensive Patients
Julian Segura,1 Vanesa Moñivas,1,2 Jose A. GarciaDonaire,1 Cesar Cerezo,1 Luis M. Ruilope.1 1Hospital
12 de Octubre, Madrid, ES; 2Hospital Puerta de Hierro,
Madrid, ES.
Periodontal Disease Severity and Albumin Excretion
in Hypertensive Patients: A Positive Association
Beyond Systemic Inflammation
C. Tsioufis, A. Kasiakogias, C. Thomopoulos, N.
Soldatos, A. Kordalis, M. Almiroudi, K. Kintis, C.
Efficacy of Amlodipine/Olmesartan Medoxomil with
or without Hydrochlorothiazide in Elderly Patients
Uncontrolled by Monotherapy
Matthew R. Weir†,1 Henry A. Punzi,2 Ali Shojaee,3
William F. Waverczak,3 Jen‑Fue Maa.3 1University
of Maryland School of Medicine, US; 2Trinity
Hypertension & Metabolic Research Institute, US;
3Daiichi Sankyo, Inc., US.
Blood Pressure Therapy and Risk of CVD:
Framingham Heart Study Experience
Peter W. F. Wilson†,1 Michael Pencina,2 Ralph B.
D’Agostino,2 Asya Lyass,2 R. S. Vasan,2 Philip A. Wolf,2
Daniel Levy.3 1Emory University, Atlanta, GA, US;
2Boston University, Boston, MA, US; 3Framingham
Heart Study, Framingham, MA, US.
96
Saturday Afternoon
May 21
Posters
Immune mechanisms in hypertension
PO-79:
PO-80:
PO-81:
PO-82:
Renal Specific Silencing of Dopamine D2 Receptors
in Mice Increases Blood Pressure and ProInflammatory Factors
Ines Armando, Santiago Cuevas, Yanrong Zhang,
Laureano Asico, Crisanto Escano, Pedro A. Jose.
Children’s National Medical Center, Washington, DC,
US.
Macrophages Regulate Pressor Responses to
Endothelin-1
E. L. Owen, N. Dhaun, M. Bailey, D. J. Webb, D. C.
Kluth. University of Edinburgh, GB.
BMI Influences the Association of an IL-6
Polymorphism on Increased Insulin Resistance in a
Hypertensive Population
P. Underwood,1 B. Chamarthi,1 J. Williams,1 B. Sun,1
P. Hopkins,2 G. Adler,1 G. Williams.1 1Brigham and
Women’s Hospital, US; 2University of Utah, US.
Correlation between Endothelial Dysfunction and
Inflammatory Markers at the Chronic Heart Failure
with Arterial Hypertension
Roman I. Yatsyshyn, Natalya G. Yatsyshyn. Medical
University, Ivano-Frankivsk, UA.
Metabolic Syndrome (Diabetes/Glycemic
Control; Dysglycemic Drugs; Insulin
Resistance)
PO-83:
PO-84:
PO-85:
Screening for Diabetes in a Developing Country
Olutayo Christopher Alebiosu,1 Olawale Ogunsemi,2
Olatunde Odusan,2 Oluranti Familoni.2 1College of
Health Sciences, Osun State University, Osogbo, Osun,
NG; 2Olabisi Onabanjo University, Sagamu Campus,
Ogun State, NG.
Metabolic Profile and Framingham Heart Scores
among Hypertensives in Turkey from 2003 to 2007
Mustafa Arici,1 Ulver Derici,2 Cetin Turgan,1 Yunus
Erdem,1 Sukru Sindel,2 Bulent Altun,1 Bulent Erbay,3
Oktay Karatan,3 Enver Hasanoglu,2 Sali Caglar.4
1Hacettepe University Faculty of Medicine, Ankara,
TR; 2Gazi University Faculty of Medicine, Ankara, TR;
3Ankara University Faculty of Medicine, Ankara, TR;
4Turkish Society of Hypertension and Renal Diseases,
Ankara, TR.
Gender-Independent Elevation of Fasting Glucose
with the Progressive Decrease in Sleep-Time
Relative Blood Pressure Decline: The Hygia Project
Diana E. Ayala,1 Juan J. Crespo,2 Ana Moya,3 Pedro A.
Callejas,2 Peregrina Eiroa,2 Alfonso Otero,4 Artemio
Mojon,1 Jose R. Fernandez,1 Ramon C. Hermida,1
Investigadores Proyecto Hygia.1 1University of Vigo,
Vigo, ES; 2Gerencia de Atención Primaria, Vigo, ES;
3Gerencia de Atención Primaria, Pontevedra, ES;
4Complejo Hospitalario Universitario, Orense, ES.
97
May 21
Saturday Afternoon
Posters
PO-86:
PO-87:
PO-88:
PO-89:
PO-90:
PO-91:
PO-92:
First-Line Aliskiren/HCTZ Lowers BP in Older
Patients with Stage 2 Hypertension and Metabolic
Syndrome or Diabetes
Jan Basile†,1 Simon Babazadeh,2 Michael Lillestol,3
Thomas Severin,4 Cheraz Cherif Papst,4 Richard
Weitzman.5 1Ralph H Johnson VA Medical Center,
Medical University of South Carolina, Charleston,
SC, US; 2Crest Clinical Trials Inc, Santa Ana, CA, US;
3Lillestol Research LLC, Fargo, ND, US; 4Novartis
Pharma AG, Basel, CH; 5Novartis Pharmaceuticals
Corporation, East Hanover, NJ, US.
Effects of Time of Day of Hypertension Treatment
on the Ambulatory Blood Pressure Pattern of
Patients with Diabetes: The Hygia Project
Juan J. Crespo,1 Manuel Dominguez‑Sardiña,1
Maria T. Rios,1 Ana Moya,2 Sonia M. Gomara,2 Luis
Meijide,2 Artemio Mojon,3 Diana E. Ayala,3 Ramon C.
Hermida,3 Investigadores Proyecto Hygia.3 1Gerencia
de Atención Primaria, Vigo, ES; 2Gerencia de Atención
Primaria, Pontevedra, ES; 3University of Vigo, Vigo,
ES.
Overweight and High Blood Pressure as the
Cardiometabolic Risk Factors Most Frequently
Related to Nonalcoholic Fatty Liver Disease
Susana Tello, Angelica Fernandez, Asuncion Guerri,
Rosa Fabregate, Martin Fabregate, Jose Campoy, Arturo
Ugalde, Jose Saban‑Ruiz. Ramon y Cajal Hospital,
Madrid, ES.
Myeloperoxidase, Leptin and Retinol Binding
Protein 4, as Biomarkers of Osteopenia and
Atherosclerosis, Two Sister-Diseases
Rosa Fabregate, Olivia Sanchez, Elena Marin, Andres
Reyes, Cristina Martinez, Susana Tello, Martin
Fabregate, Arantxa Rodriguez, Jose Saban‑Ruiz.
Unlike Sex, HDL-Cholesterol, Body Mass Index,
Homocysteine and Smoking, Blood Pressure is Not a
Determinant Factor of Plasma Leptin Levels
Martin Fabregate, Olivia Sanchez, Rosa Fabregate, Olga
Fernandez, Jose Manuel Del Rey, Susana Tello, Nuria
De la Torre, Elena Tutor, Ana Alonso, Jose Saban‑Ruiz.
Salt Sensitive Type 2 Diabetics Have Greater
Metabolic Improvements on a Paleolithic-Type Diet
Compared to an ADA Diet
Lynda A. Frassetto, Olga Schmidlin, Anthony
Sebastian, Umesh Masharani. UCSF, San Francisco,
CA, US.
Impact of Gender in Cardiovascular Control in
Hypertensive Patients with Metabolic Syndrome.
OPENMET Survey
Olga Gonzalez,1 Alberto Galgo,2 Carlos Alvarez.3
1Hospital Ramón y Cajal, Madrid, ES; 2Primary Care
Center, Madrid, ES; 3Pfizer Laboratory, Madrid, ES.
98
Saturday Afternoon
May 21
Posters
PO-93:
PO-94:
PO-95:
PO-96:
PO-97:
PO-98:
PO-99:
Microalbuminuria in Women with Prior Gestational
Diabetes
Olga Gonzalez Albarran, Marta Carrasco, Marta Cano,
Berniza Calderón, Ana Maria Matei. Hospital Ramón y
Cajal, Madrid, ES.
Elevation of Blood Suger Changes Glomerular and
Tubular Function in Normotesive Subjects
Shigeo Kakinoki,1 Tetsuya Fujimoto,2 Maiko Machida,2
Shigeru Takechi,3 Kouichi Kanda,4 Takeshi Kobayashi,5
Akikazu Nomura.2 1Otaru kyoukai Hospital, Otaru,
Hokkaido, JP; 2Hokkaido College of Pharmacy,
Otaru, Hokkaido, JP; 3Date Red Cross Hospital, Date,
Hokkaido, JP; 4Sapporo Kosei General Hospital,
Sapporo, Hokkaido, JP; 5Hokkaido Social Insurance
Health Care and Research Center, Sapporo, Hokkaido,
JP.
Effects of Simvastatin and Rosiglitazone
Combination in Patients with the Metabolic
Syndrome (The SIROCO Study)
Ivana Lazich†, Pantelis A. Sarafidis, Raymond Oliva,
Basil Burney, George Bakris. University of Chicago
Pritzker School of Medicine, Chicago, IL, US.
Pulse Wave Analysis in Type 2 Diabetic Hypertensive
Patients
Ari L. Lieber,1 Michel E. Safar,1 Julie Peroz,1 Gerard
Slama,1 Bernard I. Levy,2 Jacques Blacher.1 1Hotel-Dieu
Hospital, Paris, FR; 2Hopital Lariboisiere, Paris, FR.
Circadian Blood Pressure Pattern and Prevalence
of Nocturnal Hypertension in Subjects with and
without Type 2 Diabetes: The Hygia Project
Maria C. Castiñeira,1 Ana Moya,2 Jesus Perez de Lis,3
Lorenzo Pousa,3 Jose L. Salgado,3 Susana Hernaiz,3
Artemio Mojon,4 Jose R. Fernandez,4 Ramon C.
Hermida,4 Investigadores Proyecto Hygia.4 1Gerencia
de Atención Primaria, Lugo, ES; 2Gerencia de Atención
Primaria, Pontevedra, ES; 3Gerencia de Atención
Primaria, Vigo, ES; 4University of Vigo, Vigo, ES.
Influence of Sleep-Time Blood Pressure for the
Proper Identification of Isolated Office and Masked
Hypertension among Patients with Type 2 Diabetes:
The Hygia Project
Ana Moya,1 Elvira Sineiro,1 Maria C. Castiñeira,2
Sonia M. Gomara,1 Artemio Mojon,3 Maria J. Fontao,3
Sonia Lorenzo,3 Diana E. Ayala,3 Ramon C. Hermida,3
Investigadores Proyecto Hygia.3 1Gerencia de Atención
Primaria, Pontevedra, ES; 2Gerencia de Atención
Primaria, Lugo, ES; 3University of Vigo, Vigo, ES.
Suboptimal Control of Arterial Hypertension in
Patients with Type 2 Diabetes Mellitus
Maria Sarigianni, Eleni Mpekiari, Apostolos Tsapas,
Konstantinos Paletas. Medical School, Aristotle
University of Thessaloniki, Thessaloniki, GR.
99
May 21
Saturday Afternoon
Posters
PO-100:
PO-101:
PO-102:
Prevalence of Metabolic Syndrome According to
Different Definitions in a Mediterranean Cohort of
Hypertensives
John A. Papadakis,1 Eirini Lioudaki,1,2 George E.
Vrentzos,1 Helen Mavrogeni,1 Maria‑Helen Zeniodi,1
Emmanuel S. Ganotakis,1 Dimitri P. Mikhailidis.2
1University Hospital of Heraklion, Heraklion, GR;
2Royal Free Hospital campus, University College
London (UCL) Medical School, London, GB.
Telmisartan Prophylactic Treatment Induces TissueSpecific Gene Modulation Favoring Normal Glucose
Homeostasis in CRDH Rats
Firas Younis,1 Yoram Oron,1 Rona Limor,2 Naftali
Stern,2 Talma Rosenthal.1 1Tel Aviv Univeristy, Tel Aviv,
Ramat Aviv, IL; 2Tel Aviv-Sourasky Medical Center, Tel
Aviv, IL.
Hyperuricemia and the Pathogenesis of
Hypertension and Insulin Resistance in Murine
Model of the Metabolic Syndrome
William Baldwin,1 Steven McRae,1 George Marek,1
David Wymer,1 Varinderpal Pannu,1 Chris Baylis,2
Richard J. Johnson,1,2 Yuri Y. Sautin.1 1University of
Florida, Gainesville, FL, US; 2University of Florida,
Gainesville, FL, US; 3University of Colorado, Denver,
CO, US.
New insights into the role of uric acid in
hypertension
PO-103:
PO-104:
Relation of Uric Acid with Blood Pressure and
Health Related Quality of Life One Year Post
Myocardial Infarction
Antonios Ioannidis, Dimitrios Tsounis. Hellenic Open
University, GR.
Hypertension in Hyperuricemic Gout Subjects
Receiving Febuxostat or Allopurinol
Andrew Whelton†,1,2 Patricia MacDonald,3 Barbara
Hunt,3 Lhanoo Gunawardhana.3 1Universal Clinical
Research Center, Inc, Hunt Valley, MD, US; 2Johns
Hopkins University School of Medicine, Baltimore,
MD, US; 3Takeda Global Research & Development
Center, Inc, Deerfield, IL, US.
Pediatric Hypertension
PO-105:
Systolic and Diastolic Blood Pressures among Sickle
Cell Patients
Guillermo A. De Angulo,1 Robert J. Adams,1 Yim
Eunsil,1 Janet L. Kwiatkowski,2 Ana C. Xavier,1 Ellen
Debenham,1 Jessica A. Peterson,1 Daniel T. Lackland.1
1Medical University of South Carolina, Charleston,
SC, US; 2The Children’s Hospital of Philadelphia,
Philadelphia, PA, US.
100
Saturday Afternoon
May 21
Posters
PO-106:
PO-107:
PO-108:
PO-109:
PO-110:
PO-111:
Antihypertensive Drug Use in Children: Are the
Drugs Labeled and Indicated?
Joseph Flynn†,1 W. Pete Welch,2 Wenya Yang,2 Drew
Braucht,2 Perdita Taylor‑Zapata,3 Anne Zajicek.3
1Seattle Children’s Hospital, Seattle, WA, US; 2The
Lewin Group, Inc., Falls Church, VA, US; 3Eunice
Kennedy Shriver National Institute of Child Health
and Human Development, Bethesda, MD, US.
Clinical and Demographic Characteristics of
Children with Hypertension: New Multicenter Data
Joseph Flynn†,1 Ying Zhang,2 Susan Solar‑Yohay,2
Victor Shi.2 1Seattle Children’s Hospital, Seattle, WA,
US; 2Novartis Pharma AG, East Hanover, NJ, US.
Cardiovascular Risk Factors in Obese Children and
Adolescents
Isabel Torro,1,2 Julio Alvarez,1,2 Francisco Aguilar,1,2
Jose Alcon,1,2 Empar Lurbe.1,2 1Hospital General
Universitario, University of Valencia, Valencia, ES;
2Health Institute Carlos III, Madrid, ES.
Left Ventricular Geometry in Children with Primary
Hypertension: Prevalence and Predictors
Cozumel S. Pruette,1 Barbara A. Fivush,1 Joseph T.
Flynn,2 Tammy M. Brady.1 1Johns Hopkins University,
Baltimore, MD, US; 2Seattle Children’s Hospital,
Seattle, WA, US.
Serum Uric Acid in U.S. Adolescents: Distribution
and Relationship to Demographic Characteristics
and Cardiovascular Risk Factors
Ibrahim F. Shatat,1 Rany T. Abdallah,2 David J. Sas,1
Susan M. Hailpern.3 1Medical University of South
Carolina Children’s Hospital, Charleston, SC, US;
2Medical University of South Carolina, Charleston, SC,
US; 3Independent Consultant, Katonah, NY, US.
Clinic and Ambulatory Blood Pressure
Measurements and Patterns in Asymptomatic
Children with Sickle Cell Disease
Ibrahim F. Shatat,1 Ram V. Kalpatthi,2 Amanda E.
Blue,1 Katelyn Graeme,1 Mary A. Johnson,1 John K.
Orak,1 Sharron M. Jackson.1 1Medical University of
South Carolina Children’s Hospital, Charleston, SC,
US; 2Children’s Mercy Hospital, Kansas City, MO, US.
Risk Factors (Lipids)
PO-112:
Evaluating the Effects of Hypercholesterolemia
on Vascular Risk Profile of Treated Hypertensive
Patients. Results of a Cross-Sectional National Study
Pedro Aranda, Manuel Gorostidi, Julian Segura,
Alex de la Sierra, Jose Juan de la Cruz, Jose
Carlos Fernandez, Luis Maria Ruilope. Cardiorisk
Investigators Group, Madrid, ES.
101
May 21
Saturday Afternoon
Posters
PO-113:
PO-114:
PO-115:
Negative Influence of Hypercholesterolemia on
Blood Pressure Control. Results of a Spanish
National Survey with ABPM
Pedro Aranda, Jose Carlos Fernandez, Manuel
Gorostidi, Julian Segura, Alejandro de la Sierra, Jose
Juan de la Cruz, Luis Maria Ruilope. Cardiorisk
Investigators Group, Madrid, ES.
Association of Weight Misperception with Abnormal
Lipid Levels and Hypertension among Overweight
and Obese Reproductive-Age Women
Mahbubur Rahman, Tabassum H. Laz, Abbey B.
Berenson. University of Texas Medical Branch,
Galveston, TX, US.
Influence of Metabolic Syndrome Components in
Atherosclerotic Disease and Intima Media Thickness
of Carotid Artery Assessed by Gray Scale Method
Priscilla Lopes Sarmento, Frida Liane Plavnik, Sérgio
Aron Ajzen. Federal University of Sao Paulo, Sao
Paulo, SP, BR.
Stroke
PO-117:
PO-118:
PO-119:
Hypertension and Other Co-Morbid Conditions are
Not Determinants of Treatment in Acute Ischemic
Stroke
Jordan A. Magarik, Robert J. Adams, Christine A.
Holmstedt, Edward C. Jauch, Andrea D. Boan, Aquilla
S. Turk, Daniel T. Lackland. Medical University of
South Carolina, Charleston, SC, US.
Profile of Incidental Thyroid Nodules in 2996
Patients Undergoing Carotid Ultrasound
Saxena Naveen,1 Srivastava Vinita,1 William Bridges,2
Ricardo Abaunza,1 Chanda Craft,1 Nomita Joshi,1
Govind Rughani.1 1Internal Medicine and Cardiology
Center, Greenville, SC, US; 2Clemson University,
Clemson, SC, US.
Additional Impact of Morning Haemostatic Factors
and Blood Pressure Surgeon Stroke in Older
Japanese Hypertensives
Yuichiro Yano, Satoshi Hoshide, Kazuyuki Shimada,
Kazuomi Kario. Jichi Medical University School of
Medicine, Tochigi, JP.
Vascular Injury/Inflammation and
Remodeling
PO-120:
Non-Dipping Status is Accompanied by
Hypoadiponectinemia and Increased Aortic
Stiffness in Essential Hypertension
I. Andrikou, C. Tsioufis, D. Syrseloudis, A. Kordalis,
M. Almiroudi, I. Mpafakis, K. Kintis, T. Papaioannou,
D. Aragiannis, C. Stefanadis. Hippokration Hospital,
Athens, GR.
102
Saturday Afternoon
May 21
Posters
PO-121:
PO-122:
PO-123:
Association of Retinal Microvascular Caliber with
Blood Pressure Levels
Raz Gibstein,1 Yosi Rosman,2 Ehud Rechtman,1 Nira
Koren‑Morag,2 Yehonatan Sharabi,2 Shlomo Segev,2
Ehud Assia,1 Ehud Grossman.2 1Meir Hospital, IL; 2The
Chaim Sheba Medical Center, Tel Hashomer, Affiliated
to Sackler School of Medicine, IL.
Inhibiting the Renin-Angiotensin System with
Aliskiren and/or Valsartan Protects Against
C-Reactive Protein Mediated Vascular Injury
Response
Fadi G. Hage†, Caleb Pierce, Wei Zhang, Dongqi
Xing, Yiu‑Fai Chen, Mark A. McCrory, Suzanne
Oparil, Alexander J. Szalai. University of Alabama at
Birmingham, Birmingham, AL, US.
High Osteopontin N-Terminal/C-Terminal
Fragment Ratio is Associated with Carotid Plaque
Inflammation
Talya Wolak,1 Netta Sion‑Vrdy,1 George Grennberg,1
Gabriel Szendro,1 Assaf Rudich,2 Ori Nov,2 Victor
Novack,1 Esther Paran.1 1Soroka University Medical
Center, Bear Sheva, IL; 2Faculty of Health Sciences,
Ben-Gurion University of the Negev Israel, Bear Sheva,
IL.
103
May 22
Sunday Morning
Posters
Featured Posters
information.
104
Sunday Morning
May 22
Posters
10:00 AM – 6:30 PM • Second Floor Promenade
Featured Posters – Blood Pressure
Measurement/Monitoring
Moderators: Suzanne Oparil, MD, Birmingham, AL and
Talma Rosenthal, MD, Tel Aviv, Israel
FP-1:
Ambulatory Blood Pressure Monitoring and
Cardiovascular Events in High-Risk Patients
Alejandro de la Sierra†,1 Julian Segura,2 Jose R.
Banegas,2 Manuel Gorostidi,2 Felipe Madruga,2 Xavier
Clar,2 Teresa Gijon,2 Luis M. Ruilope.2 1Hospital
Mutua Terrassa, Terrassa, ES; 2Spanish Society of
Hypertension, Madrid, ES.
FP-2:
A Perfect Replacement for the Mercury
Sphygmomanometer: The Case of the Hybrid Blood
Pressure Monitor
George S. Stergiou, Nikos Karpettas, Anastasios Kollias,
Antonis Destounis, Dimitris Tzamouranis. University
of Athens, Athens, GR.
Improvement in Blood Pressure Control among
FP-3:
Hypertensive Patients Treated in the Department of
Veterans Affairs
Ross D. Fletcher, Vasilios Papademetriou, Richard
Amdur, Chris McManus, Ronald Jones, Charles
Faselis. Veterans Affairs and Georgetown University,
Washington, DC, US.
Clinical Characteristics of Patients with
FP-4:
Uncontrolled and Apparent Treatment Resistant
Hypertension: NHANES 1988-2008
Brent Egan,1 Yumin Zhao,1 R. Neal Axon,1 R. Neal
Axon,2 Keith Ferdinand.3 1Medical University of
S.C., Charleston, SC, US; 2Ralph H. Johnson, VAMC,
Charleston, SC, US; 3Emory University, Atlanta, GA,
US.
105
May 22
Sunday Morning
Posters
Featured Posters – Adolescent
Hypertension
Moderators: Daniel I. Feig, MD, PhD, Houston, TX and
Joseph T. Flynn, MD, Seattle, WA
FP-5:
Which BP Measurement Method Best Predicts
Target Organ Damage in Youth?
Elaine M. Urbina,1,2 Philip R. Khoury,1 Connie E.
McCoy,1 Stephen R. Daniels,3 Lawrence M. Dolan,1,2
Thomas R. Kimball.1,2 1Cincinnati Children’s Hospital
Medical Center, Cincinnati, OH, US; 2University
of Cincinnati, Cincinnati, OH, US; 3University of
Colorado, Aurora, CO, US.
FP-6:
Effects of the DASH Diet on Flow Mediated
Dilation in Adolescents with Pre-Hypertension and
Hypertension
Sarah C. Couch,1 Linda Levin,2 Amanda Thopy,1 Brian
E. Saelens,3 Mark Mitsnefes,4 Stephen R. Daniels,5
Elaine M. Urbina.4 1University of Cincinnati Medical
Center, Cincinnati, OH, US; 2University of Cincinnati,
Cincinnati, OH, US; 3Children’s Hospital and
Regional Medical Center, Seattle, WA, US; 4Cincinnati
Children’s Hospital Medical Center, Cincinnati, OH,
US; 5University of Colorado School of Medicine,
Denver, CO, US.
FP-7:
Determinants of Arterial Stiffness in Children and
Adolescents
George S. Stergiou, Anastasios Kollias, Periklis Giovas,
Leonidas Roussias. University of Athens, Athens, GR.
Prevalence of Overweight and Elevated Blood
FP-8:
Pressure in a Large Cohort of Children and
Adolescents (Age 3-17 Years) at an Initial Clinic
Examination
Kenneth F. Adams,1 Karen L. Margolis,1 David
J. Magid,2 Joan C. Lo,3 Alan R. Sinaiko,4 Elyse
O. Kharbanda,1 Nancy E. Sherwood,1 Matt F.
Daley,2 Emily D. Parker,1 Patrick J. O’Connor.1
1HealthPartners Research Foundation, Minneapolis,
MN, US; 2Kaiser Permanente Colorado, Denver, CO,
US; 3Kaiser Permanente Northern California, Oakland,
CA, US; 4University of MN, Minneapolis, MN, US.
106
Sunday Morning
May 22
Posters
Aldosterone and anti-aldosterone
agents
PO-124:
PO-125:
PO-126:
PO-127:
PO-128:
PO-129:
Aldosterone Metrics and Their Ability to
Discriminate between Incident Resistant
Hypertension during Follow-Up in a Hypertensive
Cohort
Jennifer D. Dochee, Berhane Seyoum, Phillip Levy,
Brain Ference, Shiling Zhang, Lowell Hedquist, John
Flack. Wayne State University, Detroit, MI, US.
Aldosterone-Induced Rise in Blood Pressure in
Normotensive Rats is Due to a Decrease in PGE2
Levels
Danita Eatman, Aisha Rollins-Hairston, Deborah Lyn,
Mohamed A. Bayorh. Morehouse School of Medicine,
Atlanta, GA, US.
Delayed Diagnosis of Primary AldosteronismHelp from the Web: A Yahoo Support Group for
Patients Struggling with Diagnosis and Long-Term
Management
Clarence E. Grim. High Blood Pressure Consulting,
Milwaukee, US.
Dose Titration of the Oral Potassium BinderRLY5016 to Maintain Normal Serum Potassium in
Heart Failure and Chronic Kidney Disease Patients
on Aldosterone Antagonists
Bertram Pitt†,1 David Bushinsky,2 Sherin Halfon,3
Dalane Kitzman,4 Mitja Lainscak,5 Vandana Mathur,3
Yuri Stasiv,3 I.‑Zu Huang.3 1U. of Michigan, US; 2U. of
Rochester, US; 3Relypsa, US; 4Wake Forest U., US; 5U.
Clinic Golnik, SI.
Hyperkalemia with Aldosterone Antagonist
Monotherapy in Essential Hypertension. A MetaAnalysis
Jorge Romero,1 Harikrishna Makani,1 Jonathan
Kahan,1 Omar Wever‑Pinzon,2 Clinton Colaco,1 Franz
H. Messerli.1 1St Luke’s Roosevelt Medical Center/
Surgeons, New York, NY, US; 2The University of UtahHealth Sciences Center, US.
Body Mass Index Correlates with Plasma
Aldosterone in Overweight/Obese Hypertensive
Patients Despite Drug Therapy
Riccardo Sarzani, Federico Guerra, Lucia Mancinelli,
Alessia Buglioni, Eliana Franchi, Paolo Dessì‑Fulgheri.
University Politecnica delle Marche, Ancona, IT.
107
May 22
Sunday Morning
Posters
PO-130:
Aldosterone to Renin Ratio as a Predictor of
Mortality and Cardiovascular Outcomes
John J. Sim†,1 Simran K. Bhandari,1 Jiaxiao M. Shi,2
Federico B. Calara,4 Scott A. Rasgon,1 Kamyar
Kalantar‑Zadeh.3 1Kaiser Permanente Los Angeles
Medical Center, Los Angeles, CA, US; 2Kaiser
Permanente Southern California, US; 3Harbor UCLA
Medical Center, US; 4Novartis Corporation, US.
Antihypertensive Drugs and
Pharmacology
PO-131:
PO-132:
PO-133:
PO-134:
PO-135:
PO-136:
Both Morning and Evening Dosing of Nebivolol
Reduces Trough to Morning Blood Pressure Surge in
Maria Czarina Acelajado,1 Roberto Pisoni,3 Tanja
Dudenbostel,2 David A. Calhoun,2 Stephen P. Glasser.2
1Philippine General Hospital, Manila, PH; 2University
of Alabama at Birmingham, Birmingham, AL, US;
3Medical University of South Carolina, Charleston, SC,
US.
Administration-Time-Dependent Effects on
Ambulatory Blood Pressure of Hydrochlorothiazide
as Added Therapy in Hypertensive Subjects
Uncontrolled with Valsartan
Diana E. Ayala, Ramon C. Hermida, Artemio Mojon,
Jose R. Fernandez. University of Vigo, Vigo, ES.
Irbesartan/Amlodipine Fixed Combination
in Patients Uncontrolled on Amlodipine 5 mg
(I-COMBINE Study)
Guillaume Bobrie. European George Pompidou
Hospital, Paris, FR.
Irbesartan/Amlodipine Fixed Combination in
Patients Uncontrolled on Irbesartan 150 mg (I-ADD
Study)
Guillaume Bobrie. European George Pompidou
Hospital, Paris, FR.
Poly(3-Hydroxybutyrate) Nanoparticles Loaded with
Paclitaxel Cause Prolonged Antiproliferative Action
Anton P. Bonartsev,1 Sergey A. Yakovlev,2 Elena
A. Filatova,2 Galina M. Soboleva,1 Tatiana K.
Mahina,2 Vera L. Myshkina,2 Garina A. Bonartseva.2
1M.V.Lomonosov Moscow State University, Moscow,
RU; 2Russian Academy of Sciences, Moscow, RU.
The Efficacy and Safety of Angiotensin Receptor
Blocker and Calcium Channel Blocker Combination
in Hypertension
Bulent Boyaci,1 Mehmet Berktas,2 Pinar Kizilirmak.2
1Gazi University Faculty of Medicine, Ankara, TR;
2Novartis Pharma, Istanbul, TR.
108
Sunday Morning
May 22
Posters
PO-137:
PO-138:
PO-139:
PO-140:
PO-141:
Better Control of Central Pressures and Total
Hypertensive Time in Patients with Hypertension
Receiving Telmisartan as Monotheraphy. Prospective
Study
Ricardo M. Cabrera Sole,1 Caridad Turpin Lucas,1
Santiago Garcia Ruiz,1 Rafael Fernandez,2 Erik
Luepke.3 1University General Hospital of Albacete,
Albacete, ES; 2Health Center of Villarrobledo,
Albacete, ES; 3University General Hospital “La Paz”,
Madrid, ES.
Intravenous Hydralazine for Blood Pressure
Management in the Hospitalized Patient
Patrick T. Campbell, William L. Baker, Bendel D.
Steven, William B. White. University of Connecticut
School of Medicine, Farmington, CT, US.
Long-Term Efficacy and Safety of Combination
Olmesartan Medoxomil/Amlodipine
Besylate+Hydrochlorothiazide in Study Participants
with Hypertension Based on Age: The TRINITY
Study
Steven G. Chrysant†,1 Dean J. Kereiakes,2 Suzanne
Oparil,3 Joseph Izzo,4 Thomas Littlejohn,5 Michael
Melino,6 James Lee,6 Victor Fernandez,6 Reinilde
Heyrman.6 1Oklahoma Cardiovascular and
Hypertension Center and University of Oklahoma
College of Medicine, US; 2The Christ Hospital Heart
and Vascular Center and The Carl and Edyth Lindner
Center for Research and Education at the Christ
Hospital, US; 3University of Alabama at Birmingham,
US; 4State University of New York at Buffalo, US;
5Piedmont Medical Research Associates, US; 6Daiichi
Sankyo, Inc, US.
Besylate+Hydrochlorothiazide—The TRINITY
Study: A Subgroup Analysis by Study Participant
Race
Steven G. Chrysant†,1 Dean J. Kereiakes,2 Joseph Izzo,3
Thomas Littlejohn,4 Suzanne Oparil,5 Michael Melino,6
James Lee,6 Victor Fernandez,6 Reinilde Heyrman.6
1Oklahoma Cardiovascular and Hypertension Center
and University of Oklahoma College of Medicine, US;
2The Christ Hospital Heart and Vascular Center and
The Carl and Edyth Lindner Center for Research and
Education at the Christ Hospital, US; 3State University
of New York at Buffalo, US; 4Piedmont Medical
Research Associates, US; 5University of Alabama at
Birmingham, US; 6Daiichi Sankyo, Inc, US.
Comparison of Valsartan/Amlodipine Added to
Diuretic with Losartan Added to Diuretic on BP
Load in Hypertension
Daniel Duprez†,1 Keith Ferdinand,2 Das Purkayastha,3
Rita Samuel,3 Richard F. Wright.4 1University of
Minnesota, Minneapolis, MN, US; 2Emory University,
Atlanta, GA, US; 3Novartis Pharmaceuticals
Corporation, East Hanover, NJ, US; 4Pacific Heart
Insitute, Santa Monica, CA, US.
109
May 22
Sunday Morning
Posters
PO-142:
PO-143:
PO-144:
PO-145:
PO-146:
PO-147:
PO-148:
The Impact of Initial Treatment of Hypertension
on Control in the First Year: Comparison of Initial
Monotherapy, Free-Dose Combination and FixedDose Combinations
Brent Egan†,1 Stephanie Shaftman,1 Dipankar
Bandyopadhyay,1 C. Wagner,1 Daniel Lackland,1
Kristina Yu‑Isenberg.2 1Medical University of South
Carolina, SC, US; 2Novartis Pharmaceuticals, NJ, US.
A Bedtime Dose of ARB Reduces Urinary Albumin
Excretion Via the Improvement of Baroreflex
Sensitivity – The J-TOP Study
Kazuo Eguchi, Motohiro Shimizu, Satoshi Hoshide,
Kazuyuki Shimada, Shizukiyo Ishikawa, Kazuomi
Kario. Jichi Medical University School of Medicine,
Shimotsuke, Tochigi-ken, JP.
Response to Aliskiren in Patients with NonControlled Blood Pressure Seems to be Irrespective
of Previous Therapy and Plasma Renin Activity
Angelica Fernandez, Susana Tello, Asuncion Guerri,
Olivia Sanchez, Rosa Fabregate, Martin Fabregate,
Arantxa Rodriguez, Jose Saban‑Ruiz. Ramon y Cajal
Impact of Initial Combination Therapy vs.
Monotherapy on Major Cardiovascular Events: A
Matched Cohort Study
Alan H. Gradman†,1 Hélène Parisé,2 Marie‑Hélène
Lafeuille,2 Heather Falvey,3 Patrick Lefebvre,2 Mei
Sheng Duh.2 1Temple University School of Medicine
(Clinical Campus), Pittsburgh, PA, US; 2Analysis
Group, Inc., Boston, MA, US; 3Novartis Pharma AG,
Basel, CH.
Relationship between Sleep-Time Blood Pressure
Control and Reduction of Urinary Albumin
Excretion after Timed-Treatment with Olmesartan
in Essential Hypertension
Ramon C. Hermida, Diana E. Ayala, Maria J. Fontao,
Artemio Mojon, Jose R. Fernandez. University of Vigo,
Vigo, ES.
Nebivolol and Hydrochlorothiazide in AfricanAmericans with Hypertension: Effects on Diastolic
and Endothelial Function
Bobby V. Khan†, Nadya Merchant, Tahir Haque, Syed
T. Rahman, Sujan Bhaheetharan, Keith C. Ferdinand.
Emory University School of Medicine, Atlanta, GA,
US.
Peripheral Edema Associated with Calcium
Antagonists
Harikrishna Makani, Jorge Romero, Nay Htyte,
Ronaldo Sevilla Berrios, Arpit Shah, Waddy Gonzalez,
Franz H. Messerli. St. Luke’s Roosevelt Hospital
and Columbia University College of Physicians and
110
Sunday Morning
May 22
Posters
PO-149:
PO-150:
PO-152:
PO-153:
PO-154:
PO-155:
Efficacy of a Simplified Mechanistic Algorithm
for Management of Resistant Hypertension: A
Retrospective Study
Neal S. Parikh, Samuel J. Mann†. NY Presbyterian
Hospital – Weill Cornell Med Ctr, New York, NY, US.
Besylate+Hydrochlorothiazide—The TRINITY
Study: Subgroup Analyses Based on Study
Participant Diabetes Status and BMI
Suzanne Oparil†,1 Joseph Izzo,2 Steven G. Chrysant,3
Dean J. Kereiakes,4 Thomas Littlejohn,5 Michael
Melino,6 James Lee,6 Victor Fernandez,6 Reinilde
Heyrman.6 1University of Alabama at Birmingham,
US; 2State University of New York at Buffalo, US;
3Oklahoma Cardiovascular and Hypertension Center
& University of Oklahoma College of Medicine, US;
4The Christ Hospital Heart and Vascular Center &
The Carl and Edyth Lindner Center for Research
and Education, US; 5Piedmont Medical Research
Associates, US; 6Daiichi Sankyo, Inc, US.
Differential Cardioprotective Effects of Carvedilol
and Valsartan under Different Cardiac Loading
Conditions
Minesh Rajpal†, Shaila Karan, Sirisha Srikakarlapudi,
Peter J. Osmond, Joseph L. Izzo. SUNY at Buffalo, NY,
US.
Effects of Time of Hypertension Treatment on the
Circadian Blood Pressure Pattern of Subjects with
Resistant Hypertension: The Hygia Project
Maria T. Rios,1 Manuel Dominguez‑Sardiña,1 Lorenzo
Pousa,1 Jesus Perez de Lis,1 Alfonso Otero,2 Maria
J. Fontao,3 Jose R. Fernandez,3 Diana E. Ayala,3
Ramon C. Hermida,3 Investigadores Proyecto Hygia.3
1Gerencia de Atención Primaria, Vigo, ES; 2Complejo
Hospitalario Universitario, Orense, ES; 3University of
Vigo, Vigo, ES.
Plasma Renin-Guided Treatment in Young
Untreated Hypertension: A Randomized
Comparative Pilot Study
Il‑Suk Sohn,1 Chang‑Bum Park,1 Eun‑Sun Jin,1
Chong‑Jin Kim,1 Jin‑Man Cho.2 1Kyung Hee
University Gangdong Hospital, Seoul, KR; 2Aab
Cardiovascular Research Institute, Rochester, NY, US.
Angiotensin Converting Enzyme Inhibitors or
Angiotensin Receptor Blockers as First-Line
Treatment in Patients with Uncomplicated
Hypertension?
Konstantinos Tziomalos, Maria Baltatzi, Athinodoros
Pavlidis, Konstantinos Koulousios, Vasiliki Dourliou,
Anastasios Hatzopoulos, Vaia Bougatsa, Lambrini
Kirkineska, Christos Savopoulos, Apostolos I.
Hatzitolios. Medical School, Aristotle University of
Thessaloniki, AHEPA Hospital, Thessaloniki, GR.
111
May 22
Sunday Morning
Posters
PO-156:
PO-157:
Amlodipine/Valsartan Single Pill Combination
Treatment of Arterial Hypertension in a Real Life
Practice in Russia
Irina E. Chazova,1 Yuri A. Karpov,1 Alexey V.
Vigdorchik†,2 Antonina Y. Zazulina.2 1Russian
Cardiology Scientific-Industrial Complex, Moscow,
RU; 2Novartis Pharma LLC, Moscow, RU.
Real Life Safety and Effectiveness of Amlodipine/
Valsartan Single Pill Combination in the Treatment
of Hypertension
Irina E. Chazova,1 Neelesh Dongre,2 Alexey V.
Vigdorchik†.3 1Russian Cardiology Scientific-Industrial
Complex, Moscow, RU; 2Novartis Pharma AG, Basel,
CH; 3Novartis Pharma LLC, Moscow, RU.
Clinical Trials
PO-158:
PO-159:
PO-160:
PO-161:
PO-162:
The Influence of Antihypertensive Therapy on Blood
Pressure Variability: The X-CELLENT Study
Yi Zhang,1,2 Davide Agnoletti,1 Michel E. Safar,1
Jacques Blacher.1 1Paris Descartes University, Paris,
FR; 2Jiaotong University School of Medicine, Shanghai,
CN.
A Double-Dummy Comparison of De Novo
Combination vs Sequential Add-On Therapy:
‘ACCELERATE’
Morris Brown,1,2 Gordon McInnes,1,3 Cheraz Cherif
Papst,4 Jack Zhang,4 Thomas MacDonald.1,5 1British
Hypertension Society, GB; 2University of Cambridge,
GB; 3University of Glasgow, GB; 4Novartis Pharma
AG, CH; 5University of Dundee, GB.
Amlodipine Plus Telmisartan or Amiloride for
Hypertensive Patients: Focus on Effects on Metabolic
Profiles
Hong Yuan, Jingjing Cai, Zhijun Huang. The Center of
Clinical Pharmacology of the Third Xiangya Hospital,
Central South University, Changsha, CN.
Amlodipine Plus Telmisartan or Amiloride for
Hypertension in Moderate and High-Risk Patients:
A 24-Week Observation
Jingjing Cai, Zhijun Huang, Rong Cui, Hong Yuan. The
Center of Clinical Pharmacology of the Third Xiangya
Hospital, Central South University, Changsha, CN.
Efficacy and Safety of Azilsartan Medoxomil/
Chlorthalidone vs Olmesartan/HCTZ Combinations
in Stage 2 Systolic HTN
William C. Cushman†,1 Domenic Sica,2 George L.
Bakris,3 Michael A. Weber,4 William B. White,5
Charlie Cao,6 Andrew Roberts,6 Stuart Kupfer.6 1U
of TN College of Medicine, Memphis, TN, US; 2VA
Commonwealth U Health System, Richmond, VA,
US; 3U of Chicago Pritzker School of Medicine,
Chicago, IL, US; 4New York, NY, US; 5U of CT School
of Medicine, Farmington, CT, US; 6Takeda Global
Research & Development, Deerfield, IL, US.
112
Sunday Morning
May 22
Posters
PO-163:
PO-164:
PO-165:
PO-166:
PO-167:
PO-168:
PO-169:
Effect of Aliskiren and Antihypertensive Drugs on
Diastolic Function in Hypertensives with Diastolic
Dysfunction: A Randomised Study
Maria Leonarda De Rosa. University of Naples
Federico II, Naples, IT.
Effects of Add-On Nebivolol on Blood Pressure and
Glucose Parameters in Hypertensive Patients with
Prediabetes
P. Deedwania†,1 D. G. Cheung,2 J. Shea,3 W. Chen,3 J. J.
Whalen.3 1UCSF, US; 2Long Beach Center for Clinical
Research, US; 3Forest Research Institute, US.
Incident Diabetes with Antihypertensive Drugs:
Updated Network and Bayesian Meta-Analyses of
Clinical Trial Data
William J. Elliott†,1 Sanjib Basu,2 Peter M. Meyer.2
1Pacific Northwest University of Health Sciences,
Yakima, WA, US; 2RUSH Medical College, Chicago,
IL, US.
Efficacy and Safety of Combination DRI/CCB (±
Diuretic) in US Minority Patients with Stage 2
Hypertension and Obesity
Keith C. Ferdinand†,1 Richard Weitzman,2 Das
Purkayastha,2 Kanaka Sridharan,2 Edgar A. Jaimes.3
1Emory University, Atlanta, GA, US; 2Novartis
Pharmaceuticals Corporation, East Hanover, NJ,
US; 3The University of Alabama at Birmingham,
Birmingham, AL, US.
Efficacy of Combination Aliskiren/Amlodipine with
and without Diuretic on Ambulatory Blood Pressure
in Minorities with Hypertension
Pharmaceuticals Corp, East Hanover, NJ, US; 3The
University of Alabama at Birmingham, Birmingham,
AL, US.
Role of Plasma Renin Activity on BP Response to
Aliskiren-Based Therapy in Stage 2 Hypertensive
African Americans
Birmingham, AL, US.
Efficacy and Safety of Combination DRI/CCB
(±Diuretic) Therapy in African Americans with
Stage 2 Hypertension
Birmingham, AL, US.
113
May 22
Sunday Morning
Posters
PO-170:
PO-171:
PO-172:
PO-173:
PO-174:
PO-175:
PO-176:
PO-177:
PO-178:
Combination Aliskiren/Amlodipine with and
without Diuretic in Minorities with Hypertension
and Metabolic Syndrome or Diabetes
Pharmaceuticals Corp, East Hanover, NJ, US; 3Univ of
Alabama at Birmingham, Birmingham, AL, US.
Efficacy and Safety of Olmesartan Medoxomil
Versus Losartan Potassium in Subjects with Stage 1
or 2 Hypertension
John M. Flack†,1 Alan Graff,2 Wei Li,3 Kathleen J.
Chavanu,3 Robert Dubiel.3 1Wayne State University
School of Medicine, US; 2Private Practice, US; 3Daiichi
Sankyo, Inc., US.
Decreasing Sleep-Time Blood Pressure Determined
by Ambulatory Monitoring Reduces Cardiovascular
Risk in Resistant Hypertension
Ramon C. Hermida,1 Diana E. Ayala,1 Artemio
Mojon,1 Luisa Chayan,2 Maria J. Dominguez,3 Maria
J. Fontao,1 Ignacio Alonso,1 Jose R. Fernandez.1
1University of Vigo, Vigo, ES; 2Urgencias Sanitarias
061 Galicia, Santiago, ES; 3Policlinica La Rosaleda,
Santiago, ES.
Influence of Circadian Time of Blood PressureLowering Treatment on Cardiovascular Risk in
Administration-Time Differential Benefit on
Cardiovascular Risk Reduction of the Various
Classes of Hypertension Medications
Influence of Number of Hypertension Medications
and Circadian Time of Treatment on Cardiovascular
Morbidity and Mortality
Doppler Measurement of Ankle Brachial Index is
Still the Standard in Screening of Peripheral Arterial
Disease?
Laura Rantamaula, Juha Varis, Ilkka M. Kantola. Turku
University Hospital, Turku, FI.
Comparative Effects of Carvedilol and Valsartan on
Cardiac Workload
Shaila Karan†, Sirisha Srikakarlapudi, Minesh Rajpal,
Peter J. Osmond, Joseph L. Izzo, Jr. SUNY at Buffalo,
Buffalo, NY, US.
Olmesartan + CCB vs Olmesartan + Diuretic as
Combination Therapy for Elderly Hypertensive
Patients
Johji Kato, Naoto Yokota, Toshihiro Kita, Tanenao Eto,
Kazuo Kitamura. University of Miyazaki, Miyazaki
City, Miyazaki, JP.
114
Sunday Morning
May 22
Posters
PO-179:
PO-180:
PO-181:
PO-182:
PO-183:
PO-184:
Efficacy and Safety of Olmesartan Medoxomil
Versus Losartan Potassium in Antihypertensive
Naïve/Non-Naïve Subjects
Henry A. Punzi†,1 Andrew Lewin,2 Wei Li,3 Kathleen J.
Chavanu,3 Robert Dubiel.3 1Trinity Hypertension and
Metabolic Research Institute, US; 2National Research
Institute, US; 3Daiichi Sankyo, Inc., US.
Computer-Mediated System, WHEELS-I, Provides
Evidence of Feasibility for Momentary Assessment
of DASH Diet Adherence over 8 Weeks
Margaret Scisney‑Matlock,1 Susan Steigerwalt,2
Kenneth Jamerson,1 Amanda Sen,1 Susan Pressler,1
Elizabeth Brough.1 1University of Michigan, Ann
Arbor, MI, US; 2St. John Health System, Detroit, US.
Carvedilol Reduces Aortic Wave Reflection and
Improves Left Ventricular/Vascular Coupling
Compared to Atenolol: The CENTRAL Study
Niren K. Shah†,1 Benjamin J. Epstein,1,2 Wilmer W.
Nichols,2 Steven M. Smith,2 Julie A. Johnson.2 1East
Coast Institute for Research, Jacksonville, FL, US;
2University of Florida, Gainesville, FL, US.
Fixed-Dose Combination of Azilsartan Medoxomil/
CLD Provides Superior BP Reduction to
Monotherapies in Stage 2 HTN
D. Sica†,1 G. L. Bakris,2 W. B. White,3 M. A. Weber,4
W. C. Cushman,5 A. Roberts,6 C. Cao,6 S. Kupfer.6 1VA
Commonwealth U Health System, Richmond, VA, US;
2U of Chicago Pritzker School of Medicine, Chicago,
IL, US; 3U of CT School of Medicine, Farmington,
CT, US; 4New York, NY, US; 5U of TN College of
Medicine, Memphis, TN, US; 6Takeda Global Research
& Development, Deerfield, IL, US.
Efficacy of an Amlodipine/Olmesartan Medoxomil
Algorithm in Patients Uncontrolled on Prior ACE
Inhibitor Monotherapy
Matthew R. Weir†,1 Alan Graff,2 Ali Shojaee,3 William
F. Waverczak,3 Jen‑Fue Maa.3 1University of Maryland
School of Medicine, US; 2Private Practice, US; 3Daiichi
Sankyo, Inc., US.
Pilot Randomized Controlled Trial of Intensive
Blood Pressure Control in Hemodialysis Dialysis
Patients: The BID Trial
Philip Zager,1 Dana Miskulin,2 Jennifer Gassman.3
1University of New Mexico Health Sciences Center,
Albuquerque, NM, US; 2Tufts Medical Center, Boston,
MA, US; 3Cleveland Clinic Research Foundation,
Cleveland, OH, US.
Coronary Artery Disease
PO-185:
Blood Pressure and Heart Related Quality of Life
One Year Post Myocardial Infarction
Antonios Ioannidis, Dimitrios Tsounis. Hellenic Open
University, GR.
115
May 22
Sunday Morning
Posters
PO-186:
PO-187:
PO-188:
PO-189:
PO-190:
PO-191:
False-Positive Stress Testing Results in
Hypertensives with No Coronary Artery Disease
Fei Lu,1 Gabriele Fragasso,2 Chunzeng Lu,1 Vitantonio
Di Bello,1 Roberto Pedrinelli,1 Mario Marzilli,1 Alberto
Balbarini.1 1University of Pisa, IT; 2Scientific Institute
of H San Raffaele, IT.
Inadequate Blood Pressure Control in Hypertensives
Referred for Cardiac Stress Testing
Tarek M. Mousa, Harmony Leighton, Seema Patel,
Todd Kerwin. New York Hospital Medical Center of
Queens/Cornell University Weill Medical College,
Flushing, NY, US.
Relationship between Exercise Intolerance and
Plasma Natriuretic Peptide Level in Hypertensives
with Postinfarction Cardiosclerosis
Mariya A. Orynchak, Iryna I. Vakalyuk, Igor P.
Vakalyuk. Ivano-Frankivsk National Medical
University, Ivano-Frankivsk, UA.
Influence of a History of Hypertension with Clinical
Presentation and Prognosis after Admission
with Non ST Segment Elevation Acute Coronary
Syndrome
Joaquin Rueda Soriano, Miguel Angel Arnau Vives,
Ana Osa Saez, Esther Zorio Grima, Luis Martínez
Dolz, Luis Almenar, Miguel Palencia Pérez, Antonio
Salvador Sanz. Hospital La Fe, Valencia, ES.
Characteristics of Hypertensive Response during
Exercise Echocardiography in Hypertensive Patients
with No History of Coronary Artery Disease
Il‑Suk Sohn, Chang‑Bum Park, Eun‑Sun Jin, Jin‑Man
Cho, Chong‑Jin Kim, Jong‑Hoa Bae. Kyung Hee
University School of Medicine, Seoul, KR.
The Ankle-Brachial Index as a Predictor of Coronary
Artery Disease
Svetlana Kostic, Dragan Mijalkovic, Ivan Tasic.
Institute for Therapy and Rehabilitation “Niska Banja”,
Niska Banja, RS.
Genetics/Gene Therapy/Proteomics
PO-192:
PO-193:
Cardiac BNP Gene Delivery Prevents Hypertensive
Heart Disease in Spontaneous Hypertensive Rats
Alessandro Cataliotti,1 Fernando L. Martin,1 Jason M.
Tonne,2 Diego Bellavia,1 John C. Burnett,1 Yasuhiro
Ikeda.2 1Mayo Clinic, Rochester, MN, US; 2Mayo
Clinic, Rochester, MN, US.
DNA Variants in NOS3 are Associated with
Improved Small Artery Elasticity and Decreased
Systolic Blood Pressure
Daniel Duprez,1 Natalia Florea,1 Sara Saul,1 Ryan
Palaciao,1 Steven Rich,2 Jay N. Cohn,1 Jennifer Hall.1
1University of Minnesota, Minneapolis, MN, US;
2University of Virginia, Charlottesville, VA, US.
116
Sunday Morning
May 22
Posters
PO-194:
PO-195:
PO-196:
PO-198:
SNP-SNP Interactions among Hypertension Related
Genes
Masahiko Eto,1 Takanori Aonuma,1 Masanobu
Okayama,2 Maki Kumada,2 Ritei Uehara,2 Yoshikazu
Nakamura,2 Eiji Kajii.2 1Wakuya Medical and Welfare
Center, Wakuya, Miyagi, JP; 2Jichi Medical University,
Shimotsuke, Tochigi, JP.
Blood Pressure, Endothelial Dysfunction, Lipid
Profile and CYP3A5 Gene Polymorphism in Uzbek
Amayak Kevorkov, Marietta Eliseyeva. Republican
Specialized Center of Cardiology, Tashkent, UZ.
Mitochondrial Polymorphisms are Associated
with Blood Pressure and Metabolic Traits in the
Framingham Heart Study
Chunyu Liu,1,2 Qiong Yang,3 Shih‑Jen Hwang,1,2
Fengzhu Sun,4 Caroline S. Fox,1 Ramachandran S.
Vasan,1,5 Faina Schwartz,5 Daniel Levy.1,2 1National
Heart, Lung, and Blood Institute’s Framingham Heart
Study, Framingham, MA, US; 2NHLBI, Bethesda,
MD, US; 3Boston University School of Public Health,
Boston, MA, US; 4University of Southern California,
Los Angeles, CA, US; 5Boston University School of
Medicine, Boston, MA, US.
Targeted Disruption of Npr1 Gene Upregulates
Renin-Angiotensin System and Cardiac
Hypertrophy in Null Mutant Mice
Kailash N. Pandey. Tulane University Health Sciences
School of Medicine, New Orleans, LA, US.
Heart Failure/Hypertrophy (Diastolic
Dysfunction)
PO-199:
PO-200:
PO-201:
A Meta-Analysis of the Effect of Anti-Hypertensive
Treatment on Echocardiogram Parameters in Heart
Failure Patients with Preserved Ejection Fraction
Alex Briasoulis,1 Vikram Agarwal,1 Manpreet S.
Sabharwal,1 Girish N. Nadkarni,1 Franz H. Messerli.2
1St. Luke’s-Roosevelt Hospital Center, Columbia
University College of Physicians and Surgeons, New
York, NY, US; 2St. Luke’s-Roosevelt Hospital Center,
Effects of Renin-Angiotensin System Blockade on
Mortality and Rehospitalization in Heart Failure
with Preserved Ejection Fraction
Vikram V. Agarwal,1 Alexandros Briasoulis,1 Girish
Nadkarni,1 Manpreet S. Sabharwal,1 Nidhi Hans,2
Franz H. Messerli.1 1St. Luke’s-Roosevelt Hospital
Center, New York, NY, US; 2Harvard School of Public
Health, Boston, MA, US.
Socioeconomic Status and Costs in Heart Failure
Billy G. Chacko, Tej K. Atluri, Syed U. Naqvi, Hamza
Rana, Pavel J. Levy, Kimberley J. Hansen. Wake Forest
University Baptist Medical Center, Winston Salem,
NC, US.
117
May 22
Sunday Morning
Posters
PO-202:
PO-203:
PO-204:
PO-205:
PO-206:
Can High Dose of Valsartan Improve VentricularVascular Coupling in Heart Failure?
Wook‑Jin Chung†,1 Hye‑Sun Seo,2 Sung‑Hee Shin,3
Young‑Sup Byun,4 Sung‑Kee Ryu,5 Wook‑Bum Pyun,6
Se‑Joong Rim.7 1Gachon University Gil Hospital,
Gachon University School of Medicine, Incheon,
KR; 2Inha University Hospital, KR; 3Soonchunhyang
University School of Medicine, KR; 4Sanggye Paik
Hospital, Inje University College of Medicine, KR;
5Eulji General Hospital, Eulji University School of
Medicine, KR; 6Ewha Womans University, School of
Medicine, KR; 7Gangnam Severance Hospital, Yonsei
University College of Medicine, KR.
Can N-Terminal pro-B Type Natriuretic Peptide
Predict LV Diastolic Dysfunction in Hypertensive
Heart Disease?
Wook‑Jin Chung,1 Sung‑Hee Shin,2 Hye‑Sun Seo,3
Young‑Sup Byun,4 Sung‑Kee Ryu,5 Wook‑Bum
Pyun,6 Se‑Joong Rim.7 1Gachon University Gil
Hospital, Gachon University School of Medicine,
Incheon, KR; 2Inha University Hospital, Incheon,
KR; 3Soonchunhyang University School of Medicine,
Bucheon, KR; 4Sanggye Paik Hospital, Inje University
College of Medicine, KR; 5Eulji General Hospital, Eulji
University School of Medicine, KR; 6Ewha Womans
University, School of Medicine, KR; 7Gangnam
Severance Hospital, Yonsei University College of
Medicine, KR.
PPARg Agonist Inhibits, and PPARg Antagonist
Exacerbates, Pressure Overload-Induced Cardiac
Fibrosis and Dysfunction
Kaizheng Gong, Yiu‑Fai Chen, Peng Li, Wei Zhang,
Fadi Hage, Namasivayam Ambalavanan, Suzanne
Oparil, Dongqi Xing. University of Alabama at
Left Ventricular Mass Index is Associated with
Cognitive Impairment Independently of Blood
Pressure in the Elderly
Manabu Hayakawa,1,2 Yuichiro Yano,2,3 Kazuo
Kuroki,1 Kazuyuki Shimada,3 Kazuomi Kario.3
1Kushima Shimin Hospital, Miyazaki, JP; 2University
of Miyazaki, Miyazaki, JP; 3Jichi Medical University
School of Medicine, Tochigi, JP.
Heart Failure Hospitalization in Tennessee (20062008): Race, Age, and Gender Analyses
Baqar Husaini†,1 Van Cain,1 Pamela Hull,1 Zahid
Samad,1 H. Okafor,2 Robert Levine,2 U. Sampson.3
1Tennessee State University, US; 2Meharry Medical
College, Nashville, TN, US; 3Vanderbilt University,
Nashville, TN, US.
118
Sunday Morning
May 22
Posters
PO-207:
PO-208:
PO-209:
PO-210:
PO-211:
PO-212:
Reverse Association of Early Relaxation Tissue
Doppler Waves with Left Ventricle Mass in
Hypertensive Non Diabetic Patients
Athanasios N. Kartalis, Nikolaos E. Smyrnioudis,
Stefanos H. Garoufalis, Georgios N. Benetos,
Panagiotis M. Moschouris, Panagiotis D. Sgourakis,
Nikolaos V. Papagiannis, Ioannis V. Georgiadis,
Georgios E. Georgiopoulos. General Hopsital of Chios
Island, Chios, GR.
Association of Geometric Patterns of the Left
Ventricle with Microalbuminuria in Hypertensive
Non-Diabetic Patients
Athanasios N. Kartalis, Nikolaos E. Smyrnioudis,
Stefanos H. Garoufalis, Georgios N. Benetos,
Panagiotis M. Moschouris, Panagiotis D. Sgourakis,
Nikolaos V. Papagiannis, Georgios E. Georgiopoulos.
General Hopsital of Chios Island, Chios, GR.
Relation of Ventricular Geometry to Brain
Natriuretic Peptide Levels, EF and NYHA Class in
Heart Failure
Sanjay Kumar,1 Amit Nautiyal,2 Jason Lazar.1 1SUNY
Downstate Medical Center, Brooklyn, NY, US;
2University of Wisconsin, Madison, WI, US.
The Influence of Telmisartan on Plasma Potassium
Levels in Hypertensives with Insulin Resistance and
Heart Failure
Mariya A. Orynchak, Oleg M. Sheremeta, Nestor
M. Seredyuk, Nadiya V. Skrypnyk. Ivano-Frankivsk
National Medical University, Ivano-Frankivsk, UA.
The Types of Left Ventricular Diastolic Dysfunction
and Plasma NT-pro BNP Levels in Patients with
Metabolic Syndrome
Mariya A. Orynchak, Iryna I. Vakalyuk, Iryna O.
Gaman. Ivano-Frankivsk National Medical University,
Ivano-Frankivsk, UA.
Postoperatiave B-Type Natriuretic Peptide Level
Associates with Prolonged Hospitalization after
Non-Cardiac Surgery in Patients with Hypertension
Wook Bum Pyun,1 Jae Hong Park,2 Sang‑Hak Lee,3
Wook‑Jin Chung,4 Young‑Sup Byun,5 Sung‑Kee Ryu,6
Se‑Joong Rim,7 Gil Ja Shin.1 1Mokdong Hospital,
School of Medicine, Ewha Womans University, Seoul,
KR; 2Kangnam General Hospital, Yongin, KR; 3Yonsei
Cardiovascular Center, Yonsei University College
of Medicine, Seoul, KR; 4Heart Center, Gachon
University Gil Medical Center, Incheon, KR; 5Sanggye
Paik Hospital, Inje University College of Medicine,
Seoul, KR; 6Eulji General Hospital, Eulji University
School of Medicine, Seoul, KR; 7Gangnam Severance
Hospital, Yonsei University College of Medicine, Seoul,
KR.
119
May 22
Sunday Morning
Posters
PO-213:
PO-214:
PO-215:
PO-216:
Treatment Blocking the Renin-Angiotensin System
and Two-Year Mortality in Very Old Patients with
Heart Failure and Preserved Ventricular Ejection
Fraction
Carlos Rodriguez‑Pascual,1 Emilio Paredes‑Galan,3
Arturo Vilches‑Moraga,1 Ana Isabel FerreroMartinez,1 Marta Torrente‑Carballido,1 Fernando
Rodríguez‑Artalejo.2 1Hospital Meixoeiro, Vigo,
Pontevedra, ES; 2Universidad Autonoma, Madrid, ES;
3Hospital Meixoeiro, Vigo, Pontevedra, ES.
Left Ventricular Hypertrophy in Overweight/Obese
Hypertensives with Metabolic Syndrome Depends
on Body Mass Index
Federico Guerra, Lucia Mancinelli, Luca Angelini,
Marco Fortunati, Paolo Dessì-Fulgheri, Riccardo
Sarzani. University Politecnica delle Marche, Ancona,
IT.
The Association of Left Ventricular Hypertrophy
with Exercise Induced Intraventricular Asynchrony
Hye‑Sun Seo,1 Young‑Sup Byun,2 Sung‑Kee Ryu,3
Wook‑Bum Pyun,4 Se‑Joong Rim,5 Wook‑Jin Chung,6
Sung‑Hee Shin.7 1Soonchunhyang University Hospital,
Bucheon, KR; 2Sanggye Paik Hospital, Inje University
College of Medicine, Seoul, KR; 3Eulji General
Hospital, Eulji University School of Medicine, Seoul,
KR; 4Ewha Womans University Hospital, Seoul, KR;
5Gangnam Severance Hospital, Yonsei University
College of Medicine, Seoul, KR; 6Gachon University
Gil Hospital, Gachon University School of Medicine,
Incheon, KR; 7Inha University Hospital, Incheon, KR.
Gender Specific Prognostic Differences in Regard
to the Regression of Hypertensive Left Ventricular
Hypertrophy (12 Years Follow-Up Study)
Ivan Tasic,1 Svetlana Kostic,1 Dragan Djordjevic,1
Gordana Lazarevic,2 Dragan Lovic.3 1Institute for
Therapy and Rehabilitation “Niska Banja”, Niska Banja,
RS; 2Clinic of Cardiology, Nis, RS; 3Clinic for Internal
Disease InterMedica-Dr Lovic, Nis, RS.
Hypertension in patients with chronic
kidney disease
PO-217:
PREdictors of Adequate Control of Hypertension
among Chronic Kidney Disease Patients (PREACHCKD)
Ma Czarlota M. Acelajado‑Valdenor, Angelo Dave C.
Javier, Maria Czarina M. Acelajado. Philippine General
Hospital, Manila, PH.
120
Sunday Morning
May 22
Posters
PO-218:
PO-219:
PO-220:
PO-221:
PO-222:
PO-223:
Prevalence, Awareness, Treatment and Control of
Hypertension in Chronic Kidney Disease
Bulent Altun,1 Gultekin Suleymanlar,2 Cengiz Utas,3
Turgay Arinsoy,4 Kenan Ates,5 Tevfik Ecder,6 Taner
Camsari,7 Kamil Serdengecti.8 1Hacettepe University
Faculty of Medicine, Ankara, TR; 2Akdeniz University
Medical School, Antalya, TR; 3Erciyes University
Faculty of Medicine, Kayseri, TR; 4Gazi University
Faculty of Medicine, Ankara, TR; 5Ankara University
Faculty of Medicine, Ankara, TR; 6Istanbul University
Istanbul Faculty of Medicine, Istanbul, TR; 7Dokuz
Eylul University Faculty of Medicine, Izmir, TR;
8Istanbul University Cerrahpasa Faculty of Medicine,
Istanbul, TR.
Selective Endothelin-A Receptor Antagonism
Reduces Proteinuria, Blood Pressure and Arterial
Stiffness in Chronic Proteinuric Kidney Disease
N. Dhaun, I. MacIntyre, J. Goddard, D. J. Webb.
University of Edinburgh, GB.
Discordant Estimation of the Prevalence of Masked
Hypertension According to Daytime or Nighttime
Blood Pressure in Subjects with Chronic Kidney
Disease. The Hygia Project
Ramon C. Hermida,1 Alfonso Otero,2 Luis Piñeiro,3
Diana E. Ayala,1 Ana Moya,4 Elvira Sineiro,4 Maria
J. Fontao,1 Artemio Mojon,1 Jose R. Fernandez,1
Investigadores Proyecto Hygia.1 1University of Vigo,
Vigo, ES; 2Complejo Hospitalario Universitario,
Orense, ES; 3Complejo Hospitalario Universitario,
Pontevedra, ES; 4Gerencia de Atención Primaria,
Pontevedra, ES.
Alteration of the Circadian Blood Pressure Pattern
in Subjects with Chronic Kidney Disease: The Hygia
Project
Alfonso Otero,1 Manuel Dominguez‑Sardiña,2 Maria
C. Castiñeira,3 Juan J. Crespo,2 Amelia Ferreras,2
Artemio Mojon,4 Diana E. Ayala,4 Jose R. Fernandez,4
1Complejo Hospitalario Universitario, Orense, ES;
2Gerencia de Atención Primaria, Vigo, ES; 3Gerencia
de Atención Primaria, Pontevedra, ES; 4University of
Vigo, Vigo, ES.
Usefulness of the Resistive Index in Renal Doppler
Ultrasonography as an Indicator of Vascular
Damage in Patients with Risks of Atherosclerosis
Tatsuo Kawai, Kei Kamide, Miyuki Onishi, Hiroko
Yamamoto‑Hanasaki, Yoshichika Baba, Kazuhiro
Hongyo, Izumi Shimaoka, Yuji Tatara, Yasushi Takeya,
Mitsuru Ohishi, Hiromi Rakugi. Osaka University
Graduate School of Medicine, Suita, Osaka, JP.
Intradialytic Hypertension is Not Associated with
Increased Blood Pressure Variability
Catherine Kim, Peter N. Van Buren, Robert Toto, Jula
K. Inrig. University of Texas at Southwestern, Dallas,
TX, US.
121
May 22
Sunday Morning
Posters
PO-224:
PO-225:
PO-226:
Effect of Vitamin D Supplementation on Blood
Pressure among HD Patients Undergoing Dialysis
Bharadwaj Cheruvu,1 Yap Jason,1,2 Saklayen
Mohammad.1,2 1Veterans Medical Center, Dayton, OH,
US; 2Wright State University, Dayton, OH, US.
Heme Oxygenase Induction Prevents Endothelial
Dysfunction and Renal Damage in ec-SOD KO Mice
Nitin Puri,1 Tomoko Kawakami,1 Luca Vanella,1 Lars
Bellner,2 Rita Rezzani,3 Toru Takahashi,4 Kiyoshi
Morita,4 Nader G. Abraham.1 1University of Toledo,
Toledo, OH, US; 2New York Medical College, Valhalla,
NY, US; 3University of Brescia, IT; 4Okayama
University Medical School, Okayama, JP.
Mean Hemodialysis-Unit Systolic BP is Similar in
Patients with and without Frequent Intradialytic
Hypertension
Peter N. Van Buren, Catherine Kim, Robert D. Toto,
Jula K. Inrig. University of Texas Southwestern
Medical Center, Dallas, TX, US.
Kidney and Hypertension
PO-227:
PO-228:
PO-229:
PO-230:
PO-231:
Nighttime Hemodynamics and Arterial Stiffness
Exert a Powerful Additive Predictive Effect on the
Occurrence of Microalbuminuria in Hypertension:
A 6-year Follow-Up Study
E. Andrikou, C. Tsioufis, C. Thomopoulos, A. Kordalis,
I. Andrikou, M. Giakoumis, L. Lioni, M. Almiroudi, I.
Eleftheriadou, C. Stefanadis. Hippokration Hospital,
Athens, GR.
Learning Nephrology through Mobile Devices: The
Nephrology On-Demand Mobile Experience
Tejas Desai,1 Maria Ferris.2 1East Carolina University
Brody School of Medicine, US; 2The University of
North Carolina at Chapel Hill, US.
Characteristics of Hypertensive Patients Using
Either Aliskiren or Other Antihypertensive
Medications
Debra F. Eisenberg†,1 Jinhee Park,2 Christy Fang,1
Jean Lian,2 Andrea DeVries.1 1HealthCore, Inc.,
Wilmington, DE, US; 2Novartis Pharmaceuticals, East
Hanover, NJ, US.
The Dopamine D1-Like Receptors Interact with the
a1A Adrenergic Receptor in Human Renal Epithelial
Tubule Cells
Riley C. Ennis, Van Anthony M. Villar, Julie A. Jurgens,
John E. Jones, Pedro A. Jose. Children National
Medical Center, Washington, DC, US.
Uncoupled NOS is a Major Source of Renal
Superoxide in Angiotensin II-Induced Hypertension
Maria C. Gongora, Li Li, Wei Chen, Kin Lung Siu,
David G. Harrison. Emory University, Atlanta, GA,
US.
122
Sunday Morning
May 22
Posters
PO-232:
PO-233:
PO-234:
PO-235:
PO-236:
PO-237:
PO-238:
Loss of SNX5 Impairs Dopamine D1 Receptor
Endocytosis and Recycling and Aggravates the
Blood Pressure in SHR
Van Anthony M. Villar,1,2 Ines Armando,1,2 Lauren
C. Frazer,2 Kristen M. Russo,2 Patricia M. Notario,2
Hewang Li,1,2 Hironobo Sanada,3 Yingjin Luo,2 Lauren
Comisky,2 Holly Ann Russell,2 Yu Yang,1 Pedro A.
Jose,1,2 John E. Jones.1,2 1Children’s National Medical
Center, Washington, DC, US; 2Georgetown University
School of Medicine, Washington, DC, US; 3Fukushima
Medical University School of Medicine, Fukushima, JP.
Ambulatory Blood Pressure Measurement in
Patients with Chronic Kidney Disease: Outcomes
and Correlation with Clinic BP and BpTRU
Ashok L. Kirpalani, Aditya S. Bhabhe, Dilip A.
Kirpalani, Hardik K. Shah. Bombay Hospital Institute
of Medical Sciences, Mumbai, Maharashtra, IN.
Perinatal Dietary Protein and NaCl on Offspring’s
Ambulatory Blood Pressure and Renal Injury
Jong Y. Lee, Silvia H. Azar. Univ of MN School of
Medicine, Minneapolis, MN, US.
Effects of a Direct Renin Inhibitor on RRI in
Francesco Natale, Chiara Cirillo, Chiara Granato,
Claudia Concilio, Alessandro Siciliano, Luigi Aronne,
Maria Credendino, Emanuela Lo Priore, Alessandro
Ranieri, Maria Giovanna Russo, Raffaele Calabrò.
Second University of Naples, Monaldi Hospital,
Naples, IT.
Uncontrolled Hypertension in CKD Patients is
Associated with Higher Heart Rate
Alexander Kagan,1,2,3 Hedy Feibel,3 Ishay Shoval,3
Jayson Rapoport.1,2 1Kaplan Medical Center, Rehovot,
IL; 2Hebrew University, Jerusalem, IL; 3”Meuhedet”
Sick Fund, IL.
Analysis of Left Ventricular Function and of
Coronary Circulation in Relationship to Renal
Function
César S. Rosa,1,2 Bruno B. Pelazza,1,2 Sebastião R.
Filho.1 1Federal University of Uberlândia, Uberlândia,
Minas Gerais, BR; 2Heart Institute of Triangulo
Mineiro, Uberlândia, Minas Gerais, BR.
Discrepancies in Hypertension Control Rates
Evaluated by Means of Office BP and Ambulatory
BP Monitoring in Hypertensive Patients with and
without Chronic Kidney Disease
Manuel Gorostidi,1 Julian Segura,2 Alejandro de la
Sierra,3 Juan J. de la Cruz,4 Jose R. Banegas,4 Luis M.
Ruilope.2 1Hospital Central de Asturias, Oviedo, ES;
2Hospital 12 de Octubre, Madrid, ES; 3Hospital Mutua
Terrasa, Universidad de Barcelona, Barcelona, ES;
4Universidad Autónoma, Madrid, ES.
123
May 22
Sunday Morning
Posters
PO-239:
PO-240:
PO-241:
PO-242:
Impaired Coronary Microcirculation is Associated
with Increased Urine Albumin Excretion in
Untreated Hypertensives
D. Tsiachris, C. Tsioufis, K. Dimitriadis, D. Rousos,
I. Tatsis, A. Kordalis, A. Kefala, C. Stefanadis.
Associations of Renal Hemodynamics with Target
Organ Damage in Untreated Hypertensives. An
Invasive Approach
C. Tsioufis, D. Tsiachris, K. Dimitriadis, D. Rousos, I.
Tatsis, D. Syrseloudis, G. Latsios, V. Papademetriou, C.
Albuminuria is Related to Circulating Soluble
Receptor for Advanced Glycation End Products
and Biomarkers of Endothelial Function in
Hypertension
C. Tsioufis, K. Dimitriadis, A. Aggelis, M. Poulakis, A.
Kefala, A. Kasiakogias, A. Miliou, M. Almiroudi, C.
Chronic Kidney Disease Education in the
Community Health Center Setting Improves
Prescription Filling Rates for Antihypertensive
Medications
Paul Bolin, Cindy Christiano, Melanie Hames,
Tejas Desai, Hsiao Lai, Karen Parker, Rachel Ward,
Courtland Winborne, Lacy Dean. East Carolina
University Brody School of Medicine, US.
Off-target cardiovascular effects of
non-cardiovascular drugs
PO-243:
PO-244:
Sitagliptin is Associated with Increased Blood
Pressure in Rats
Dov Gavish,1,3 Eyal Leibovitz,1,3 Yonatan Shrabi,2,3
Ehud Grosman,2,3 Dror Harats.2,3 1Wolfson Hospital,
Holon, IL; 2Sheba Medical Center, Ramat Gan, IL; 3Tel
Aviv Univeristy, Tel Aviv, IL.
Blood Pressure Evaluation in Oncology and CNS
Indications: Implementation of ABPM and Home
BP Telemonitoring
Jeffrey Heilbraun. Scientific Affairs, Rockville, MD, US.
124
Monday Morning
Afternoon
May 23
21
Posters
Featured Posters
Neutral Hormonal Mechanisms (Renin; Neutral Control; Vasoactive
Autacoids.......................................................................(PO-310 – PO-312)
Obesity...........................................................................(PO-331 – PO-339)
Pregnancy......................................................................(PO-359 – PO-361)
information.
125
May 23
21
Monday
Monday
Afternoon
Morning
Posters
Featured Posters – Cardiac Structure and Function
Moderators: John D. Bisognano, MD, PhD, Rochester, NY and
Robert A. Phillips, MD, PhD, Worcester, MA
FP-9:
Parallel Deterioration of Albuminuria, Arterial
Stiffness and Left Ventricular Mass in Essential
Hypertension: Integrating Target Organ Damage
E. Andrikou, C. Tsioufis, K. Dimitriadis, D. Flessas, K.
Kintis, I. Mpafakis, M. Almiroudi, G. Chlapoutakis, M.
Poulakis, M. Giakoumis, C. Stefanadis. Hippokration
Hospital, Athens, GR.
FP-10:
The Prognostic Value of Left Ventricular
Hypertrophy in the Very Elderly: The PROTEGER
Study
Yi Zhang,1,2 Davide Agnoletti,1 Julie Peroz,1 Ari
Lieber,1 Pierre Iaria,1 Athanase D. Protogerou,3 Michel
E. Safar,1 Jacques Blacher.1 1Paris Descartes University,
Paris, FR; 2Jiaotong University School of Medicine,
Shanghai, CN; 3University of Athens, Athens, GR.
FP-11:
Cornell Product Left Ventricular Hypertrophy
in Electrocardiogram and Mortality in a General
Population
Joji Ishikawa,1 Shizukiyo Ishikawa,2 Kazunori Kayaba,3
Kazuomi Kario.1 1Jichi Medical University School
of Medicine, Tochigi, JP; 2Jichi Medical University,
Tochigi, JP; 3Saitama Prefectural University, Saitama,
JP.
FP-12:
Identification of Myocardial Viability in
Hypertensive Patients Receiving Beta-Blockers by
Dobutamine Echocardiography
Fei Lu, Vitantonio Di Bello, Chunzeng Lu, Mario
Marzilli, Alberto Balbarini. University of Pisa, IT.
FP-13:
Targeted Delivery of Endothelial Cells
Overexpressing IL8RA and IL8RB Receptors
Promotes Structural and Functional Recovery of
the Left Ventricle in Rats Following Myocardial
Infarction
Peng Li, Dongqi Xing, Kaizheng Gong, Fadi Hage,
Onyedika John IIonze, Suzanne Oparil, Yiu‑Fai Chen.
UAB, Birmingham, AL, US.
126
Monday Morning
Afternoon
May 23
21
Posters
Arterial Structure and Compliance
PO-245:
PO-246:
PO-247:
PO-248:
PO-249:
PO-250:
PO-251:
PO-252:
Vascular Injury in Hypertensive Patients. are Men
and Women Equal? PARITE Study
Claire Mounier‑Vehier,1 Simon Tabassome,2
Dominique Guedj,3 Assya Achouba,4 Emmanuel
Ghannad,5 Stéphane Quéré,4 Maxime Guenoun.6
1Cardiologic Hospital, Lille, FR; 2CHU Saint-Antoine,
Paris, FR; 3Cardiologist, Paris, FR; 4Novartis Pharma
SAS, Rueil-Malmaison, FR; 5Cardiologist, Gif sur
Yvette, FR; 6Cardiologist, Marseille, FR.
Peripheral Pulse Pressure Strongly Correlates with
Central Systolic Blood Pressure in Adults: Bogalusa
Heart Study
Rebecca I. Clark, Camilo Fernandez, Gerald S.
Berenson, Thomas D. Giles, Gary E. Sander. Tulane
University Health and Sciences Center, New Orleans,
LA, US.
Addition of Eplerenone to RAAS Blockade in
Patients with CKD and Proteinuria Correlates with
Baseline Vascular Compliance
Debbie L. Cohen†, Kevin A. Sterling, Raymond R.
Townsend. University of Pennsylvania, Philadelphia,
PA, US.
Arterial Stiffness Evaluation in HIV Patients
Antonio J. Delgado‑Leon,1 Zenaida Castillo,1 Jose M.
Rojas,1 Susana I. Celis,2 Jennifer Moreno.1 1University
of Carabobo, Valencia, Carabobo, VE; 2Instituto
Docente de Urologia, Valencia, Carabobo, VE.
A New Vibrational Approach for Carotid Pulse Wave
Velocity Assessment
Francesco Faita,1 Vincenzo Gemignani,1 Elisabetta
Bianchini,1 Rosa Maria Bruno,2 Lorenzo Ghiadoni.2
1Institute of Clinical Physiology – National Research
Council, Pisa, IT; 2University of Pisa, Pisa, IT.
Central-Peripheral Blood Pressure Differences are
Greater in Hispanics and African-Americans
Haroon Kamran, Louis Salciccioli, Rinkesh Patel,
Mohamed Munshi, Stephen Littman, Jason Lazar.
SUNY Downstate Medical Center, Brooklyn, NY, US.
The Left Ventricular Septal – Aortic Angle
Relationship with the Augmentation Index and
Central Blood Pressures
Mediha Ibrahim, Kinda Venner-Jones, Haroon
Kamran, Louis Salciccioli, Carl Bastien, Jason Lazar.
SUNY Downstate Medical Center, Brooklyn, NY, US.
Differences in Post-Ischemic Reactive Hyperemia
Tissue Oxygen Saturation between Normals and
Hypertensive Subjects
Revathy Thangaratnavel, Haroon Kamran, Louis
Salciccioli, Wah Wah Htun, Ilir Maraj, Edinrin Rae
Obasare, Jason Lazar. Downstate Medical Center,
Brooklyn, NY, US.
127
May 23
21
Monday
Monday
Afternoon
Morning
Posters
PO-253:
PO-254:
PO-255:
PO-256:
PO-257:
PO-258:
PO-259:
The Relationship between Impaired Lung Function
and Cardiac Function in Older Individuals
Barry J. McDonnell,1 Iain Munnery,2 Margaret M.
Munnery,2 Charlotte Bolton,2 Carmel M. McEniery,3
Ian B. Wilkinson,3 John R. Cockcroft.2 1University
of Wales Institute, Cardiff, Cardiff, GB; 2Cardiff
University, Cardiff, GB; 3University of Cambridge,
Cambridge, GB.
Hyperemia Induced Changes in Carotid-Radial
Pulse Wave Velocity before and after Pre and Post
Ischemic Conditioning
Nwamaka Onuigbo, Haroon Kamran, Louis Salciccioli,
Abhishek Sharma, Jason Lazar. SUNY Downstate
Medical Center, Brooklyn, NY, US.
The Predictive Value of Carotid Artery Features over
Traditional Risk Factors and Endothelial Function
Oana Sandu,1 Iulian Nastac,2 Jaime Uribarri.1 1MSSM,
NY, US; 2UPB, Bucharest, RO.
Determinants of Central Reflected Pressure Waves
Sirisha Srikakarlapudi, Minesh Rajpal, Shaila Karan,
Peter J. Osmond, Joseph L. Izzo. SUNY at Buffalo,
Buffalo, NY, US.
Regular Exercise-Induced Upregulation of
Circulating Endothelial Progenitor Cells Attenuates
Age-Related Decline in Arterial Elasticity in Healthy
Men
Jun Tao, Zhen Yang. The First Affilaited Hospital. Sun
Yat-Sen University, CN.
Subendocardial Viability Ratio as an Index of
Impaired Coronary Flow Reserve in Untreated
Hypertensives
D. Tsiachris, C. Tsioufis, K. Dimitriadis, D. Rousos,
A. Kordalis, I. Anastasopoulos, D. Syrseloudis, C.
Impaired Coronary Microcirculation is Not
Accompanied by Adverse Vascular Remodeling in
Untreated Hypertensives
D. Tsiachris, C. Tsioufis, D. Rousos, C. Thomopoulos,
A. Kasiakogias, A. Kordalis, G. Latsios, C. Stefanadis.
Blood Pressure Measurement/Monitoring
PO-260:
Comparison of Central Hemodynamics between
A_PULSE and Other Two Tonometry-Based Devices
Yi Zhang,1,2 Davide Agnoletti,1 Julie Peroz,1 Ari
Lieber,1 Michel E. Safar,1 Paolo Salvi,3,4 Jirar
Topouchian,1 Jacques Blacher.1 1Paris Descartes
University, Paris, FR; 2Jiaotong University School of
Medicine, Shanghai, CN; 3University of Nancy, Nancy,
FR; 4University of Bologna, Bologna, IT.
128
Monday Morning
Afternoon
May 23
21
Posters
PO-261:
PO-262:
PO-263:
PO-264:
PO-265:
PO-266:
PO-267:
Two Office Blood Pressure Readings Taken on
Each of Two Visits are Not Enough for an Accurate
Estimation and an Adequate Hypertension
Diagnosis
María M. Martínez,1 María T. Díaz,1 María T. Ríos,1
Rocío Del Tío,1 Jesús Barros,1 Victoria Mota,1 Isabel
Bueno,1 Moncho Velhas,1 Javier Pérez,2 Ignacio
Alonso.2 1Sergas (Health Department of Galicia), ES;
2University of Vigo, ES.
Prevalence of Self-Monitoring Blood Pressure
among Adults – Healthstyles, 2005 and 2008
Carma Ayala, Xin Tong, Nora L. Keenan. CDC/
NCCDPHP/DHDSP, Atlanta, GA, US.
Prognostic Value of Clinic and Ambulatory Blood
Pressure Measurements in Resistant Hypertension
Diana E. Ayala,1 Ramon C. Hermida,1 Artemio
Mojon,1 Luisa Chayan,2 Maria J. Dominguez,3 Maria
J. Fontao,1 Ignacio Alonso,1 Jose R. Fernandez.1
1University of Vigo, Vigo, ES; 2Urgencias Sanitarias
061 Galicia, Santiago, ES; 3Policlinica La Rosaleda,
Santiago, ES.
Can Personal Exposures to Higher Nighttime
and Early Morning Temperatures Increase Blood
Pressure?
Robert D. Brook,1 Hwashin H. Shin,2 Robert L. Bard,1
Richard T. Burnett,2 Alan Vette,3 Carry Croghan,3
Ron Williams.3 1University of Michigan, US; 2Health
Canada, CA; 3USEPA, US.
24-h Ambulatory Blood Pressure and
Cardiovascular Events in Elderly Hypertensive
Patients Followed-Up for Seven Years
Jose Mesquita Bastos,1 Susana Bertoquini,2 Jorge
Polonia.3 1Universidade de Aveiro, Aveiro, PT;
2Faculdade Psicologia e Ciências da Educação, PT;
3Faculdade de Medicina do Porto, PT.
Total Peripheral Resistance and its Relationship with
Hypertension in Patients with Severe Sleep Apnea
Ricardo M. Cabrera Sole,1 Ramon Coloma,1 Caridad
Turpin Lucas,1 Ana Galdamez Nuñez,2 Erik Luepke,3
Juan Cañas,4 Manuel Aguilera Saldaña.1 1University
General Hospital of Albacete, Albacete, ES; 2Health
Center of Villacerrada, Albacete, ES; 3University
General Hospital “La Paz”, Madrid, ES; 4Health Center
No. 3, Albacete, ES.
Patients with Hypertensive Crisis Have Higher Risk
Following First Month after the Crisis Compared
with Hypertensive Patients at Similar Blood
Pressure
Ricardo M. Cabrera Sole,1 Caridad Turpin Lucas,1 Ana
Galdamez Nuñez,2 Juan Cañas,3 Manuel Aguilera
Saldaña.1 1University General Hospital of Albacete,
Albacete, ES; 2Health Center of Villacerrada, Albacete,
ES; 3Health Center No. 3, Albacete, ES.
129
May 23
21
Monday
Monday
Afternoon
Morning
Posters
PO-268:
PO-269:
PO-270:
PO-271:
PO-272:
PO-273:
PO-274:
PO-275:
PO-276:
Correlation between Left Ventricular Mass and
Ambulatory or Clinic Blood Pressure in Very Elderly
Subjects
S. Carugo,1 A. Esposito,1 D. Solari,1 M. Maisaidi,1
G. Mancia.2 1ASP IMMeS e PAT, University of Milan,
Milan, IT; 2University Milano-Bicocca, S. Gerardo
Hospital, Monza, IT.
Clinical and Ambulatory Blood Pressure Values in
Centenaries
S. Carugo,1 A. Esposito,1 D. Solari,1 M. Maisaidi,1
G. Mancia.2 1ASP IMMeS e PAT, University of Milan,
Milan, IT; 2University Milano-Bicocca, S. Gerardo
Hospital, Monza, IT.
Usefulness of Automated Office Blood Pressure
Measurement by BpTRU for the Diagnosis of
Giuseppe Crippa,1 Antonino Cassi,1 Matteo Bosi,2
Maria Luisa Fares.1 1Guglielmo da Saliceto Hospital,
Piacenza, IT; 2Universita’ Cattolica, Piacenza, IT.
Effects of Aliskiren- and Ramipril-Based Treatment
on Central Aortic Blood Pressure in Systolic
Hypertension
Daniel Duprez†,1 Fabio Baschiera,2 Alan Charney,3
InYoung Baek,2 Patrick Brunel.2 1University of
Minnesota, Minneapolis, MN, US; 2Novartis Pharma
AG, Basel, CH; 3Novartis Pharmaceutical Corporation,
East Hanover, NJ, US.
Apparent Treatment Resistant Hypertension in a
Community-Based Practice Network
Brent Egan†, Yumin Zhao, W. Adam Brzezinski,
Benjamin Clyburn, Jan Basile, Daniel Lackland.
Medical University of South Carolina, Charleston, SC,
US.
Progression from Pre-Hypertension to Hypertension
is Accelerated in African Americans
Anbesaw Selassie, C. Shaun Wagner, Brent Egan†.
Medical University of South Carolina, Charleston, US.
Clinical Characteristics of Patients with
Uncontrolled and Apparent Treatment Resistant
Hypertension: NHANES 2005-2008
Brent Egan†,1 Yumin Zhao,1 R. Neal Axon,1 Keith
Ferdinand.2 1Medical University of South Carolina,
Charleston, SC, US; 2Emory University, Atlanta, GA,
US.
Impacting Population Cardiovascular Health
through a Community-Based Practice Network:
Update on An-ASH-Supportive Collaborative
Brent Egan†, Marilyn Laken, Daniel Lackland. Medical
University of S.C., Charleston, SC, US.
Estimation of Central Cardiovascular Parameters
from Brachial Cuff Pressure Waveform
Kenji Fujii,1 Tatsuya Kobayashi,1 Toshihiko Ogura,1
Hirofumi Tomiyama,2 Akira Yamashina.2 1Omron
Healthcare Co., Ltd, JP; 2Tokyo Medical University, JP.
130
Monday Morning
Afternoon
May 23
21
Posters
PO-277:
PO-278:
PO-279:
PO-280:
PO-281:
PO-282:
PO-283:
Blood Pressure Measurement-Device and
Calibration Patterns in Home Health Care
F. W. Germino,1,2 Megan M. Germino.3 1Orland
Primary Care Specialists, Orland Park, IL, US; 2Rush
School of Medicine, Chicago, IL, US; 3Rush University,
Chicago, IL, US.
ABPM in Octogenarians
Eduardo Podjarny,1 Jacques Bernheim,1,2 Eliezer
Golan.1,2 1Meir Medical Center, Kfar-Saba, IL; 2TelAviv University, Tel-Aviv, IL.
Impact of Initial Antihypertensive Treatment with
a Single-Pill Combination on Blood Pressure Goal
Attainment: A Matched Cohort Study
Alan H. Gradman†,1 Hélène Parisé,2 Marie‑Hélène
Lafeuille,2 Heather Falvey,3 Patrick Lefebvre,2 Mei
Sheng Duh.2 1Temple University School of Medicine
(Clinical Campus), Pittsburgh, PA, US; 2Analysis
Group, Inc., Boston, MA, US; 3Novartis Pharma AG,
Basel, CH.
Influence of Dipping Classification on Fasting
Glucose in Subjects with and without Elevated
Ambulatory Blood Pressure: The Hygia Project
Manuel Dominguez‑Sardiña,1 Pedro A. Callejas,1
Peregrina Eiroa,1 Juan J. Crespo,1 Jose L. Salgado,1
Alfonso Otero,2 Maria J. Fontao,3 Sonia Lorenzo,3
1Gerencia de Atención Primaria, Vigo, ES; 2Complejo
Hospitalario Universitario, Orense, ES; 3University of
Vigo, Vigo, ES.
Influence of Duration of Ambulatory Blood Pressure
Monitoring (48 vs. 24 Hours) on Cardiovascular
Risk Assessment
Ramon C. Hermida, Diana E. Ayala, Maria J. Fontao,
Artemio Mojon, Jose R. Fernandez. University of Vigo,
Vigo, ES.
Reproducibility of Nocturnal Blood Pressure
Dipping is Influenced by Day-to-Day Changes in
Sleep Quality
Alan L. Hinderliter,1 Faye S. Routledge,2 James A.
Blumenthal,2 William K. Wohlgemuth,3 Andrew
Sherwood.2 1University of North Carolina School
of Medicine, Chapel Hill, NC, US; 2Duke University
Medical Center, Durham, NC, US; 3University of
Miami School of Medicine, Miami, FL, US.
Using Telephonic Outreach to Improve Blood
Pressure Control
Timothy Ho,1 Joel Handler,1 Michael Kanter,2 Kristi
Reynolds,3 Ruthie Goldberg,2 Joe Kimura.1 1Kaiser
Permanente Medical Center, Anaheim, CA, US;
2Southern California Permanente Medical Group,
Pasadena, CA, US; 3Kaiser Permanente Southern
California, Pasadena, CA, US.
131
May 23
21
Monday
Monday
Afternoon
Morning
Posters
PO-284:
PO-285:
PO-287:
PO-288:
PO-289:
PO-290:
PO-291:
Relationship between the Reduction of Left
Ventricular Mass Index and the Changes in Sleep
Blood Pressure with Sodium Restriction and/or
Diuretic Treatment
Joji Ishikawa, Kazuo Eguchi, Satoshi Hoshide,
Kazuyuki Shimada, Kazuomi Kario. Jichi Medical
University School of Medicine, Tochigi, JP.
BpTRU – A Useful Alternative to 24 Hour
Ambulatory Blood Pressure Monitoring in
Evaluation and Management of Hypertension in
India
Dilip A. Kirpalani, Hardik K. Shah, Aditya S. Bhabhe,
Ashok L. Kirpalani. Bombay Hospital Institute of
Medical Sciences, Mumbai, Maharashtra, IN.
Effects of Traffic-Related Particles on Blood Pressure
and DNA Methylation
Denise P. Lamoureux, Edgar A. Diaz, Yeonseung
Chung, Mark S. Long, Joy Lawrence, Vasileios
Papapostolou, Phuong‑son Nguyen, John J. Godleski.
Harvard School of Public Health, US.
Ambulatory Blood Pressure in the Biological Time
Structures
Mary S. Lee,1 John S. Lee,2 Jong Y. Lee,3 Franz
Halberg.4 1Northwestern Univ. School of Medicine,
Chicago, IL, US; 2Univ of Minnesota School of
Medicine, Minneapolis, MN, US.
Hypertensive Smokers: Evidence of Impaired NightResponse
Linda Landini,1 Aurelio Leone.2 1University of Pisa,
Pisa, Pi, IT; 2City Hospital, Massa, Ms, IT.
Oscillometric and Auscultatory Blood Pressure
Measurements before and after Acute Exercise and
Rest in the Elderly
Leandra Gonçalves Lima, Iara Felício Anunciato,
Fernanda Jatte, Júlio Cesar Moriguti, Eduardo Ferriolli,
Nereida K. Costa Lima. Ribeirao Preto Medical School
Sao Paulo University, Ribeirao Preto, SP, BR.
Home Blood Pressure Monitoring Requires
Feedback to Patients to Improve Treatment of
Hypertension
Alexander G. Logan,1 Warren McIsaac,2 Jane Irvine,3
Andras Tisler,4 Denice Feig,5 Joseph Cafazzo.6 1Mount
Sinai Hospital, Toronto, ON, CA; 2Mount Sinai
Hospital, Toronto, ON, CA; 3York University, Toronto,
ON, CA; 4Semmelweis University, Budapest, HU;
5Mount Sinai Hospital, Toronto, ON, CA; 6Toronto
General Hospital, Toronto, ON, CA.
132
Monday Morning
Afternoon
May 23
21
Posters
PO-292:
PO-293:
PO-294:
PO-295:
PO-297:
PO-298:
PO-299:
Blood Pressure in Firefighters
Steven M. Moffatt†,1,4 Suchita Garg,2 Michael J.
Epstein,2 Nandini Hadker,2 Lora Lex,1,4 Feride FrechTamas.3 1Indianapolis Fire Department, Indianapolis,
IN, US; 2United BioSource Corporation, Lexington,
MA, US; 3Novartis Pharmaceuticals, East Hanover, NJ,
US; 4Public Safety Medical, Indianapolis, IN, US.
Long-Term Effects of Telemetric Blood Pressure
Monitoring in Adequately Treated Patients with
Arterial Hypertension
Claas L. Neumann, Eike M. Rieken, Jan‑Marc Schmidt
Thrun, Egbert G. Schulz. Nephrologisches Zentrum
Göttingen, Göttingen, Niedersachsen, DE.
Relationship between Central and Peripheral Blood
Pressure in Type 2 Diabetic and Prediabetic Patients
Anna Oliveras,1,3 Julián Segura,3 Carmen Suárez,3
Manuel Gómez,3 Luis García‑Ortiz,3 Nieves Martell,3
María Abad,3 Luis Vigil,3 David Ferrero,3 Juan J. de
la Cruz,2 Luis M. Ruilope,3 Alejandro de la Sierra.3
1Hosp.del Mar. Parc Salut Mar, Barcelona, ES;
2Autonomous University of Madrid, ES; 3On Behalf of
the PRESCEN Study, ES.
Clinical Characteristics, Blood Pressure Control,
and Antihypertensive Treatment Patterns among
Elderly Patients with Hypertension
Sujata P. Sarda,1 Si‑Tien Wang,1 Priyanka
Ramamurthy,1 Robert Wei,1 Jinhee Park†,2 L. M.
Andrews,2 Feride Frech‑Tamas,2 Mei Sheng Duh.1
1Analysis Group, Inc., Boston, MA, US; 2Novartis
Pharmaceuticals Corporation, East Hanover, NJ, US.
Antihypertensive Effectiveness of Combination
Lercanedipine with Diltiazemi in Patients with Mild
to Moderate Arterial Hypertension
Oksana L. Rekovets, Yuriy M. Sirenko, Anna S.
Dobrokhod, Galina F. Primak, Alla S. Vaschilko,
Evhenia A. Pavlyuk. Institute of Cardiology, Kyiv, UA.
Higher Night-Time Blood Pressure and Cardiac
Damage in 1176 Patients: Effects of BMI and Drug
Therapy
Riccardo Sarzani, Federico Guerra, Massimiliano
Fedecostante, Paolo Barbatelli, Elena Giannini, Letizia
Lancioni, Emma Espinosa, Paolo Dessì‑Fulgheri.
Seasonality of 24 H, Daytime and Night-Time Blood
Pressure: Summer Does Not Always Mean Lower
Federico Guerra, Massimiliano Fedecostante, Letizia
Lancioni, Elena Giannini, Paolo Barbatelli, Emma
Espinosa, Paolo Dessì‑Fulgheri, Riccardo Sarzani.
133
May 23
21
Monday
Monday
Afternoon
Morning
Posters
PO-300:
PO-301:
PO-302:
PO-303:
PO-304:
PO-305:
PO-305A: Improvement in Hypertension Control after a 2-Year
Participation in a Web-Based Program on High BP
Management
Julian Segura,1 Manuel Gorostidi,2 Alejandro de la
Sierra,3 Jose R. Banegas,4 Juan J. de la Cruz,4 Luis
M. Ruilope.1 1Hospital 12 de Octubre, Madrid, ES;
2Hospital Central de Asturias, Oviedo, ES; 3Hospital
Mutua Terrasa, Universidad de Barcelona, Barcelona,
ES; 4Universidad Autónoma, Madrid, ES.
Prehypertension
Gabor Simonyi, Mihaly Medvegy. Flor Ferenc Hospital
of County Pest, Kistarcsa, HU.
Diagnostic Accuracy of Home Versus Ambulatory
Blood Pressure Monitoring
George S. Stergiou, Efthimia G. Nasothimiou, Dimitrios
Tzamouranis, Vagia Rarra, Leonidas G. Roussias.
University of Athens, Athens, GR.
Patients’ Preference for Out-of-Office Blood
Pressure Evaluation Method: Ambulatory or Home
Monitoring?
Efthimia G. Nasothimiou, Nikolaos Karpettas,
Antonios Destounis, George S. Stergiou. University of
Athens, Athens, GR.
Preditive Value of Ambulatory Blood Pressure for
Cardiovascular Events in Hypertensive Patients after
a First Event
Tiago Teixeira,1 José Nuno Figueiredo,1 Jose Mesquita
Bastos,1 Jose Nobre Santos,1 Jorge Polonia.2 1Hospital
Infante D.Pedro, EPE, Aveiro, PT; 2Faculdade de
Medicina do Porto, PT.
Methods for Fast and Accurate Normalization of
Real-World Prescription Data: A Report from the
O’QUIN Hypertension Initiative
C. Shaun Wagner, Brent Egan. Medical University of
South Carolina, Charleston, SC, US.
High Blood Pressure Treatment among Black and
White Stroke Patients
Andrea D. Boan, David L. Bachman, Robert J. Adams,
Brent M. Egan, Joyce S. Nicholas, Andrew B. Lawson,
Daniel T. Lackland. Medical University of South
Carolina, Charleston, SC, US.
Coagulation/Thrombosis; Growth
Factors; Ion Channels)
PO-306:
Pharmacological Inhibition of PI3Kg Reduces Blood
Pressure by a Vasorelaxant Akt/LTCC Mechanism
Daniela Carnevale,1 Giada Mascio,1 Giuseppe Cifelli,1
Carmine Vecchione,1 Giuseppe Lembo.1,2 1IRCCS
Neuromed, Pozzilli, IT; 2”Sapienza” University of
Rome, Rome, IT.
134
Monday Morning
Afternoon
May 23
21
Posters
PO-307:
PO-308:
Hypertension Induces b-Amyloid Deposition and
Cognitive Impairment by Activating RAGE in Brain
Endothelium
Daniela Carnevale,1 Giada Mascio,1 Giuseppe Cifelli,1
Shi Du Yan,3 Giuseppe Lembo.1,2 1IRCCS Neuromed,
Pozzilli, IT; 2”Sapienza” University of Rome, Rome, IT;
3Columbia University, New York, US.
Downmodulation of Peroxiredoxin-3 Expression in
Cardiac Fibroblasts by Angiotensin II
Paul J. Lijnen, Jos F. van Pelt. University of Leuvan
(KULeuven), Leuven, BE.
Lipid Metabolism
PO-309:
Does the Association between Lipid Profile and
Obesity Indices Vary through Decades in Essential
Hypertensive Patients?
Stella Maria Kyvelou,1 Gregory Vyssoulis,1 Eva
Karpanou,2 I. Skoumas,1 C. Stefanadis.1 11st
Cardiology Clinic Athens University Hippokration
Hospital Athens Greece, GR; 21st Cardiology Clinic
Onassis Cardiosurgery Center Athens, GR.
Neural hormonal Mechanisms (Renin;
Neural Control; Vasoactive Autacoids)
PO-310:
PO-311:
PO-312:
Long Term Follow-Up of Patients with Postural
Orthostatic Tachycardia Syndrome
Joao Freitas,1,2 Alexandra Sousa,1 Ana Lebreiro,1 Maria
Julia Maciel,1,2 Francisco Rocha Goncalves.2 1Hospital
de Sao Joao -E.P.E., Porto, PT; 2Unoversidade do Porto,
Porto, PT.
Resistant Hypertension and Intravascular Volume
Expansion
Guilherme Augusto Mariano Pego, João Bernardo Pego,
Maria Fátima Leitão, Helia Martins, Nadia Moreira,
Luis Augusto Providência. University Hospital of
Coimbra, PT.
Expression of the Renin-Angiotensin System in a
Human Placental Cell Line
Nan Pan,1 Wayne L. Frome,1 Richard A. Dart,1 Duane
A. Tewksbury,1 Jiangming Luo.2 1Marshfield Clinic
Research Foundation, Marshfield, WI, US; 2Marshfield
Clinic, Marshfield, WI, US.
135
May 23
21
Monday
Monday
Afternoon
Morning
Posters
Non-Pharmacological Therapy
(Alternative Medicine; Diet; Physical
Activity)
PO-313:
PO-314:
PO-315:
PO-316:
PO-317:
PO-318:
PO-319:
The HARMONY Study: Hypertension Analysis of
Stress Reduction Using Mindfulness Meditation and
Yoga
Kimberly C. Blom,1 Brian Baker,2 Jane Irvine,4 Susan
Abbey,2 Beth Abramson,3 Martin Myers,1 Nancy
Perkins,1 Sheldon W. Tobe.1 1Sunnybrook Health
Sciences Centre, Toronto, ON, CA; 2University Health
Network, Toronto, ON, CA; 3St. Michael’s Hospital,
Toronto, ON, CA; 4York University, Toronto, ON, CA.
Impact of Smoking Cessation on Nocturnal Blood
Pressure
Patrick T. Campbell, Carla J. Rash, Sheila M. Alessi,
Nancy M. Petry, William B. White. University of
Connecticut, Farmington, CT, US.
Leisure Physical Activity and Emergent
Cardiovascular Risk Factors in Hypertensive
Patients
Cristiana Catena, GianLuca Colussi, Andrea Russo,
Gabriele Brosolo, Leonardo A. Sechi. University of
Udine, IT.
Aerobic Exercise Training Improves Renal Function
in African Americans
Keith M. Diaz,1 Deborah L. Feairheller,1 Kathleen
M. Sturgeon,1 Praveen Veerabhadrappa,1 Sheara
Williamson,1 Jan Kretzschmar,1 Michael D. Brown.1
1Temple University, Philadelphia, PA, US; 2Temple
University, Philadelphia, PA, US.
Actions to Control Hypertension among Adults with
Hypertension
Jing Fang, Nora L. Keenan. CDC, Atlanta, GA, US.
Exercise Capacity is Inversely Related to Mortality
Risk in Hypertensive Individuals with Sleep Apnea
Peter Kokkinos,1,2,3 Shikha Khosla,1 Marshal Balish,1
Raya Kheirbek,1 Helen Sheriff,1 Eric Nylen,1,3
Charles Faselis.1,3 1Veterans Affairs Medical Center,
Washington, DC, US; 2Georgetown University
School of Medicine, Washington, DC, US; 3George
Washington University School of Medicine,
Washington, DC, US.
Heart Rate Recovery, Fitness and Mortality Risk in
Hypertensive Individuals
Peter Kokkinos,1,2,3 Charles Faselis,1,3 Michael
Doumas,1,3 Ross Fletcher,1,2 Andreas Pittaras,1
Athanasios Manolis,1 Rhea Kheirbek,1 Vasilios
Papademetriou.1,2 1Veterans Affairs Medical Center,
Washington, DC, US; 2Georgetown University
School of Medicine, Washington, DC, US; 3George
Washington University, Washington, DC, US.
136
Monday Morning
Afternoon
May 23
21
Posters
PO-321:
PO-322:
The Cost-Effectiveness of Interventions Designed to
Reduce Sodium Intake
Guijing Wang, Darwin Labarthe. Centers for Disease
Control and Prevention, Atlanta, GA, US.
Seasonal Effects of Blood Pressure in
Postmenopausal Women
Adrian D. Wood,1 Frank Thies,1 William D. Fraser,2
Lorna Aucott,1 Karen R. Secombes,1 William G.
Simpson,3 David M. Reid,1 Helen M. Macdonald.1
1University of Aberdeen, Aberdeen, GB; 2University of
Liverpool, Liverpool, GB; 3Aberdeen Royal Infirmary,
Aberdeen, GB.
Nutrition and Cardiovascular Prevention
PO-323:
PO-324:
PO-325:
PO-325A:
PO-326:
Antihypertensive Effect of Dietary Integration with
Grana Padano Cheese in Hypertensive Patients
Giuseppe Crippa,1 Matteo Bosi,2 Cassi Antonino,1
Lucia Fiorentini,2 Filippo Rossi.2 1Guglielmo da
Saliceto Hospital, Piacenza, IT; 2Universita’ Cattolica
del Sacro Cuore, Piacenza, IT.
Abnormal Circadian Blood Pressure Variability in
Healthy Adults: A Function of Weight Gain, Increase
in Waist Circumference and Insulin Resistance
Alok K. Gupta,1 Germaine G. Cornelissen‑Guillaume,2
William D. Johnson,1 Frank L. Greenway,1 Darcy
Johannsen,1 Eric Ravussin.1 1Pennington Biomedical
Research Center, Louisiana State University System,
Baton Rouge, LA, US; 2University of Minnesota,
Minneapolis, MN, US.
Endothelial Dysfunction in Healthy Adults:
A Function of Weight Gain, Increase in Waist
Circumference and Insulin Resistance
Alok K. Gupta, William D. Johnson, Darcy Johannsen,
Eric Ravussin. Pennington Biomedical Research
Center, Louisiana State University System, Baton
Rouge, LA, US.
Dysglycemia Induces Abnormal Circadian
Variability of Blood Pressure
Alok K. Gupta,1 Kathirvel Gopalakrishnan,2 Sivarajan
Kumarasamy,2 William D. Johnson,1 Bina Joe.2
1Pennington Biomedical Research Center, Louisiana
State University System, Baton Rouge, LA, US;
2University of Toledo College of Medicine, Toledo,
OH, US.
Relationship between Salt Intake and Central
Aortic Hemodynamics in a Cohort of Untreated
Jorge J. Polonia, Jose A. Silva, Susana P. Bertoquini,
Barbosa Loide. Faculdade Medicina Porto, Matosinhos
Porto, PT.
137
May 23
21
Monday
Monday
Afternoon
Morning
Posters
PO-327:
PO-328:
PO-329:
PO-330:
Effect of Lifestyle Modification in Menopausal
Women with Obesity, Hypertension, Autonomic and
Endothelial Dysfunction
Rosa M. Santos,1 Joao Freitas,1 Agostinho Monteiro,3
Espiga Macedo,3 Eduardo Tejera,2 Irene Rebelo.2
1Hospital S Joao, Porto, PT; 2Faculty Pharmacy, Porto,
PT; 3Faculty Medicine, Porto, PT.
At Risk Older Latino Men and Women: Blood
Pressure, Body Mass Index and DASH Accordance
Beth A. Staffileno,1 Christy Tangney,1 David X.
Marquez,2 Louis Fogg,1 Eduardo E. Bustamante,2
Martha Clare Morris,1 Ruby Hoyem,1 Alexis
Manning,1 JoEllen Wilbur.1 1Rush University Medical
Center, Chicago, IL, US; 2University of Illinois at
Chicago, Chicago, IL, US.
Medical Avatar Can Select Patients with
Cardiovascular Risk Factors
Jerzy T. Tyszkiewicz, Bartosz Symonides, Zbigniew
Gaciong. Medical University of Warsaw, Warsaw, PL.
Aerobic Exercise Training Improves Endothelial
Function in Pre-Hypertensive African Americans
Sheara T. Williamson, Deborah L. Feairheller, Kathleen
M. Sturgeon, Praveen Veerabhadrappa, Michael
D. Brown, Jan Kretzschmar. Temple University,
Philadelphia, PA, US.
Obesity
PO-331:
PO-332:
PO-334:
PO-335:
The Effect of BMI on the Systemic Catecholamine
and Haemodynamic Response to Increased
Sympathetic Activity in Young Adults: A Pilot Study
James M. Coulson†, John R. Cockcroft. Cardiff
University, Cardiff, Wales, GB.
Aldosterone Release is Positively Correlated with
Increasing Body Weight in Patients with Resistant
Hypertension
Tanja Dudenbostel, Maria Czarina Acelajado, Roberto
Pisoni, Suzanne Oparil, David A. Calhoun. Vascular
Biology and Hypertension, University of Alabama at
Beta2-Adrenoceptor Polymorphisms (Arg16Gly)
Accompanying High Plasma Norepinephrine is
Related to Cardiovascular and Renal Complications
in Obese Subjects
Kazuko Masuo,1 Hiromi Rakugi,2 Toshio Ogihara,2
Murray D. Esler,1 Gavin W. Lambert.1 1Baker IDI
Heart & Diabetes Institute, Melbourne, VIC, AU;
2Osaka University Graduate School of Medicine, Suita,
Osaka, JP.
Efficacy of an Amlodipine/Olmesartan Medoxomil
Algorithm on BP Control in Obese Patients
Uncontrolled by Monotherapy
Joel M. Neutel†,1 Willa Hsueh,2 Ali Shojaee,3 William F.
Waverczak,3 Jen‑Fue Maa.3 1Orange County Research
Center, US; 2The Methodist Hospital Research
Institute, US; 3Daiichi Sankyo, Inc., US.
138
Monday Morning
Afternoon
May 23
21
Posters
PO-336:
PO-337:
PO-338:
PO-339:
Resolution of Hypertension after Adjustable Gastric
Banding – 1 Year Interim Results of the LAP-BAND
AP® EXperience (APEX) Study
John Dixon,1 Michael Oefelein,2 Ted Okerson†.2
1Monash University, Melbourne, AU; 2Allergan, Inc,
Irvine, CA, US.
Initial Aliskiren/HCTZ Combination Therapy
Lowers BP in Obese Patients with Stage 2
Hypertension and Type 2 Diabetes
Raymond R. Townsend,1 Alan Forker,2 Thomas
Severin,3 Cheraz Cherif Papst,3 Anthony Yadao.4
1University of Pennsylvania Medical Center,
Philadelphia, PA, US; 2St Luke’s Lipid and Diabetes
Research Center, Kansas City, MO, US; 3Novartis
Aliskiren/HCTZ Inhibits RAAS Activity in Obese
and Non-Obese Patients with Stage 2 Hypertension
and Type 2 Diabetes
Raymond R. Townsend,1 Alan Forker,2 Thomas
Severin,3 Cheraz Cherif Papst,3 Anthony Yadao.4
1University of Pennsylvania Medical Center,
Philadelphia, PA, US; 2St Luke’s Lipid and Diabetes
Research Center, Kansas City, MO, US; 3Novartis
Aliskiren/Amlodipine Combination Lowers BP in
Obese and Non-Obese Patients with Moderate-toSevere Hypertension
Rudiger C. Braun‑Dullaeus,1 Sergey B. Shustov,2
Carmen Alvarez,3 Gregorio G. Rogelio,4 Cheraz Cherif
Papst,5 Jack Zhang†.6 1Otto-von-Guericke University,
Magdeburg, DE; 2State Educational Institution of
High Professional Education, St Petersburg, RU; 3ABS
Centelles, Barcelona, ES; 4St Luke’s Medical Center,
Quezon, PH; 5Novartis Pharma AG, Basel, CH;
6Novartis Pharmaceuticals Corporation, East Hanover,
NJ, US.
Patient-Provider-Healthcare System
Issues
PO-340:
PO-341:
Clinical Inertia in Hypertension: Identifying
Barriers to Improve Quality
Bryan Batson,1 JaNae Joyner,2 Philip Mellen,1 William
Smith.1 1Hattiesburg Clinic, Hattiesburg, PA, US; 2The
Consortium for Southeastern Hypertension Control
(COSEHC), Winston-Salem, NC, US.
Renal Artery Stent Management: A Survey of Local
Practice Patterns
Frank K. Boateng, Daniel L. Landry, Barbara A. Greco.
Baystate Medical Center, Springfield, MA, US.
139
May 23
21
Monday
Monday
Afternoon
Morning
Posters
PO-342:
PO-343:
PO-344:
PO-345:
PO-346:
PO-347:
Impact of Switching from Valsartan to a LowerTiered Angiotensin Receptor Blocker on Subsequent
Treatment Patterns
E. K. Buysman†,1 L. M. Andrews,2 T. J. Bancroft,1 H.
B. Dastani,2 J. Zhang,2 M. L. Monsalvo.3 1i3 Innovus,
Eden Prairie, MN, US; 2Novartis Pharmaceuticals
Corporation, East Hanover, NJ, US; 3i3 Research,
Buenos Aires, AR.
Hypertension Specialists’ Current and Potential
Impact on Resistant Hypertension in the Medicare
Population
William J. Elliott†,1 Brent M. Egan,2 Thomas D. Giles,3
George L. Bakris,4 Torry Mark Sansone.5 1Pacific
Northwest University of Health Sciences, Yakima, WA,
US; 2Medical University of South Carolina, Charleston,
SC, US; 3Tulane University School of Medicine, New
Orleans, LA, US; 4The University of Chicago, Chicago,
IL, US; 5The American Society of Hypertension, New
York, NY, US.
Mitigating Risk – Cardiovascular Health Assessment
for the Men/Ms of Paterson and Passaic County –
MR CHAMMP
Robert T. Faillace, Margaret Latrella, Carolyn Strimike,
Deborah Terrone, James Pruden, Ken Morris, Kathleen
Sauter. St. Joseph’s Healthcare System, Paterson, NJ,
US.
Quantification of Clinical Inertia during GP’s
Management of Uncontrolled Hypertensive Patients
– Clepsydre Study
Xavier Girerd,1 Béatrice Fiquet,2 Stéphane Quéré,2
Alain Francillon.2 1Pitié-Salpétrière Hospital, Paris, FR;
2Novartis Pharma SAS, Rueil-Malmaison, FR.
Time to Talk CARDIO Communication Tool Use
Improves Cardiovascular Disease Management
Behaviors and Satisfaction
Brian Forrest,1 Stephanie Brinson,1 Susan Harris
Bavisotto,1 JaNae Joyner.2 1Access Healthcare,
Apex, NC, US; 2The Consortium for Southeastern
Hypertension Control (COSEHC), Winston Salem,
NC, US.
Automated Outreach for Antihypertensive
Medication Refill Reminders
Kelley R. Green,1 Joel Handler,2 Southida S.
Vansomphone,3 Claire Mesirov,4 Kristi Reynolds.4
1Kaiser Permanente Southern California Permanente
Medical Group, Pasadena, CA, US; 2Kaiser Permanente
Medical Center, Anaheim, CA, US; 3Kaiser
Permanente, Downey, CA, US; 4Kaiser Permanente
Southern California, Pasadena, CA, US.
140
Monday Morning
Afternoon
May 23
21
Posters
PO-348:
PO-350:
PO-351:
PO-352:
PO-353:
PO-354:
PO-355:
Impact of Non-Medical Switching between Different
Angiotensin Receptor Blockers on Blood Pressure
and Medical Resource Utilization
Khalid M. Kamal†,1 Christopher Zacker,2 Louis
Civitarese.3 1Duquesne University Mylan School
of Pharmacy, Pittsburgh, PA, US; 2Novartis
Pharmaceuticals Corporation, Emmaus, NJ, US;
3Preferred Primary Care Physicians, Pittsburgh, PA,
US.
Simple Drug Preference Questions are Predictive of
Antihypertensive Response: A STITCH2 Substudy
Sigrid A. Nelson,1 George K. Dresser,2,3 Jeffrey L.
Mahon,1,2,3 Brian G. Feagan,1,2,3 Guang Y. Zou,1,3
Margaret K. Vandervoort,1 Cindy J. Wong,1 Ross D.
Feldman.1,2,3 1Robarts Research Institute, CA; 2London
Health Sciences Centre, CA; 3University of Western
Ontario, CA.
Increased Clinical Outcomes at One Year Follow-Up
Found in a Diabetic Patient-Centered Medical Home
Pilot Program
Jennifer O’Donnell,1 Cyndi Shull,2 Amber Winkler,1
JaNae Joyner,3 Laura Long.2 1Palmetto Primary Care
Physicians, US; 2Blue Cross and Blue Shield of South
Carolina, US; 3The Consortium for Southeastern
Hypertension Control, Winston-Salem, NC, US.
Single Pill vs Free-Equivalent Combination
Therapies for Hypertension: Meta-Analysis of
Adherence and Costs
Beth Sherrill,1 Michael Halpern,2 Sumeet Panjabi†,3
Shahnaz Khan,1 Jie Zhang.1 1RTI Health Solutions,
Research Triangle Park, NC, US; 2RTI International,
Washington, DC, US; 3Daiichi Sankyo, Inc, Parsippany,
NJ, US.
Differences and Similarities in Explanatory Models
of Hypertension in the U.S., Tanzania and Jamaica
John Purakal,1 Jean Williams‑Johnson,2 Eric Williams,2
Ibtissam Ammary,3 Senga Pemba,4 Joseph Kambona,4
Robert Welch,1 John Flack,1 Phillip Levy.1 1Wayne
State University School of Medicine, Detroit, MI,
US; 2University Hospital of the West Indies, JM;
3University of Michigan School of Public Health,
Ann Arbor, MI, US; 4Tanzanian Training Centre for
International Health, TZ.
Treat to Target using Interactive Voice Messaging
to Enhance Primary Care Physican Management of
Hypertension
Graham A. Scott. Kaiser Permanente Medical Center,
Riverside, CA, US.
Is Poor Blood Pressure Control in Patients
Presenting for Elective Surgery Predictable?
Patrick E. Benedict, Sachin Kheterpal, Amy M. Shanks,
Alan B. Weder. University of Michigan, Ann Arbor,
MI, US.
141
May 23
21
Monday
Monday
Afternoon
Morning
Posters
Preclinical Models/Experimental
Hypertension
PO-357:
PO-358:
Paraventricular Nucleus of the Hypothalamus
Neurons Project to Parasympathetic Brainstem
Neurons that Control Heart Rate
David Mendelowitz, Ramon Pinol. George Washington
University, Washington, DC, US.
Effects of Sex on Sympathetic Neural and
Hemodynamic Responses to Head-Up Tilt in
Hypertensive Seniors
Yoshiyuki Okada,1,2 M. Melyn Galbreath,1,2 Shigeki
Shibata,1,2 Sara S. Jarvis,1,2 Tiffany B. VanGundy,1
Rhonda L. Meier,1 Wanpen Vongpatanasin,2 Benjamin
D. Levine,1,2 Qi Fu.1,2 1Institute for Exercise and
Environmental Medicine, Texas Health Presbyterian
Hospital, Dallas, TX, US; 2The UT Southwestern
Medical Center at Dallas, Dallas, TX, US.
Pregnancy
PO-359:
PO-360:
PO-361:
Autoantibodies to the Angiotensin II Type 1
Receptor in Preeclampsia
Maciej Adamczyk, R. Jeffrey Brashear, Stephen C. Hsu,
Phillip G. Mattingly. Abbott Laboratories, Abbott Park,
IL, US.
The Correlation between the Serum Testosterone
Level and Insulin Sensitivity in Pre-Eclampsia –
Eclampsia Syndrome
M. Yousri K. Amin, Ibrahim L. Abdellatifi, Yousri
A. Mohyeldin, Abdelmoneim A. Fawzy, Akram A.
Deghedi, Mohamed A. Harb. Alexandria University,
Alexandria, EG.
Effects of High Altitude and Ancestry on Uterine
Artery Shear Stress and Blood Pressure in Normal
Pregnant vs. Preeclamptic Women
Ronald Magness,1 Ira Bernstein,2 Stacy Zamadio.3
1University of Wisconsin - Madison, Madison, WI,
US; 2University of Vermont, Vermont, US; 3New Jersey
Medical School, New Jersey, US.
Salt-Sensitive Mechanisms of
Hypertension
PO-362:
PO-363:
Silencing of PKG1 Gene Sensitizes Vascular Smooth
Muscle Cells to Marinobufagenin: Impact on Aging,
Fibrosis, and Salt-Sensitivity
Olga V. Fedorova,1 Victoria Y. Shilova,1 Joseph I.
Shapiro,2 Edward G. Lakatta,1 Alexei Y. Bagrov.1
1Intramural Research Program, National Institute on
Aging, NIH, Baltimore, MD, US; 2College of Medicine,
University of Toledo, Toledo, OH, US.
Heritability of Na/K Excretion during the Saline/
Lasix Protocol in African American Twins
Clarence E. Grim, Robinson Miguel. High Blood
Pressure Consulting, Milwaukee, WI, US.
142
Monday Morning
Afternoon
May 23
21
Posters
PO-364:
Gender Difference in the Relationship of
Marinobufagein to Salt-Sensitivity of Blood Pressure
Alexei Y. Bagrov,1 Olga V. Fedorova,1 Philippe Burri,2
Edward G. Lakatta,1 Olle Melander.2 1National Institute
on Aging, NIH, Baltimore, MD, US; 2Lund University,
Malmö, SE.
Secondary Hypertension
PO-365:
PO-366:
PO-367:
Association of Renal Artery Stenosis with Acute
Pulmonary Edema in Hypertensive Patients
Roxana O. Darabont,1 Alexandru Corlan,2 Mircea
Cinteza,1 Dragos Vinereanu.1 1University of Medicine
and Pharmacy ‘Carol Davila’, Bucharest, RO;
2University Emergency Hospital, Bucharest, RO.
Big Endothelin-1 and Nitric Oxid Levels in
Hypertensive Elderly with and without Obstructive
Sleep Apnea
Nereida K. C. Lima, Iara F. Anunciato, Romulo R.
Lobo, Alan L. Eckeli, Regina M. R. Fernandes, Paulo
R. B. Evora, Fernando Nobre, Waldiceu A. VerriJunior, Julio C. Moriguti, Eduardo Ferriolli, Eduardo B.
Coelho. Ribeirao Preto School of Medicine – Sao Paulo
University, Ribeirao Preto, SP, BR.
Pheochromocytoma and Coronary Artery Disease
Galina N. Potapova,1 L. M. Sergakova,1 G. V.
Ryabikina,1 L. N. Lyutikova,1 I. E. Chazova,1 N. S.
Kuznetsov,2 E. G. Popov,1 I. Y. Gavrilov.1 1Cardiology
Research Complex, Moscow, RU; 2Endocrinology
Research Center, Moscow, RU.
143
May 23
21
Monday
Monday
Afternoon
Morning
Posters
Late-Breaking
Posters
LB-PO-01:
LB-PO-02:
LB-PO-03:
ANP-cGMP-PKG Activation Inhibits TGF-bInduced Smad3 Nuclear Translocation by Increasing
Smad3 Binding to Cytosolic b2-Tubulin in Rat
Pulmonary Arterial Smooth Muscle Cells
Kaizheng Gong,1,2 Dongqi Xing,1 Peng Li,1
Namasivayam Ambalavanan,3 Suzanne Oparil,1 YiuFai Chen.1 1University of Alabama at Birmingham,
Birmingham, AL, US; 2The Second Medical School of
Yangzhou University, Yangzhou, CN; 3University of
Alabama at Birmingham, Birmingham, AL, US.
Effect of Carvedilol CR, Lisinopril and Their
Combination on Markers of Early Cardiovascular
Disease in Subjects with High-Normal Blood
Pressure: The DETECT Study
Sara M. Saul,1 Daniel A. Duprez,1 Wei Zhong,2
Gregory A. Grandits,2 Jay N. Cohn.1 1University of
Minnesota Medical School, Minneapolis, MN, US;
2University of Minnesota School of Public Health,
Minneapolis, MN, US.
Consistency of Masked Hypertension in African
Americans during Repeat Office Visits
Praveen Veerabhadrappa, Keith M. Diaz, Sheara M.
Williamson, Jan Kretzschmar, Deboarh L. Feairheller,
Kathleen M. Sturgeon, Shannon B. Watkins, Michael
D. Brown. Temple University, Philadephia, PA, US.
144
Faculty Disclosure Listing
Rajiv Agarwal, MD
Advisor/Consultant: Abbott, Merck, Daiichi-Sankyo, Reata, Amgen.
Trustee/Board Member/Committee Member: Abbott. Speakers’ Bureau/Speaking/Teaching: Abbott, Merck.
Lawrence J. Appel, MD, MPH
I have no relationships to disclose.
Donna K. Arnett, PhD, MSPH
Nancy Artinian, RN, BSN
Phyllis August, MD, MPH
Advisor/Consultant: Otsuka.
Abraham Aviv, MD
Employment Income/Salary: University of Medicine and Dentistry,
New Jersey Medical School. Grant/Research Support: National Institutes of Health.
George L. Bakris, MD
Advisor/Consultant: Takeda, Abbott, CVRx, Ardian, Walgreen’s,
Johnson & Johnson, Merck. Trustee, Board Member, Committee
Member: National Kidney Foundation. Grant/Research Support:
Forest Labs, Novartis. Speaker’s Bureau/Speaking/Teaching: Forest
Labs, Novartis. President, ASH Board of Directors.
Jan N. Basile, MD
Advisor/Consultant: Boehringer-Ingelheim, Forest Laboratories,
Daiichi-Sankyo, Takeda. Speakers’ Bureau/Speaking/Teaching:
Daiichi-Sankyo, Forest, Takeda.
John D. Bisognano, MD, PhD
Advisor/Consultant: CVRx. Grant/Research Support: CVRx. Secretary, ASH Board of Directors.
Henry R. Black, MD
Advisor/Consultant: Servier, Mitsubushi, Xoma, Ligand, Bristol-Myers Squibb, Biosante, Novartis. Grant/Research Support: AHRQ/HHS.
Speakers’ Bureau/Speaking/Teaching: Daiichi-Sankyo, BoehringerIngelheim, MSD. Immediate Past President, ASH Board of Directors.
Michael J. Bloch, MD
Advisor/Consultant: Takeda. Grant/Research Support: Novartis.
Speakers’ Bureau/Speaking/Teaching: AstraZeneca, Abbott, Boehringer-Ingelheim.
Royalties (Including Trademarks or Patents): UpToDate, Inc. Grant/
Research Support: National Institutes of Health. Speakers’ Bureau/
Speaking/Teaching: American Heart Association, Spotlight Speaker.
Other Relevant Financial Benefit or Relationship: National Lipid Association Web Presentation.
Emmanuel Bravo, MD
145
Faculty Disclosure Listing continued
Angela L. Brown, MD
Advisor/Consultant: Takeda. Speakers’ Bureau/Speaking/Teaching:
Novartis, Forest, Pfizer.
Nancy J. Brown, MD
Advisor/Consultant: Novartis, Merck. Grant/Research Support: Forest, Shire HGT. Ownership/Partnership or Principal of Non-Profit or
for Profit Corporation: Protein Discovery.
David A. Bushinksy, MD
Employment Income/Salary: Univeristy of Rochester. Advisor/Consultant: Amgen, Genzyme, Relypsa, Cytochroma. Grant/Research
Support: National Institutes of Health, Renal Research Institute. Ownership Interest (Stocks, Excluding Diversified Mutual Funds): Amgen,
Relypsa. Speakers’ Bureau/Speaking/Teaching: Amgen, Genzyme.
Norman R.C. Campbell, MD
Other Relevant Financial Benefit or Relationship: Boehringer-Ingelheim.
Oscar A. Carretero, MD
Grant/Research Support: National Institutes of Health, Roche Pharmaceuticals.
Grant/Research Support: National Institutes of Health.
Advisor/Consultant: Forest, Novartis, Genzyme, GlaxoSmithKline.
Grant/Research Support: GlaxoSmithKline. Speakers’ Bureau/Speaking/Teaching: Genzyme, Amgen.
Jay N. Cohn, MD
Steven D. Crowley, PhD
William C. Cushman, MD
Advisor/Consultant: Takeda, Novartis.
Stephen R. Daniels, MD, PhD
Michael H. Davidson, MD
Advisor/Consultant: Abbott, Aegerion, Amgen, AstraZeneca, Atherotech, Daiichi-Sankyo, DTC MD, Esperion, GlaxoSmithKline, iMD
(Intelligent Medical Decisions), Kinemed, LipoScience, Merck, Novo
Nordisk, Roche, Sanofi-Aventis, Synarc, Takeda, Vindico Medical
Education. Trustee/Board Member/Committee Member: DTC MD,
Omthera, Professional Education, Inc. Medical Education Company,
Sonogene. Grant/Research Support: Abbott, Daiichi-Sankyo, GlaxoSmithKline, Merck, Roche.
Daniel Duprez, MD, PhD
Advisor/Consultant: Novartis, Abbott, Pfizer, Merck. Grant/Research
Support: Novartis, Roche, Merck. Speakers’ Bureau/Speaking/Teaching: Novartis, Pfizer, Merck, Boehringer-Ingelheim, Forest, Abbott.
Lance D. Dworkin, MD
Advisor/Consultant: Questcor. Grant/Research Support: Questcor,
Pfizer, AstraZeneca.
146
Brent M. Egan, MD
Advisor/Consultant: NiCox. Grant/Research Support: Daiichi-Sankyo,
Novartis, Takeda.
Paula T. Einhorn, MD, MS
William J. Elliott, MD, PhD
Royalties (Including Trademarks or Patents): Elsevier, Inc. Grant/
Research Support: Forest Research Institute. Speakers’ Bureau/Speaking/Teaching: Forest Laboratories, Boehringer-Ingelheim, NiCox,
Inc., American Society of Hypertension.
Murray Epstein, MD
Advisor/Consultant: Bristol-Myers Squibb, AstraZeneca.
Murray D. Esler, MBBS, PhD
Advisor/Consultant: ADRIAN Corporation, Chief Investigator International Trial. Speakers’ Bureau/Speaking/Teaching: Solvay Australia.
Bonita Falkner, MD
Advisor/Consultant: AstraZeneca, Pfizer, Merck.
Sadaf Farooqi, PhD
Ross Feldman, MD
Advisor/Consultant: AstraZeneca, Boehringer-Ingelheim, BristolMyers Squibb, Merck, Forest Canada, Novartis, Pfizer, Sanofi-Aventis,
Servier, Takeda. Trustee/Board Member/Committee Member: Servier,
Takeda.
Keith C. Ferdinand, MD
Advisor/Consultant: AstraZeneca, Merck, Pfizer, Novartis, Takeda,
Forest. Grant/Research Support: Daiichi-Sankyo. Speakers’ Bureau/
Speaking/Teaching: Novartis, AstraZeneca. Member, ASH Board of
Directors.
Advisor/Consultant: Novartis, Daiichi-Sankyo. Grant Research/
Support: Novartis. Speakers’ Bureau/Speaking/Teaching: Novartis,
Daiichi-Sankyo, Boehringer-Ingelheim.
Joseph T. Flynn, MD
Advisor/Consultant: Pfizer, Novartis, PTC Therapeutics.
Stanley S. Franklin, MD
William H. Frishman, MD
Ownership Interest (Stocks, Excluding Diversified Mutual Funds):
Merck, Pfizer. Speakers’ Bureau/Speaking/Teaching: NCME (BristolMyers Squibb), Pfizer, Forest Laboratories, Boehringer-Ingelheim.
James B. Froehlich, MD, MPH
Advisor/Consultant: Merck, Sanofi-Aventis. Speakers’ Bureau/Speaking/Teaching: Merck, Schering-Plough.
Leonard M. Fromer, MD
Trustee/Board Member/Committee Member: TransferMed, LLC.
Jeffrey L. Garvin, PhD
147
Advisor/Consultant: Medivation, Merck. Speakers’ Bureau/Speaking/
Teaching: Novartis.
F. Wilford Germino, MD
Thomas D. Giles, MD
Advisor/Consultant: Amylin, Forest, NiCox. Grant/Research Support:
Forest. Speakers’ Bureau/Speaking/Teaching: Forest. Member, ASH
Board of Directors. Chair, ASH Specialists Program Inc.
Alan H. Gradman, MD
Advisor/Consultant: Novartis, Forest, Takeda, Daiichi-Sankyo. Speakers’ Bureau/Speaking/Teaching: Novartis, Forest, Takeda. Member,
ASH Board of Directors.
Richard H. Grimm, MD, PhD
Advisor/Consultant: Abbott. Grant/Research Support: Roche. Speakers’ Bureau/Speaking/Teaching: Merck.
Yuan Guo, MD, MS
John E. Hall, PhD
Joel Handler, MD
David Harder, MD, PhD
Raymond C. Harris, MD
Joseph A. Hill, MD
Norman K. Hollenberg, MD, PhD
Advisor/Consultant: Novartis, Merck, Vitae Pharmaceuticals. Grant/
Research Support: Vitae Pharmaceuticals.
Suzanne Hughes, MSN, RN
Joseph L. Izzo, Jr., MD
Advisor/Consultant: Pharmacists Mutural, Boehringer-Ingelheim,
Novartis, Curry Rockfeller, Thornton Medical, Daiichi-Sankyo, SCS
Healthcare, Takeda, Maritz Travel Co. Grant/Research Support:
Novartis, Daiichi-Sankyo. Speakers’ Bureau/Speaking/Teaching: Novartis, Daiichi-Sankyo, SCS Healthcare, Maritz Travel Co.
Edgar A. Jaimes, MD
Advisor/Consultant: Novartis.
148
Kenneth A. Jamerson, MD
Advisor/Consultant: Boehringer-Ingelheim, Eli Lily, Daiichi-Sankyo,
Novartis. Trustee/Board Member/Committee Member: American
Society Of Hypertension, International Society of Hypertension
in Blacks. Grant/Research Support: National Institutes of Health,
National Institute of Diabetes and Digestive and Kidney Diseases, National Heart, Lung, and Blood Institute, Novartis. Speakers’ Bureau/
Speaking/Teaching: Daiichi-Sankyo.
Julie A. Johnson, PharmD
Advisor/Consultant: Medco.
Grant/Research Support: National Institutes of Health. Other Relevant
Financial Benefit or Relationship: Patent on the Use of Allopurinol to
Treat Hypertension.
Pedro A. Jose, MD
Grant/Research Support: National Heart, Lung, and Blood Institute,
National Institutes of Health, National Institute of Diabetes and
Digestive and Kidney Diseases, BIAL. Ownership/Partnership or
Principal of Non-Profit or for Profit Corporation: Hypogen, Inc.
Luis I. Juncos, MD
Rae‑Ellen W. Kavey, MD, MPH
Donald E. Kohan, MD, PhD
Advisor/Consultant: Abbott, Pfizer, Gilead, Bristol-Myers Squibb.
Grant/Research Support: National Institutes of Health. VA, Gilead.
David S. Kountz, MD
Henry Krum, MBBS
Grant/Research Support: Ardian.
Louis Kuritzky, MD
Advisor/Consultant: Boehringer-Ingelheim, Takeda. Speakers’ Bureau/Speaking/Teaching: Boehringer-Ingelheim, Takeda.
Robert F. Kushner, MD
Daniel T. Lackland, DrPH
Speakers’ Bureau/Speaking/Teaching: Sanofi-Aventis, BoehringerIngelheim. Member, ASH Board of Directors.
Edward G. Lakatta, MD
Babbette LaMarca, PhD
Grant/Research Support: American Heart Association, National
Institutes of Health.
Marc B. Lande, MD, MPH
149
Daniel Levy, MD
Member, ASH Board of Directors.
Nita A. Lindi, PharmD, PhD, MSPH
Tianh Liu, MD
Employment Income/Salary: Pi County People’s Hospital.
Charles J. Lowenstein, MD
Jianfang Luo, MD
James M. Luther, MD
Giuseppe Mancia, MD
Advisor/Consultant: Bayer, Boehringer-Ingelheim, MSD, Menaribni
International, Novartis, Recordati, Sanofi-Aventis, Servier. Grant/
Research Support: Gilead, Servier.
Samuel J. Mann, MD
Grant/Research Support: Forest. Speaker’s Bureau/Speaking/Teaching:
Forest.
Athanasios J. Manolis, MD, PhD
Advisor/Consultant: Menarini, Abbott. Speakers’ Bureau/Speaking/
Teaching: Menarini, Recordati.
Allyn L. Mark, MD
Barry J. Materson, MD, MBA
Grant/Research Support: Forest, Takeda, Merck.
David L. Mattson, PhD
Richard J. McManus, MD
Grant/Research Support: Omron Europe (potential).
John Merenich, MD
Franz H. Messerli, MD
Advisor/Consultant: Novartis, Daiichi-Sankyo, Sanofi-Aventis,
Takeda, Abbott. Grant/Research Support: Forest, Daiichi-Sankyo,
Boehringer-Ingelheim. Treasurer, ASH Board of Directors.
Nancy Houston Miller, RN, BSN
Advisor/Consultant: Abbott, Gilead, Novartis.
Mark E. Molitch, MD
Advisor/Consultant: Novartis, Abbott. Grant/Research Support: Eli
Lily.
Krzysztof Narkiewicz, MD, PhD
Speakers’ Bureau/Speaking/Teaching: Berlin Chernie Menarini,
Boehringer-Ingelheim, Daiichi-Sankyo, Krka, Novartis, Servier.
150
Advisor/Consultant: Forest, Novartis, Nicor, Merck & Co., Boehringer-Ingelheim. Trustee/Board Member/Committee Member: American
Heart Association, American Society of Hypertension, InterAmerican
Society of Hypertension. Grant/Research Support: National Heart,
Lung and Blood Institute, NCRR, Merck, Forest. Ownership Interest
(Stocks, Excluding Diversified Mutual Funds): Abbott, AstraZeneca,
Baxter International, Merck & Co., Pfizer, Inc. Speakers’ Bureua/
Speaking/Teaching: Merck & Co., Forest Pharmaceuticals.
Shawna D. Nesbitt, MD, MS
Advisor/Consultant: Daiichi-Sankyo. Speakers’ Bureau/Speaking/
Teaching: Novartis, Gilead, Boehringer-Ingelheim.
Joel M. Neutel, MD
Speakers’ Bureau/Speaking/Teaching: Novartis, Forest, Bristol-Myers
Squibb – Sanofi-Aventis, Takeda, Boehringer-Ingelheim, DaiichiSankyo.
Susanne B. Nicholas, MD, PhD, MPH
Eoin O’Brien, MD
Gbenga Ogedegbe, MD, MPH, MS
Suzanne Oparil, MD
Advisor/Consultant: Boehringer-Ingelheim, Daiichi-Sankyo, Eli Lily,
Forest, NiCox, Novartis, Omron. Grant/Research Support: Amgen,
Inc., Merck & Co. Speakers’ Bureau/Speaking/Teaching: DaiichiSankyo, Novartis, Pfizer.
Julio A. Panza, MD
Vasilios Papademetriou, MD
Thomas A. Pearson, MD, PhD, MPH
Aldo J. Peixoto, MD
Robert A. Phillips, MD, PhD
Member, ASH Board of Directors.
F. Xavier Pi‑Sunyer, MD, MPH
Advisor/Consultant: Novo Nordisk, AstraZeneca. Grant/Research
Support: Novo Nordisk.
Bertram Pitt, MD
Advisor/Consultant: Relypsa. Ownership Interest (Stocks, Excluding
Diversified Mutual Funds): Relypsa, BG-Medicine, Nile Therapeutics.
Velvie A. Pogue, MD
Employment Income/Salary: Columbia University Affiliation at the
Harlem Hospital Center. Grant/Research Support: Amgen.
David M. Pollock, PhD
Advisor/Consultant: Abbott Laboratories.
Howard J. Pratt, MD
151
Henry A. Punzi, MD
Advisor/Consultant: Daiichi-Sankyo, Boehringer-Ingelheim, Forest
Pharamaceuticals. Grant/Research Support: Daiichi-Sankyo, Boehringer-Ingelheim, Forest Pharmaceuticals, Abbott. Speakers’ Bureau/
Speaking/Teaching: Daiichi-Sankyo, Boehringer-Ingelheim, Forest
Pharmaceuticals, Abbott.
Leopoldo Raij, MD
C. Venkata S. Ram, MD
Advisor/Consultant: Daiichi-Sankyo, Forest. Speakers’ Bureau/Speaking/Teaching: Peer Group Med Knowledge.
James Rippe, MD
Advisor/Consultant: ConAgra Foods, Corn Refiners Association.
Grant/Research Support: ConAgra Foods, Corn Refiners Association.
Talma Rosenthal, MD
Royalties (Including Trademarks or Patents): Patent (2%) Allyl
Mercaptocptopril), Weitzmann Institute. Trustee/Board Member/
Committee Member: Tel-Aviv University Sackler School of Medicine.
Grant/Research Support: Boehringer-Ingelheim. Speakers’ Bureau/
Speaking/Teaching: Tel-Aviv University Sackler School of Medicine.
Luis M. Ruilope, MD
Advisor/Consultant: AstraZeneca, Novartis, Bayer, Servier, DaiichiSankyo, Takeda, Pfizer, Otsuka. Menarini, Bayer. Speakers’ Bureau/
Speaking/Teaching: AstraZeneca, Novartis, Bayer, Servier, DaiichiSankyo, Takeda, Pfizer, Otsuka. Menarini, Bayer.
Grant/Research Support: National Institutes of Health/ National
Heart, Lung and Blood Institute.
Elijah Saunders, MD
Advisor/Consultant: Pfizer, Novartis, Forest, Bristol-Myers SquibbSanofi-Aventis, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli
Lilly. Grant/Research Support: Pfizer, Novartis, Forest, Bristol-Myers
Squibb-Sanofi-Aventis. Speakers’ Bureau/Speaking/Teaching: Pfizer,
Novartis, Forest, Bristol-Myers Squibb-Sanofi-Aventis, BoehringerIngelheim, Bristol-Myers Squibb, Eli Lilly.
Roland E. Schmieder, MD
Grant/Research Support: Ardian.
Antoinette Schoenthaler, EdD
Advisor/Consultant: Harlem Hospital Stroke Center.
Domenic A. Sica, MD
Advisor/Consultant: Novartis, Takeda, Merck, Boehringer-Ingelheim,
CVRx. Grant/Research Support: CVRx. Speakers’ Bureau/Speaking/
Teaching: Takeda.
Matthew Sorrentino, MD
Thomas A. Sos, MD
Royalties (Including Trademarks or Patents): AngioDynamics, Cook
Medical.
152
James R. Sowers, MD
Advisor/Consultant: Novartis Pharmaceuticals. Grant/Research Support: National Institutes of Health, VA Merit.
Lesley A. Stevens, MD, MS
Allan D. Struthers, MD
Royalties (Including Trademarks or Patents): Filed a patent on the
use of xanthine oxidate inhibitors in angina.
Laura P. Svetkey, MD
Sandra J. Taler, MD
Vice President, ASH Board of Directors.
Ting Tao, MD
Addison A. Taylor, MD, PhD
Employment Income/Salary: Baylor College of Medicine. Advisor/
Consultant: National Association of Managed Care Physicians. Grant/
Research Support: Bristol-Myers Squibb, Novartis, National Institues
of Health. Speakers’ Bureau/Speaking/Teaching: Forest Pharmaceuticals, Novartis, The Methodist Hospital, University of Texas. Member,
ASH Board of Directors.
Jens Titze, MD
Sheldon W. Tobe, MD
Advisor/Consultant: Pfizer, Bristol-Myers Squibb, Merck, Abbott.
Grant/Research Support: Pfizer, Novartis, Amgen. Speakers’ Bureau/
Speaking/Teaching: Abbott,
Bristol-Myers Squibb, Pfizer, Merck.
Royalties (Including Trademarks or Patents): UptoDate. Advisor/Consultant: GlaxoSmithKline, Merck, Novartis. Grant/Research Support:
National Institutes of Health.
Ronald G. Victor, MD
Advisor/Consultant: Merck Research Laboratories. Grant/Research
Support: Pfizer, Forest Research Laboratories.
Hongyu Wang, MD, PhD
R. Clinton Webb, PhD
David J. Webb, MD
Advisor/Consultant: Abbott, Pfizer. Grant/Research Support: Pfizer.
Michael A. Weber, MD
Advisor/Consultant: Bristol-Myers Squibb, Boehringer-Ingelheim,
Takeda, Novartis, Daiichi-Sankyo. Trustee/Board Member/Committee Member: Center for Medicine in the Public Interest. Member,
ASH Board of Directors. Editor-In-Chief, The Journal of Clinical
Hypertension (JCH).
153
Alan B. Weder, MD
Employment Income/Salary: American Society Of Hypertension
(Editor-in-Chief, Journal of the American Society of Hypertension
(JASH)). Member, ASH Board of Directors.
Matthew R. Weir, MD
Advisor/Consultant: Amgen, Daiichi-Sankyo. Member, ASH Board of
Directors.
Adam Whaley‑Connell, DO
Andrew Whelton, MD
Advisor/Consultant: Takeda. Speakers’ Bureau/Speaking/Teaching:
Takeda.
William B. White, MD
Advisor/Consultant: Astellas, Forest, Novartis, Roche, Teva, Takeda.
Grant/Research Support: Novartis. Other Relevant Financial Benefit
or Relationship: Pfizer, Inc., DMC Consultant. President-Elect ASH
Board of Directors. ASH Scientific Program Committee Chair.
Ian B. Wilkinson, MD
Advisor/Consultant: GlaxoSmithKline, MSD. Grant/Research Support: GlaxoSmithKline.
Bryan Williams, MD
Gordon H. Williams, MD
Peter F. Wilson, MD
Nathan D. Wong
Advisor/Consultant: Abbott. Grant/Research Support: Merck, BristolMyers Squibb.
Martin S. Zand, MD
154
ASH Hypertension Resource Pavilion
Hilton New York • Americas Hall I • Third Floor
Innovations Theater
Americas Hall I
(Third Floor)
ASH
Outreach
1600
ASH
Outreach
Takeda
Pharmaceuticals
North American Inc.
1400
1600
Daiichi Sankyo Inc.
Takeda
Pharmaceuticals
North American Inc.
1400
Wiley-Blackwell
1202
Elsevier Inc.
1204
ESCALATOR
TO AMERICAS HALL II
AtCor Medical, Inc.
1105 1107
DaiichiDavid
Sankyo Inc. ISHIB
Lerner
1100
1102 1103
1200
Omron Healthcare
1000
ENTRANCE
Woman
Heart
Mortara HoMedics
Novartis
Pharmaceuticals
UP
National
Kidney
1206
1200
E
N
Innovations Theater
1106
Wiley-Blackwell
1202
1110
Elsevier Inc.
Ajinomoto
1204
National
Kidney
1104
1206
Woman
Heart
Mortara HoMedics
Novartis
Forest Lippincott
1105
Novartis
Pharmaceuticals
David
Lerner
A&D
1107
Medical
ISHIB
1004 1006 1008 1010
1100
1102 1103
1014Ajinomoto
1104
Novartis
1000
1004 1006 1008 1010
ATED FIRE ALARMS
155
1110
SunTech
Medical
1106
Omron Healthcare
ATED FIRE EXITS
Forest Lippincott
AtCor Medical, Inc.
A&D
Medical
SunTech
Medical
1014
ASH Posters
(Second Floor Promenade)
ASH Exposition Guide
Saturday, May 21, 4:30 PM – 7:30 PM
Hours: Sunday, May 22, 10:00 AM – 1:00 PM, 3:30 PM – 6:30 PM
Monday, May 23, 10:00 AM – 1:30 PM, 4:00 PM – 5:30 PM
Hilton New York • Americas Hall I • Third Floor
ASH Hypertension Resource Pavilion
America’s Hall I – Third Floor
American Society of
Hypertension Community
Outreach
Booth Number: 1600
Controlling your blood pressure is a
check away!
Get your blood pressure checked
today at our Outreach Booth!!
In 2011, we are proud to continue
with our Fourth Annual Hypertension
Community Outreach Program in the
Greater New York City area, Northern
New Jersey, and Long Island, NY.
View videos and photos of all of our
past Outreach Programs from New
Orleans (2008), San Francisco (2009),
and New York (2010). Our recently
released educational videos will also
be on view. The ASH published “Blood
Pressure and Your Health” patient
information pamphlets are available
here as well.
Check it out!!—go to Times Square—
42nd Street between 7th and 8th Avenues and look up at the CBS “Super
Screen” and you will see the new ASH
Public Service Announcement shown
18 times a day.
A & D Medical
Booth Number: 1010
A&D Medical / LifeSource manufacturers blood pressure monitors and
other home health care products for
home and professional use. Models include automatic, manual, ambulatory,
kiosk style and accessories including
stethoscopes.
A&D Medical is a division of A&D
Engineering, and is ISO 13485:2003
certified. Since 1977, A&D Medical
has manufactured and distributed a
full line of advanced electronic blood
pressure monitoring equipment and
health care products for home and
professional use. The company has
established itself as a leader in home
health monitoring technology through
the development and introduction
of a variety of unique products.
A&D’s LifeSource® blood pressure
monitor line has garnered numerous
industry awards. Recent product
introductions include: the LifeSource®
digital thermometers, personal scales,
stethoscopes, and Ambulatory Blood
Pressure Monitors.
Ajinomoto USA, Inc.
Booth Number: 1104
Since 1909, Ajinomoto Co., a leader
in the development of pharmaceutical
quality amino acids and distributor of products that offer a holistic,
side-effect free solution to today’s top
health concerns of weight management, sleep quality improvement and
healthy blood pressure management.
These products are Capsiate Natura®,
a patented, side effect-free dietary
supplement with natural capsinoids
shown to boost the body’s metabolism; Glysom™, a safe, effective and
scientifically-proven amino acid-based
solution for deeper, sounder and
more satisfying sleep, and Natura
Guard BP™, a milk protein-derived
nutraceutical to help maintain healthy
blood pressure levels already within
the normal range.
For more information, visit
www.capsiatenatura.com,
www.glysom.com and
www.naturaguardbp.com
AtCor Medical, Inc. (USA)
Booth Number: 1106
AtCor Medical developed and markets
SphygmoCor® systems, the global gold
standard in noninvasive assessment
of central blood pressure and arterial
stiffness. Featured in over 600 published studies, SphygmoCor systems
are used worldwide in leading medical
centers, physicians’ offices, in research
and in pharmaceutical clinical trials.
Booth Number: 1200
Daiichi Sankyo, Inc. (DSI), headquartered in Parsippany, NJ, is the
U. S. subsidiary of Daiichi Sankyo
Co., Ltd., a global pharmaceutical
company. DSI was formed in 2006
from the integration of two leading
pharmaceutical companies, Sankyo
Pharma, Inc. and Daiichi Pharmaceutical Corporation. Its team of nearly
3,000 U.S. employees is dedicated to
the creation and supply of innovative
pharmaceutical products to address
the diversified, unmet medical needs
of patients. DSI concentrates in the
therapy areas of hypertension, thrombosis, dyslipidemia, diabetes and
acute coronary syndrome. Clinical
development and regulatory activities
are headquartered at Daiichi Sankyo
Pharma Development in Edison, NJ.
Visit www.dsi.com.
156
David Lerner Associates
Booth Number: 1102
Financial Investments at David Lerner
Associates
We believe gambling and investing are
not the same.
We believe the stock market should make
for interesting dinner conversation but
should not be a matter of financial life
or death.
We believe we have an obligation to
guide our investors in directions we feel
will help them achieve their financial
objectives.
We believe investors should not be chasing financial rainbows.
We do not run with the herd. We pursue
these fundamental investment principles
regardless of market conditions.
While offering a full range of investments, we feature those that we believe
are based on real value and regularly pay
dividends or interest.
Elsevier
Booth Number: 1204
ELSEVIER, a premier worldwide health
science publishing company, is proud
to publish Journal of the AMERICAN
SOCIETY OF HYPERTENSION, the
official journal of the American Society of
Hypertension. Please stop by our booth
to view the latest issue of the journal.
Forest Pharmaceuticals, Inc.
Booth Number: 1006
Forest Pharmaceuticals, Inc welcomes
you to New York! We invite you to visit
our exhibit. Please visit our website at
www.forestpharm.com
Community Partner of the ASH
Hypertension Community Outreach
Program
HoMedics
Booth Number: 1107
Since HoMedics was founded in 1987,
they have become the #1 name in health
and wellness with an extensive line of
products that allow you to take a proactive role in managing your health.
HoMedics blood pressure monitors are
clinically proven accurate and offer a
wide range of innovative features and
technologies that make monitoring your
blood pressure at home easier than ever.
Select arm and wrist models offer Voice
Assist® Talking Function, Supersize
Digits®, Risk Category Index, Easy One
Button Operation, Dual User Memory
and 2 cuffs to fit most arm sizes.
Program
International Society on
Hypertension in Blacks, Inc. (ISHIB)
Booth Number: 1103
Founded in 1986, ISHIB is a non-profit
organization of healthcare professions
and leaders in cardiovascular disease
and related disorders. Our mission is to
improve the health and life expectancy of
ethnic minorities and eliminate racial and
ethnic health disparities in cardiovascular
disease through professional and public
education, targeted clinical research, and
facilitation of the delivery of higher quality cardiovascular health care. We host
an annual conference, membership and
other programs.
Lippincott, Williams & Wilkins, a
Wolters Kluwer Health Company
Booth Number: 1008
Lippincott Williams & Wilkins, Wolters
Kluwer Health Company, is the proud
publisher of Hypertension, Journal of
the American Heart Association, and
the Journal of Hypertension, Official
Journal of the International Society of
Hypertension and the European Society
of Hypertension. We offer a full range
of specialized books, journals, and electronic media. Visit us today!
Mortara Instrument
Booth Number: 1105
Mortara Instrument is proud to offer its
Ambulo™ 2400 ambulatory blood pressure (ABPM) technology at the American
Society of Hypertension’s 2011 Annual
Scientific Meeting and Exposition. Designed and made in the USA, the Ambulo
2400 system allows clinicians, researchers
and other health professionals to better
assess a patient’s blood pressure fluctuations throughout the 24-hour circadian
rhythm.
For over 25 years, Mortara Instrument
has distinguished itself in the field of
non-invasive cardiology by providing
ECG, Holter and stress systems to customers worldwide. We are excited to be
adding thorough blood pressure assessment tools to our portfolio of products.
Booth Number: 1206
NKF offers the nephrology community the latest science through clinical
practice guidelines, free kidney screening
programs held around the world, and
educational materials for patients and
professionals. Learn more about the
soon-to-be published guidelines, including: KDIGO’s Acute Kidney Injury and
the Update on CKD and Diabetes by
KDOQI™. Please visit the booth to signup to review KDIGO’s Clinical Practice
Guideline on Blood Pressure in CKD.
Novartis Pharmaceuticals
Corporation
Booth Number: 1100, 1004
Novartis Pharmaceuticals is dedicated to
discovering, developing, manufacturing
and marketing prescription drugs that
help meet our customers’ medical needs
and improve their quality of life. Please
visit the Novartis exhibit where our sales
representatives will be available to discuss
our products.
Program
Omron Healthcare
Booth Number: 1000
Omron Healthcare, Inc., is the leading
manufacturer and distributor of blood
pressure monitors for home use. Omron
Healthcare markets clinically proven
products that provide accurate health
information to consumers and physicians
and support position lifestyle changes and
health improvement.
Program
SunTech Medical, Inc.
Booth Number: 1014
For over twenty years, SunTech Medical
has been the preeminent supplier of
clinical grade blood pressure monitoring
products and technologies. SunTech is the
world’s foremost manufacturer of ambulatory blood pressure monitors, including
the Oscar 2 ABPM system, now available
with Pediatric ABPM Interpretation
function, which automatically generates
guidelines specific to analyzing the
24-hour blood pressure data of pediatric
patients. Additionally, SunTech offers solutions for in-office BP measurement with
the SunTech 247, the first clinical grade
automated blood pressure device to offer
a manual back-up mode, as well as a complete line of blood pressure cuffs. Please
visit our booth for more information.
Takeda Pharmaceuticals North
America, Inc.
Booth Number: 1400
Based in Deerfield, IL. Takeda Pharmaceuticals North America, Inc. and Takeda
Global Research & Development Center,
Inc. market oral diabetes, insomnia, rheumatology and gastroenterology treatments
and seek to bring innovative products to
patients through a pipeline that includes
compounds in development for diabetes,
cardiovascular disease, gastroenterology
and neurology. www.tpna.com.
Wiley-Blackwell
Booth Number: 1202
Wiley-Blackwell is the international
scientific, technical, medical and scholarly
publishing business of John Wiley & Sons,
with strengths in every major academic
and professional field and partnerships
with many of the world’s leading societies.
Wiley-Blackwell publishes over 1,400
peer-reviewed journals as well as 1,500+
new books annually in print and online,
as well as databases, major reference
works and laboratory protocols. For more
information, please visit
www.wileyblackwell.com or
http://onlinelibrary.wiley.com/
WomenHeart
Booth Number: 1110
WomenHeart was founded by three
women who had heart attacks while in
their 40s. In addition to being faced with
many obstacles, including misdiagnosis
and social isolation, they were each
amazed how little information about
or services for women with heart
disease were available and how the issue
seemed invisible within the women’s
health community. But in March 1999
everything changed.
2011 ASH Innovations Theater
Rhinelander Gallery – 2nd Floor
Saturday, May 21, 2011 • 6:30 PM to 7:30 PM
Daiichi Sankyo, Inc. presents,
The Growing Need for Combination Antihypertensive Therapy
“The Innovations Theater content and the views expressed
therein are those of the presenting corporate entity and not of
the American Society of Hypertension, Inc. The content is not
part of the ASH Annual Scientific Meeting as approved by the
“Annual Scientific Program Committee.”
Sunday, May 22, 2011 • 12:00 PM to 1:00 PM
Takeda Pharmaceuticals, North American, Inc. presents,
A Clinical Update in Hypertension.
“Annual Scientific Program Committee.”
Sunday, May 22, 2011 • 5:30 PM to 6:30 PM
Novartis Pharmaceuticals Corporation Presentation
Annual Scientific Program Committee.”
157
2011 ASH Exhibitors
ASH Hypertension Resource Pavilion • America’s Hall I – 3rd Floor
American Society of Hypertension Community Outreach
Contact: Gilda Caputo-Hansen
148 Madison Ave. 5th Floor
New York, NY 10016
Phone:
212-696-9099
Fax:
212-696-0711
Email:
gcaputo@ash-us.org
Website: www.ash-us.org
Booth Number: 1600
Controlling your blood pressure is a check away!
Get your blood pressure checked today at our Outreach
Booth!!
In 2011, we are proud to continue with our Fourth Annual
Hypertension Community Outreach Program in the Greater
New York City area, Northern New Jersey, and Long Island,
NY. View videos and photos of all of our past Outreach
Programs from New Orleans (2008), San Francisco (2009), and
New York (2010). Our recently released educational videos will
also be on view. The ASH published “Blood Pressure and Your
Health” patient information pamphlets are available here as
well.
Check it out!!—go to Times Square—42nd Street between
7th and 8th Avenues and look up at the CBS “Super Screen”
and you will see the new ASH Public Service Announcement
shown 18 times a day.
158
2011 ASH Exhibitors continued
A & D Medical
Contact: Amit Ghia
1756 Automation Parkway
San Jose, CA 95131
Phone: 408-263-5333
Fax:
408-263-0119
E-mail:
aghia@andmedical.com
Website: www.andmedical.com
Booth Number: 1010
A&D Medical / LifeSource manufacturers blood pressure
monitors and other home health care products for home
and professional use. Models include automatic, manual,
ambulatory, kiosk style and accessories including stethoscopes.
A&D Medical is a division of A&D Engineering, and is
ISO 13485:2003 certified. Since 1977, A&D Medical has
manufactured and distributed a full line of advanced
electronic blood pressure monitoring equipment and health
care products for home and professional use. The company
has established itself as a leader in home health monitoring
technology through the development and introduction of a
variety of unique products. A&D’s LifeSource® blood pressure
monitor line has garnered numerous industry awards.
Recent product introductions include: the LifeSource® digital
thermometers, personal scales, stethoscopes, and Ambulatory
Blood Pressure Monitors.
Ajinomoto USA, Inc.
Contact: Junichi Tashiro
400 Kelby Street
Fort Lee, NJ 07024
Phone:
201-292-3244
Fax:
201-346-5639
Email:
tashiroj@ajiusa.com
Booth Number: 1104
Since 1909, Ajinomoto Co., a leader in the development
of pharmaceutical quality amino acids and distributor of
products that offer a holistic, side-effect free solution to today’s
top health concerns of weight management, sleep quality
improvement and healthy blood pressure management. These
products are Capsiate Natura®, a patented, side effect-free
dietary supplement with natural capsinoids shown to boost the
body’s metabolism; Glysom™, a safe, effective and scientificallyproven amino acid-based solution for deeper, sounder and
more satisfying sleep, and Natura Guard BP™, a milk proteinderived nutraceutical to help maintain healthy blood pressure
levels already within the normal range.
For more information, visit www.capsiatenatura.com,
www.glysom.com and www.naturaguardbp.com
159
AtCor Medical, Inc. (USA)
Contact: Beth Boyer
One Pierce Place, Suite 225W
Itasca, IL 60143
Phone:
630-228-8871
Fax:
630-228-8872
Email:
info@atcormedical.com
Website: www.atcormedical.com
Booth Number: 1106
AtCor Medical developed and markets SphygmoCor® systems,
the global gold standard in noninvasive assessment of central
blood pressure and arterial stiffness. Featured in over 600
published studies, SphygmoCor systems are used worldwide in
leading medical centers, physicians’ offices, in research and in
pharmaceutical clinical trials.
Contact: Ann Marie Bermudez
2 Hilton Court
Parsippany, NJ 07054
Phone:
973-944-2600
Fax:
973-944-2891
Email:
abermudez@dsi.com
Website: www.dsi.com
Booth Number: 1200
Daiichi Sankyo, Inc. (DSI), headquartered in Parsippany, NJ,
is the U. S. subsidiary of Daiichi Sankyo Co., Ltd., a global
pharmaceutical company. DSI was formed in 2006 from the
integration of two leading pharmaceutical companies, Sankyo
Pharma, Inc. and Daiichi Pharmaceutical Corporation.
Its team of nearly 3,000 U.S. employees is dedicated to the
creation and supply of innovative pharmaceutical products to
address the diversified, unmet medical needs of patients. DSI
concentrates in the therapy areas of hypertension, thrombosis,
dyslipidemia, diabetes and acute coronary syndrome. Clinical
development and regulatory activities are headquartered at
Daiichi Sankyo Pharma Development in Edison, NJ. Visit
www.dsi.com.
160
David Lerner Associates
Contact: James Faillace
568 Yamato Road 3rd Floor
Boca Raton FL 33431
Phone:
561-226-4500
Fax:
561-226-4598
Email:
jon.jarow@davidlerner.com
Booth Number: 1102
Financial Investments at David Lerner Associates
We believe gambling and investing are not the same.
We believe the stock market should make for interesting
dinner conversation but should not be a matter of financial life
or death.
We believe we have an obligation to guide our investors
in directions we feel will help them achieve their financial
objectives.
We believe investors should not be chasing financial rainbows.
We do not run with the herd. We pursue these fundamental
investment principles regardless of market conditions.
While offering a full range of investments, we feature those that
we believe are based on real value and regularly pay dividends
or interest.
Elsevier
Contact: Jeffrey Francis
Elsevier, Inc.
1600 JFK Blvd. Suite 1800
Philadelphia, PA 19103
Phone:
215-239-3491
Fax:
215-239-3494
Email:
j.francis@elsevier.com
Website: www.elsevierhealth.com
Booth Number: 1204
ELSEVIER, a premier worldwide health science publishing
company, is proud to publish Journal of the American Society
of Hypertension, the official journal of the American Society of
Hypertension. Please stop by our booth to view the latest issue
of the journal.
161
Forest Pharmaceuticals, Inc.
Contact: info@forestpharm.com
13600 Shoreline Drive
St. Louis, MO 63045
Phone:
800-678-1605
Fax:
314-493-7450
Email:
info@forestpharm.com
Website: www.forestpharm.com
Booth Number: 1006
Forest Pharmaceuticals, Inc welcomes you to New York! We
invite you to visit our exhibit. Please visit our website at
www.forestpharm.com
Community Partner of the ASH Hypertension Community
Outreach Program
HoMedics
Contact: Anthony Vigliotti
3000 Pontiac Trail
Commerce Township, MI 48390
Phone:
248-863-3000
Fax:
248-863-3103
Email:
anthony.vigliotti@homedics.com
Website: www.HoMedics.com
Booth Number: 1107
Since HoMedics was founded in 1987, they have become the #1
name in health and wellness with an extensive line of products
that allow you to take a proactive role in managing your health.
HoMedics blood pressure monitors are clinically proven
accurate and offer a wide range of innovative features and
technologies that make monitoring your blood pressure at
home easier than ever.
Select arm and wrist models offer Voice Assist® Talking
Function, Supersize Digits®, Risk Category Index, Easy One
Button Operation, Dual User Memory and 2 cuffs to fit most
arm sizes.
Outreach Program
162
International Society on Hypertension in Blacks, Inc. (ISHIB)
Contact: Terry E. Jackson
2111 Wilson Boulevard, Suite 700
Arlington, VA. 22201
Phone:
703-351-5023
Fax:
703-351-9292
Email:
terry-jackson@ishib.org
Website: www.ishib.org
Booth Number: 1103
Founded in 1986, ISHIB is a non-profit organization of
healthcare professions and leaders in cardiovascular disease
and related disorders. Our mission is to improve the health
and life expectancy of ethnic minorities and eliminate racial
and ethnic health disparities in cardiovascular disease through
professional and public education, targeted clinical research,
and facilitation of the delivery of higher quality cardiovascular
health care. We host an annual conference, membership and
other programs.
Lippincott, Williams & Wilkins, a Wolters Kluwer Health
Company
Contact: Jeff Thompson (PSG)
16522 Hunters Green Parkway
Hagerstown, MD 21740 U.S.A.
Phone:
1-800-638-3030 (North America)
+44 (0) 20 7981 0525 (Europe)
1-301-223-2300 (Rest of World)
Fax:
1-301-223-2400 (North America)
+44 (0) 20 7981 0535 (Europe)
1-301-223-2400 (Rest of World)
Email:
Jeff.Thompson@wolterskluwer.com or
customerservice@lww.com
Website: www.lww.com
Booth Number: 1008
Lippincott Williams & Wilkins, Wolters Kluwer Health
Company, is the proud publisher of Hypertension, Journal
of the American Heart Association, and the Journal of
Hypertension, Official Journal of the International Society of
Hypertension and the European Society of Hypertension. We
offer a full range of specialized books, journals, and electronic
media. Visit us today!
163
Mortara Instrument
Contact: Cynthia Muise
7865 N. 86th Street
Milwaukee, WI 53224
Phone:
414-354-1600 x7738
Fax:
414-354-4760
Email:
Cynthia.muise@mortara.com
Booth Number: 1105
Mortara Instrument is proud to offer its Ambulo™ 2400
ambulatory blood pressure (ABPM) technology at the
American Society of Hypertension’s 2011 Annual Scientific
Meeting and Exposition. Designed and made in the USA, the
Ambulo 2400 system allows clinicians, researchers and other
health professionals to better assess a patient’s blood pressure
fluctuations throughout the 24-hour circadian rhythm.
For over 25 years, Mortara Instrument has distinguished itself
in the field of non-invasive cardiology by providing ECG,
Holter and stress systems to customers worldwide. We are
excited to be adding thorough blood pressure assessment tools
to our portfolio of products.
Contact: David Rexroad
30 East 33rd Street
New York, NY 10016
Phone:
212-889-2210
Fax:
212-889-2310
Email:
davidr@kidney.org
Website: www.kidney.org
Booth Number: 1206
NKF offers the nephrology community the latest science
through clinical practice guidelines, free kidney screening
programs held around the world, and educational materials for
patients and professionals. Learn more about the soon-to-be
published guidelines, including: KDIGO’s Acute Kidney Injury
and the Update on CKD and Diabetes by KDOQI™. Please
visit the booth to sign-up to review KDIGO’s Clinical Practice
Guideline on Blood Pressure in CKD.
164
Contact: Becca Baileys
One Health Plaza
East Hanover, NJ 07936
Phone: 862-778-8300
Email:
rebecca.baileys@novartis.com
Website: www.novartis.com
Booth Number: 1100, 1004
Novartis Pharmaceuticals is dedicated to discovering,
developing, manufacturing and marketing prescription drugs
that help meet our customers’ medical needs and improve their
quality of life. Please visit the Novartis exhibit where our sales
representatives will be available to discuss our products.
Outreach Program
Omron Healthcare
Contact: Dan Aske
1200 Lakeside Drive
Bannockburn, IL 60015
Phone:
847-680-6200
Fax:
847-680-6269
Email:
info@omron.com
Booth Number: 1000
Omron Healthcare, Inc., is the leading manufacturer and
distributor of blood pressure monitors for home use. Omron
Healthcare markets clinically proven products that provide
accurate health information to consumers and physicians and
support position lifestyle changes and health improvement.
Outreach Program
165
SunTech Medical, Inc.
Contact: Rod Thomson
507 Airport Blvd.., Suite 117
Morrisville, NC 27560
Phone:
+1 919 654 2300 x 355
Fax:
+1 919 654 2301
Email:
sales @suntechmed.com
Website: www.SunTechMed.com
Booth Number: 1014
For over twenty years, SunTech Medical has been the
preeminent supplier of clinical grade blood pressure
monitoring products and technologies. SunTech is the
world’s foremost manufacturer of ambulatory blood pressure
monitors, including the Oscar 2 ABPM system, now available
with Pediatric ABPM Interpretation function, which
automatically generates guidelines specific to analyzing the
24-hour blood pressure data of pediatric patients. Additionally,
SunTech offers solutions for in-office BP measurement with the
SunTech 247, the first clinical grade automated blood pressure
device to offer a manual back-up mode, as well as a complete
line of blood pressure cuffs. Please visit our booth for more
information.
Contact: One Takeda Parkway
Deerfield, Il 60015
Phone:
224-554-6500
Website: www.tpna.com
Booth Number: 1400
Based in Deerfield, IL. Takeda Pharmaceuticals North
America, Inc. and Takeda Global Research & Development
Center, Inc. market oral diabetes, insomnia, rheumatology
and gastroenterology treatments and seek to bring innovative
products to patients through a pipeline that includes
compounds in development for diabetes, cardiovascular
disease, gastroenterology and neurology. www.tpna.com.
166
Wiley-Blackwell
Contact: 350 Main Street
Malden, MA 02148
Phone:
781-388-8250
Fax:
781-338-8250
Website: www.wiley.com
Booth Number: 1202
Wiley-Blackwell is the international scientific, technical,
medical and scholarly publishing business of John Wiley &
Sons, with strengths in every major academic and professional
field and partnerships with many of the world’s leading
societies. Wiley-Blackwell publishes over 1,400 peer-reviewed
journals as well as 1,500+ new books annually in print and
online, as well as databases, major reference works and
laboratory protocols. For more information, please visit
www.wileyblackwell.com or http://onlinelibrary.wiley.com/
WomenHeart
Contact: Mary McGowan, COO
818 18th Street NW
Washington DC 20006
Phone:
202-464-8735
Email:
mmcgowan@womenheart.org
Website: www.womenheart.org
Booth Number: 1110
WomenHeart was founded by three women who had heart
attacks while in their 40s. In addition to being faced with many
obstacles, including misdiagnosis and social isolation, they
were each amazed how little information about or services for
women with heart disease were available and how the issue
seemed invisible within the women’s health community. But in
March 1999 everything changed.
167
Author Index
A
Abad, María, 133
Abaunza, Ricardo, 102
Abbey, Susan, 136
Abdallah, Rany T., 101
Abdellatifi, Ibrahim L., 142
Abecasis, Goncalo R., 79
Abraham, Nader G., 66, 122
Abramson, Beth, 136
Acelajado, Maria Czarina, 88, 108,
138
Acelajado, Maria Czarina M., 120
Acelajado‑Valdenor, Ma Czarlota
M., 120
Achouba, Assya, 92, 127
Adamczyk, Maciej, 142
Adams, Kenneth F., 106
Adams, Robert J., 100, 102, 134
Adler, G., 97
Agarwal, Rajiv, 60, 145
Agarwal, Vikram, 66, 93, 117
Agarwal, Vikram V., 87, 117
Aggelis, A., 66, 91, 124
Agnoletti, Davide, 112, 126, 128
Aguilar, Francisco, 101
Ajzen, Sérgio Aron, 102
Albarran, Olga Gonzalez, 99
Alcon, Jose, 101
Alebiosu, Olutayo Christopher, 97
Alessi, Sheila M., 136
Almenar, Luis, 116
Almiroudi, M., 92, 96, 102, 122,
124, 126
Alonso, Ana, 91, 98
Alonso, Ignacio, 114, 129
Altun, Bulent, 97, 121
Alvarez, Carlos, 98
Alvarez, Carmen, 139
Alvarez, Julio, 101
Ambalavanan, Namasivayam, 118,
144
Ambrosio, Giuseppe, 91
Amdur, Richard, 96, 105
Amin, M. Yousri K., 142
Ammary, Ibtissam, 141
Anastasopoulos, I., 128
Andrews, L. M., 133, 140
Andrikou, E., 122, 126
Andrikou, I., 92, 102, 122
Angelini, Luca, 120
Antonino, Cassi, 137
Anunciato, Iara F., 143
Anunciato, Iara Felício, 132
Aonuma, Takanori, 117
Appel, Lawrence J., 82, 145
Aragiannis, D., 102
Aranda, Pedro, 101, 102
Arbique, Debbie, 59
Arici, Mustafa, 97
Arinsoy, Turgay, 121
Armando, Ines, 47, 97, 123
Arnett, Donna K., 145
Aronne, Luigi, 123
Artinian, Nancy, 45, 145
Asche, Stephen E., 89
Ascione, Frank, 87
Asico, Laureano, 97
Asico, Laureano D., 47
Aslam, S., 91
Asmar, Ali, 78
Assia, Ehud, 103
Ates, Kenan, 121
Atkinson, Hal, 61
Atluri, Tej K., 117
Aucott, Lorna, 137
August, Phyllis, 43, 145
Aviv, Abraham, 76, 145
Axon, R. Neal, 105, 130
Ayala, Carma, 129
Ayala, Diana E., 60, 97, 98, 99, 108,
110, 111, 114, 121, 129, 131
Azar, Silvia H., 123
B
Baba, Yoshichika, 121
Babazadeh, Simon, 98
Baber, Nigel, 95
Bachman, David L., 134
Bae, Jong‑Hoa, 116
Baek, InYoung, 130
Bagrov, Alexei Y., 142, 143
Bailey, M., 97
Bajaj, Jennifer, 90
Baker, Brian, 136
Baker, William L., 109
Bakhtar, Omid, 93
Bakris, George, 67, 78, 99
Bakris, George L., 44, 50, 58, 68, 75,
76, 78, 112, 140, 145
Bakris, G. L., 115
Balbarini, Alberto, 116, 126
Baldo, Manuela S., 87
Baldwin, William, 100
Balish, Marshal, 136
Ballesteros, Maria Jose, 95
Baltatzi, Maria, 111
Bancroft, T. J., 140
Bandyopadhyay, Dipankar, 110
Banegas, Jose R., 93, 123, 134
Baraniuk, Sarah, 60
Baranova, Elena I., 87
Barbatelli, Paolo, 133
Barbetseas, I., 61
Barbosa, Loide, 96
Bard, Robert L., 65, 129
Barros, Jesús, 129
Baschiera, Fabio, 130
Basile, Jan, 98, 130
Basile, Jan N., 49, 50, 64, 145
Bastien, Carl, 127
Bastos, Jose Mesquita, 129, 134
Basu, Sanjib, 47, 113
Batisky, Donald L., 40, 51, 145
Batson, Bryan, 139
Baur, Dorothee M., 95
Bavisotto, Susan Harris, 140
Baylis, Chris, 100
Bayorh, Mohamed A., 107
Bellavia, Diego, 116
Bellner, Lars, 122
Belyaeva, Olga D., 87
Ben‑Dov, Iddo Z., 93
Benedict, Patrick E., 141
Benetos, Georgios N., 119
Berenson, Abbey B., 95, 102
Berenson, Gerald S., 93, 94, 127
168
Author Index
Berezina, Aelita V., 87
Berkovich, Olga O., 87
Berktas, Mehmet, 108
Bernard, Gutin, 47
Bernheim, Jacques, 131
Bernstein, Ira, 142
Berrios, Ronaldo Sevilla, 110
Bertoquini, Susana, 129
Bertoquini, Susana P., 137
Bhabhe, Aditya S., 123, 132
Bhaheetharan, Sujan, 110
Bhandari, Simran, 67
Bhandari, Simran K., 108
Bianchini, Elisabetta, 91, 127
Biggi, Almerina, 91
Bisognano, John, 67
Bisognano, John D., 40, 49, 67, 126,
145
Blacher, Jacques, 99, 112, 126, 128
Black, Henry R., 40, 81, 145
Bloch, Michael J., 50, 145
Blom, Kimberly C., 136
Blue, Amanda E., 101
Blumenthal, James A., 131
Boan, Andrea D., 102, 134
Boateng, Frank K., 139
Bobrie, Guillaume, 108
Bochud, Murielle, 79
Boden, William E., 44
Boerrigter, Guido, 91
Bolin, Paul, 124
Bolondi, Luigi, 95
Bolshakova, Olga O., 87
Bolton, Charlotte, 128
Bonartseva, Garina A., 108
Bonartsev, Anton P., 108
Borghi, Claudio, 93
Bosi, Matteo, 130, 137
Bougatsa, Vaia, 111
Bowden, Charles, 78
Boyaci, Bulent, 108
Bracho, Mayela J., 87
Brady, Tammy M., 101
Brands, Michael W., 40, 72, 145
Brashear, R. Jeffrey, 142
Braucht, Drew, 101
Braun‑Dullaeus, Rudiger C., 139
Braun, Lynne T., 45, 145
Bravo, Emmanuel, 50, 145
Briasoulis, Alex, 93, 117
Briasoulis, Alexandros, 87, 117
Bridges, William, 102
Brinson, Stephanie, 140
Brook, Robert D., 65, 129
Brosolo, Gabriele, 136
Brough, Elizabeth, 90, 115
Brown, Angela L., 49, 50, 146
Brown, Michael D., 136, 138, 144
Brown, Morris, 112
Brown, Nancy J., 40, 146
Brunel, Patrick, 130
Bruno, Rosa Maria, 127
Brzezinski, W. Adam, 130
Bueno, Isabel, 129
Buglioni, Alessia, 107
Buren, Peter Van, 60
Burnett, John C., 91, 116
Burnett, Jr., John C., 47
Burnett, Richard T., 129
Burney, Basil, 99
Burri, Philippe, 143
Bursztyn, Michael, 93
Bushinksy, David A., 146
Bushinsky, David, 107
Bushinsky, David A., 70
Bustamante, Eduardo E., 138
Buysman, E. K., 140
Byun, Young‑Sup, 118, 119, 120
C
Cafazzo, Joseph, 132
Caglar, Sali, 97
Cai, Jingjing, 112
Cain, Van, 118
Calabrò, Raffaele, 123
Calara, Federico, 67
Calara, Federico B., 108
Calderon, Berniza, 91
Calderón, Berniza, 99
Calhoun, David A., 88, 108, 138
Callejas, Pedro A., 97, 131
Calmon, Gustavo E., 87
Calvo, Sara, 91
Campbell, Norman R.C., 54, 146
Campbell, Patrick T., 109, 136
Campese, Vito M., 88
Campoy, Jose, 98
Camsari, Taner, 121
Cañas, Juan, 129
Cannone, Valentina, 47, 91
Cano, Marta, 91, 99
Cao, C., 115
Cao, Charlie, 112
Capobianco, Frine, 88
Carlberg, Bo, 93
Carnevale, Daniela, 134, 135
Carrasco, Marta, 91, 99
Carreño, Agustin, 95
Carretero, Oscar A., 20, 76, 146
Carter, Barry L., 45, 49, 146
Carugo, S., 130
Cassi, Antonino, 130
Castillo, Zenaida, 127
Castiñeira, Maria C., 99, 121
Castresana, Elena, 91
Cataliotti, Alessandro, 22, 47, 76, 91,
116, 146
Catena, Cristiana, 59, 88, 136
Caulfield, Mark, 78
Caulfield, Mark J., 79
Celis, Susana I., 127
Cerezo, Cesar, 67, 93, 96
Chacko, Billy G., 117
Chakravarti, Aravinda, 78, 79
Chamarthi, B., 97
Charney, Alan, 130
Chasman, Daniel I., 79
Chavanu, Kathleen J., 114, 115
Chayan, Luisa, 60, 114, 129
Chazova, I. E., 143
Chazova, Irina E., 112
Cheh, Christopher Newton, 79
Cheng, Dunlei, 94
Chen, W., 113
Chen, Wei, 93, 94, 122
169
Author Index
Chen, Yiu‑Fai, 103, 118, 126, 144
Cheruvu, Bharadwaj, 122
Cheung, D. G., 113
Childers, W. Kurtis, 47
Chlapoutakis, G., 126
Cho, Eun‑Joo, 88
Choi, Kyu‑Young, 88
Cho, Jin‑Man, 111, 116
Chow, Josephine X., 87
Christensen, Niels Juel, 78
Christiano, Cindy, 124
Chrysant, Steven G., 109, 111
Chung, Wook‑Jin, 118, 119, 120
Chung, Yeonseung, 132
Cicero, Arrigo, 93
Cifelli, Giuseppe, 134, 135
Cinteza, Mircea, 143
Cirillo, Chiara, 123
Civitarese, Louis, 141
Clark, Rebecca I., 127
Clark, Sarah, 87
Clar, Xavier, 105
Clyburn, Benjamin, 130
Cockcroft, John R., 46, 95, 128, 138,
146
Coelho, Eduardo B., 143
Cohen, Debbie L., 127
Cohn, Jay N., 51, 116, 144, 146
Cohn, Lisa, 87
Colaco, Clinton, 107
Colby, Chris, 89
Coloma, Ramon, 129
Colussi, Gian Luca, 59
Colussi, GianLuca, 59, 88, 136
Comisky, Lauren, 123
Concilio, Claudia, 123
Connell, Barry, 92
Corlan, Alexandru, 143
Cornelissen‑Guillaume, Germaine
G., 137
Cosentino, Eugenio Roberto, 93
Cosentino, Francesco, 91
Couch, Sarah C., 106
Coulson, James M., 138
Craft, Chanda, 102
Credendino, Maria, 123
Crespo, Juan J., 97, 98, 121, 131
Crippa, Giuseppe, 130, 137
Croghan, Carry, 129
Crowley, Steven D., 40, 146
Cuevas, Santiago, 97
Cui, Rong, 112
Cushman, W. C., 115
Cushman, William C., 54, 62, 78,
112, 146
D
d’Addato, Sergio, 93
D’Agostino, Ralph B., 96
Dahlström, John K. F., 93
Daley, Matt F., 106
Damasceno, Albertino, 96
Daniels, Stephen R., 47, 106, 146
Daoud, Yahya, 94
Darabont, Roxana O., 143
Dart, Richard A., 135
DasMahapatra, Pronabesh, 93, 94
Dastani, H. B., 140
Davidson, Michael H., 44, 146
Davis, Barry R., 60
Day, Wesley, 78
De Angulo, Guillermo A., 100
Dean, Lacy, 124
Debenham, Ellen, 100
Deedwania, P., 113
Deghedi, Akram A., 142
de la Cruz, Jose Juan, 101, 102
de la Cruz, Juan J., 93, 123, 133, 134
de la Sierra, Alejandro, 102, 105,
123, 133, 134
de la Sierra, Alex, 101
De la Torre, Nuria, 47, 91, 92, 98
Delgado‑Leon, Antonio J., 127
de Lis, Jesus Perez, 99
Del Tío, Rocío, 129
Derici, Ulver, 97
De Rosa, Maria Leonarda, 113
Desai, Tejas, 122, 124
DeSouza, Christopher A., 92
Dessì-Fulgheri, Paolo, 120
Dessì‑Fulgheri, Paolo, 107, 133
Destounis, Antonios, 134
Destounis, Antonis, 105
DeVries, Andrea, 122
Dhaun, N., 97, 121
Diaz, Edgar A., 132
Diaz, Keith M., 136, 144
Díaz, María T., 129
Di Bello, Vitantonio, 116, 126
Dimitriadis, K., 66, 91, 92, 124, 126,
128
Diogo, Domingos, 96
Dionne, Janis M., 87
Dixon, John, 139
Djordjevic, Dragan, 120
Dobrokhod, Anna S., 133
Dochee, Jennifer D., 107
Does, Alec V., 90
Dolan, Lawrence M., 106
Dolz, Luis Martínez, 116
Dominguez, Maria J., 114, 129
Dominguez‑Sardiña, Manuel, 98,
111, 121, 131
Dongre, Neelesh, 94, 112
Dong, Yanbin, 47
Dormi, Ada, 93
Doumas, Michael, 94, 96, 136
Dourliou, Vasiliki, 111
Drawz, Paul E., 60
Dresser, George K., 141
Dresser, G. K., 89
Dubiel, Robert, 114, 115
Dudenbostel, Tanja, 88, 108, 138
Duh, Mei Sheng, 110, 131, 133
Duprez, Daniel, 73, 109, 116, 130,
146
Duprez, Daniel A., 144
Dvonch, J. Timothy, 65
Dworkin, Lance D., 56, 146
E
Eatman, Danita, 107
Ecder, Tevfik, 121
Eckeli, Alan L., 143
Egan, Brent, 105, 110, 130, 134
Egan, Brent M., 40, 49, 134, 140, 147
170
Author Index
Eguchi, Kazuo, 110, 132
Ehret, Georg, 78
Ehret, Georg B., 79
Einhorn, Paula T., 49, 147
Eiroa, Peregrina, 97, 131
Eisenberg, Debra F., 122
Eleftheriadou, I., 122
Eliseyeva, Marietta, 117
Elliott, Paul, 79
Elliott, William J., 47, 50, 61, 73, 113,
140, 147
Ennis, Riley C., 122
Entcheva, Miglena, 93, 94
Epstein, Benjamin J., 115
Epstein, Michael J., 133
Epstein, Murray, 24, 70, 76, 77, 147
Erbay, Bulent, 97
Erdem, Yunus, 97
Escano, Crisanto, 97
Esis, Carlos E., 87
Esler, Murray D., 77, 138, 147
Espinosa, Emma, 133
Esposito, A., 130
Eto, Masahiko, 117
Eto, Tanenao, 114
Eunsil, Yim, 100
Evans, Gregory, 61
Evora, Paulo R. B., 143
Exuzides, Alex, 89
F
Fabregate, Martin, 47, 91, 92, 98, 110
Fabregate, Rosa, 47, 91, 92, 98, 110
Faillace, Robert T., 140
Faita, Francesco, 91, 127
Falck, John R., 66
Falkner, Bonita, 40, 147
Falvey, Heather, 110, 131
Familoni, Oluranti, 97
Fang, Christy, 122
Fang, Jing, 136
Fares, Maria Luisa, 130
Farooqi, Sadaf, 58, 147
Faselis, Charles, 94, 96, 105, 136
Fawzy, Abdelmoneim A., 142
Feagan, B. G., 89
Feagan, Brian G., 141
Feairheller, Deboarh L., 144
Feairheller, Deborah L., 136, 138
Fedecostante, Massimiliano, 133
Fedorova, Olga V., 142, 143
Fedorov, Sergiy V., 92
Fedrizzi, Stefania, 88
Feibel, Hedy, 123
Feig, Daniel I., 66, 106, 147
Feig, Denice, 132
Feldman, R. D., 89
Feldman, Ross, 54, 147
Feldman, Ross D., 141
Ferdinand, Keith, 105, 109, 130
Ferdinand, Keith C., 44, 62, 110, 113,
114, 147
Ference, Brain, 107
Ference, Brian A., 93
Fernandes, Regina M. R., 143
Fernandez, Angelica, 47, 91, 98, 110
Fernandez, Camilo, 93, 94, 127
Fernandez, Jose Carlos, 101, 102
Fernandez, Jose R., 60, 97, 99, 108,
110, 111, 114, 121, 129, 131
Fernandez, Olga, 98
Fernandez, Rafael, 109
Fernandez, Victor, 109, 111
Ferrario, Carlos M., 89
Ferreras, Amelia, 121
Ferrero, David, 133
Ferrero‑Martinez, Ana Isabel, 120
Ferriolli, Eduardo, 132, 143
Ferris, Maria, 122
Figueiredo, José Nuno, 134
Filatova, Elena A., 108
Filho, Sebastião R., 123
Fiorentini, Lucia, 137
Fiquet, Béatrice, 140
Fivush, Barbara A., 101
Flack, John, 107, 141
Flack, John M., 62, 93, 114, 147
Fleg, Jerome L., 90
Flessas, D., 66, 126
Fletcher, Ross, 94, 136
Fletcher, Ross D., 96, 105
Florea, Natalia, 116
Flori, Serena, 95
Flynn, Joseph, 101
Flynn, Joseph T., 40, 58, 101, 106,
147
Fogari, Roberto, 87, 88
Fogg, Louis, 138
Foiato, Tariane F., 87
Fontao, Maria J., 60, 99, 110, 111,
114, 121, 129, 131
Forker, Alan, 139
Forrest, Brian, 89, 140
Fortunati, Marco, 120
Fox, Caroline S., 117
Fragasso, Gabriele, 116
Franchi, Eliana, 107
Francillon, Alain, 140
Franklin, Stanley S., 46, 147
Fraser, William D., 137
Frassetto, Lynda A., 98
Frazer, Lauren C., 123
Frech‑Tamas, Feride, 133
Freed, Gary, 87
Freitas, Joao, 135, 138
Frishman, William H., 64, 147
Froehlich, James B., 49, 147
Fromer, Leonard M., 50, 147
Frome, Wayne L., 135
Fujii, Kenji, 130
Fujimoto, Tetsuya, 99
Fu, Qi, 142
G
Gaciong, Zbigniew, 138
Gaida, Susan, 93, 94
Galbreath, M. Melyn, 142
Galgo, Alberto, 98
Gaman, Iryna O., 119
Ganotakis, Emmanuel S., 100
Garcia‑Donaire, Jose A., 67, 96
García‑Ortiz, Luis, 133
Garg, Suchita, 133
Garoufalis, Stefanos H., 119
Garrett, Andrew T., 95
Garvin, Jeffrey L., 80, 147
171
Author Index
Gassman, Jennifer, 115
Gavish, Dov, 124
Gavras, Haralambos, 52, 148
Gavrilov, I. Y., 143
Gemignani, Vincenzo, 91, 127
Georgiadis, Ioannis V., 119
Georgiopoulos, Georgios E., 119
Germino, F. W., 131
Germino, F. Wilford, 49, 148
Germino, Megan M., 131
Ghannad, Emmanuel, 92, 127
Ghiadoni, Lorenzo, 91, 127
Giakoumis, M., 122, 126
Gialernios, T., 94
Giannini, Elena, 133
Gibstein, Raz, 103
Gijon, Teresa, 105
Giles, Thomas D., 47, 127, 140, 148
Giovas, Periklis, 106
Giralt, Patricio, 95
Girerd, Xavier, 140
Glasser, Stephen P., 108
Go, Alan S., 81
Goddard, J., 121
Godleski, John J., 132
Golan, Eliezer, 131
Goldberg, Ruthie, 131
Gomara, Sonia M., 98, 99
Gómez, Manuel, 133
Gong, Kaizheng, 118, 126, 144
Gongora, Maria C., 122
Gonzalez‑Albarran, Olga, 91
Gonzalez, Alicex C., 87
Gonzalez, Olga, 98
Gonzalez, Santiago Cuevas, 47
Gonzalez, Waddy, 110
Gopalakrishnan, Kathirvel, 137
Gorostidi, Manuel, 101, 102, 105,
123, 134
Gradman, Alan H., 54, 110, 131, 148
Graeme, Katelyn, 101
Graff, Alan, 114, 115
Granato, Chiara, 123
Grandits, Gregory A., 144
Granger, Joey P., 43, 77, 148
Grant, Joshua, 93, 94
Greco, Barbara A., 139
Green, Kelley R., 140
Greenway, Frank L., 137
Greiner, Jared J., 92
Grennberg, George, 103
Grima, Esther Zorio, 116
Grim, Clarence E., 107, 142
Grimm, Jr., Richard H., 57
Grimm, Richard H., 148
Grosman, Ehud, 124
Grossman, Ehud, 103
Guedj, Dominique, 92, 127
Guenoun, Maxime, 92, 127
Guerra, Federico, 107, 120, 133
Guerri, Asuncion, 47, 98, 110
Gunawardhana, Lhanoo, 100
Guo, Yuan, 53, 148
Gupta, Alok K., 137
Gutierrez, G., 95
H
Hadker, Nandini, 133
Hage, Fadi, 118, 126
Hage, Fadi G., 103
Hailpern, Susan M., 101
Halberg, Franz, 132
Halfon, Sherin, 107
Hall, Jennifer, 116
Hall, John E., 43, 59, 148
Halpern, Michael, 141
Hamad, Mazen, 89
Hames, Melanie, 124
Hamilton, Bruce, 61
Handler, Joel, 40, 90, 131, 140, 148
Hansen, Kimberley J., 117
Hans, Nidhi, 66, 117
Haque, Tahir, 92, 110
Harats, Dror, 124
Harb, Mohamed A., 142
Harder, David, 57, 148
Harrison, David G., 57, 72, 76, 122,
148
Harris, Raymond C., 65, 148
Hartmann, Camila, 87
Hasanoglu, Enver, 97
Hasegawa, Kenichi, 59
Hatzitolios, Apostolos I., 111
Hatzopoulos, Anastasios, 111
Haun, Daniel W., 91
Hayakawa, Manabu, 118
Hebert, Christopher, 94
Hedquist, Lowell, 93, 107
Heilbraun, Jeffrey, 124
Hermida, Ramon C., 60, 65, 97, 98,
99, 108, 110, 111, 114, 121, 129,
131
Hernaiz, Susana, 99
Heublein, Denise M., 91
Heyrman, Reinilde, 109, 111
Hill, Joseph A., 76, 148
Hinderliter, Alan L., 131
Hollenberg, Norman K., 76, 148
Holmstedt, Christine A., 102
Hongyo, Kazuhiro, 121
Hopkins, P., 97
Hoshide, Satoshi, 102, 110, 132
Ho, Timothy, 131
Houston Miller, Nancy, 40, 45, 150
Howard, Barbara V., 90
Hoyem, Ruby, 138
Hsueh, Willa, 138
Hsu, Stephen C., 142
Htun, Wah Wah, 127
Htyte, Nay, 110
Huang, I.‑Zu, 107
Huang, Zhijun, 112
Hughes, Suzanne, 45, 148
Hull, Pamela, 118
Hunt, Barbara, 100
Huntley, Brenda K., 91
Husaini, Baqar, 118
Hwang, Shih‑Jen, 117
Hygia, Investigadores Proyecto, 97,
98, 99, 111, 121, 131
I
Iaria, Pierre, 126
Ibrahim, Mediha, 127
Ichiki, Tomoko, 47
IIonze, Onyedika John, 126
172
Author Index
Ikeda, Yasuhiro, 116
Imamura, Takuro, 96
Inrig, Jula K., 60, 121, 122
Ioannidis, Antonios, 100, 115
Irvine, Jane, 132, 136
Ishikawa, Joji, 126, 132
Ishikawa, Shizukiyo, 110, 126
Ishizaka, Nobukazu, 59
Ito, Sadayoshi, 67
Iwakura, Yoshitugu, 67
Izzo, Joseph, 109, 111
Izzo, Joseph L., 111, 128
Izzo, Jr., Joseph L., 61, 114, 148
J
Jackson, Sharron M., 101
Jaffe, Marc G., 61
Jaimes, Edgar A., 52, 113, 114, 148
Jamerson, Kenneth, 90, 115
Jamerson, Kenneth A., 62, 149
Jang, Sung‑Won, 88
Jarvis, Sara S., 142
Jason, Yap, 122
Jatte, Fernanda, 132
Jauch, Edward C., 102
Javier, Angelo Dave C., 120
Jin, Eun‑Sun, 111, 116
Joe, Bina, 137
Johannsen, Darcy, 137
Johnson, Andrew D., 79
Johnson, Julie A., 42, 115, 149
Johnson, Mary A., 101
Johnson, Richard J., 66, 100, 149
Johnson, Toby, 78, 79
Johnson, William D., 137
Jones, John E., 122, 123
Jones, Ronald, 105
Jose, Pedro A., 47, 51, 97, 122, 123,
149
Joshi, Nomita, 102
Josse, Robert, 61
Joyner, JaNae, 89, 139, 140, 141
Juncos, Luis, 52
Juncos, Luis I., 149
Jurgens, Julie A., 122
K
Kaciroti, Niko, 65
Kaeser, Martha A., 91
Kagan, Alexander, 123
Kahan, Jonathan, 107
Kajii, Eiji, 117
Kakinoki, Shigeo, 99
Kalantar‑Zadeh, Kamyar, 108
Kales, Stefanos N., 95
Kallikazaros, I., 92
Kalpatthi, Ram V., 101
Kamal, Khalid M., 141
Kambona, Joseph, 141
Kamide, Kei, 95, 121
Kamran, Haroon, 127, 128
Kanda, Kouichi, 99
Kanter, Michael, 131
Kantola, Ilkka M., 114
Karan, Shaila, 111, 114, 128
Karatan, Oktay, 97
Kario, Kazuomi, 96, 102, 110, 118,
126, 132
Karpanou, Eva, 61, 94, 135
Karpettas, Nikolaos, 134
Karpettas, Nikos, 105
Karpov, Yuri A., 112
Kartalis, Athanasios N., 119
Kasiakogias, A., 92, 96, 124, 128
Kato, Johji, 114
Kavey, Rae‑Ellen W., 58, 149
Kawai, Tatsuo, 121
Kawakami, Tomoko, 122
Kayaba, Kazunori, 126
Keenan, Nora L., 129, 136
Kefala, A., 124
Kerby, Tessa J., 89
Kereiakes, Dean J., 109, 111
Kershaw, David, 87
Kerwin, Todd, 116
Kettner, Norman W., 91
Kevorkov, Amayak, 117
Khan, Bobby V., 92, 110
Khan, Shahnaz, 141
Kharbanda, Elyse O., 106
Kheirbek, Raya, 94, 136
Kheirbek, Rhea, 136
Kheterpal, Sachin, 141
Khosla, Shikha, 136
Khoury, Philip R., 106
Kimball, Thomas R., 106
Kim, Catherine, 60, 121, 122
Kim, Chong‑Jin, 111, 116
Kim, Dong‑Bin, 88
Kim, DongHyun, 66
Kim, Jae‑Hyung, 88
Kimura, Joe, 131
Kintis, K., 92, 96, 102, 126
Kirkineska, Lambrini, 111
Kirpalani, Ashok L., 123, 132
Kirpalani, Dilip A., 123, 132
Kitamura, Kazuo, 96, 114
Kita, Toshihiro, 114
Kitzman, Dalane, 107
Kizilirmak, Pinar, 108
Kluth, D. C., 97
Kobayashi, Takeshi, 99
Kobayashi, Tatsuya, 130
Kohan, Donald E., 80, 149
Kokkinos, Peter, 94, 96, 136
Kollias, Anastasios, 105, 106
Kordalis, A., 96, 102, 122, 124, 128
Koren‑Morag, Nira, 103
Kostic, Svetlana, 116, 120
Koulousios, Konstantinos, 111
Kountz, David S., 82, 149
Krakoff, Lawrence R., 47, 63, 149
Kretzschmar, Jan, 136, 138, 144
Kroner, Beverly, 90
Krum, Henry, 67, 149
Kudo, Masataka, 67
Kudyakov, Rustam, 94
Ku, Elaine, 88
Kumada, Maki, 117
Kumarasamy, Sivarajan, 137
Kumar, Sanjay, 119
Kupfer, S., 115
Kupfer, Stuart, 78, 112
Kuritzky, Louis, 49, 149
Kuroki, Kazuo, 118
Kurtz, Theodore W., 42, 149
173
Author Index
Kushner, Robert F., 40, 149
Kuznetsov, N. S., 143
Kwiatkowski, Janet L., 100
Kwon, Beom‑June, 88
Kyvelou, S., 66
Kyvelou, Stella Maria, 61, 94, 135
L
Labarthe, Darwin, 137
Lackland, Daniel, 89, 110, 130
Lackland, Daniel T., 62, 100, 102,
134, 149
Lafeuille, Marie‑Hélène, 110, 131
Laghi, Luca, 93
Lai, Hsiao, 124
Lainscak, Mitja, 107
Lai, Wen‑Ter, 94
Lakatta, Edward G., 46, 142, 143,
149
Laken, Marilyn, 130
LaMarca, Babbette, 72, 149
Lambert, Gavin W., 138
Lamoureux, Denise P., 132
Lancioni, Letizia, 133
Lande, Marc B., 51, 149
Landini, Linda, 132
Landry, Daniel L., 139
Lanza, Gaetano A., 91
Latrella, Margaret, 140
Latsios, G., 124, 128
Lavange, L., 65
Lawrence, Joy, 132
Lawson, Andrew B., 134
Lazarevic, Gordana, 120
Lazar, Jason, 119, 127, 128
Lazich, Ivana, 99
Laz, Tabassum H., 95, 102
Lazzari, Pierangelo, 87, 88
Lebreiro, Ana, 135
Ledezma, Mateo Levine, 89
Lee, James, 109, 111
Lee, John S., 132
Lee, Jong Y., 123, 132
Lee, Mary S., 132
Lee, Sang‑Hak, 119
Lee‑Son, Kathy K. Y., 87
Lefebvre, Patrick, 110, 131
Leiba, Adi, 95
Leibovitz, Eyal, 124
Leighton, Harmony, 116
Leitão, Maria Fátima, 135
Lembo, Giuseppe, 134, 135
Leone, Aurelio, 95, 132
Leoni, Simona, 95
Leon‑Muñoz, Luz, 95
Levine, Benjamin D., 142
Levine, Robert, 118
Levin, Linda, 106
Levy, Bernard I., 99
Levy, Daniel, 61, 78, 79, 96, 117, 150
Levy, Pavel J., 117
Levy, Phillip, 107, 141
Levy, Phillip D., 93
Lewin, Andrew, 115
Lex, Lora, 133
Liakos, M., 94
Lian, Jean, 122
Lieber, Ari, 126, 128
Lieber, Ari L., 99
Li, Hewang, 123
Lijnen, Paul J., 135
Li, Li, 122
Lillestol, Michael, 98
Lima, Jr., Emilton, 87
Lima, Leandra Gonçalves, 132
Lima, Nereida K. C., 143
Lima, Nereida K. Costa, 132
Limdi, Nita A., 42
Limor, Rona, 100
Lindholm, Lars‑Hjalmar, 93
Lindi, Nita A., 150
Lioni, L., 66, 122
Lioudaki, Eirini, 100
Li, Peng, 118, 126, 144
Littlejohn, Thomas, 109, 111
Littman, Stephen, 127
Liu, Chunyu, 117
Liu, In Lu, 67
Liu, Tianh, 150
Liu, Tianhu, 53
Li, Wei, 114, 115
Lloyd, Eric, 78
Lobo, Romulo R., 143
Logan, Alexander G., 132
Loide, Barbosa, 137
Lo, Joan C., 106
Long, Laura, 141
Long, Mark S., 132
Lopez‑Garcia, Esther, 95
Lorenzo, Sonia, 99, 131
Lovic, Dragan, 120
Lowenstein, Charles J., 59, 150
Lucas, Caridad Turpin, 88, 109, 129
Lucas, Stephanie, 90
Lu, Chunzeng, 116, 126
Luepke, Erik, 88, 109, 129
Lu, Fei, 116, 126
Luo, Jianfang, 53, 150
Luo, Jiangming, 135
Luo, Yingjin, 123
Lurbe, Empar, 101
Luther, James M., 59, 150
Lu, Yee, 88
Lyass, Asya, 96
Lyn, Deborah, 107
Lyutikova, L. N., 143
M
Maa, Jen‑Fue, 96, 115, 138
Macdonald, Helen M., 137
MacDonald, Patricia, 100
MacDonald, Thomas, 112
Macedo, Espiga, 138
Machida, Maiko, 99
Maciel, Maria Julia, 135
MacIntyre, I., 121
Maciosek, Michael V., 89
Madede, T., 96
Madruga, Felipe, 105
Magarik, Jordan A., 102
Magid, David J., 106
Magness, Ronald, 142
Mahina, Tatiana K., 108
Mahon, Jeffrey L., 141
Mahon, J. L., 89
Maisaidi, M., 130
174
Author Index
Makani, Harikrishna, 107, 110
Mancia, G., 130
Mancia, Giuseppe, 75, 150
Mancinelli, Lucia, 107, 120
Manning, Alexis, 138
Mann, Samuel J., 49, 111, 150
Manolis, Athanasios, 136
Manolis, Athanasios J., 75, 150
Maraj, Ilir, 127
Marasi, Gianluigi, 87, 88
Marek, George, 100
Margolis, Karen, 61
Margolis, Karen L., 89, 106
Marin, Elena, 92, 98
Mark, Allyn L., 77, 80, 150
Marquez, David X., 138
Marquis, A., 65
Martell, Nieves, 133
Martinez, Cristina, 91, 92, 98
Martínez, María M., 129
Martinez, Marie F., 89
Martinez, Santos J., 88
Martin, Fernando L., 116
Martins, Helia, 135
Marzilli, Mario, 116, 126
Mascio, Giada, 134, 135
Masharani, Umesh, 98
Masica, Andrew, 94
Masuo, Kazuko, 138
Matei, Ana Maria, 91, 99
Materson, Barry J., 71, 150
Mathur, Vandana, 107
Matsell, Douglas G., 87
Matsuda, Hirohisa, 59
Matsumura, Yasuo, 59
Mattingly, Phillip G., 142
Mattson, David L., 72, 150
Mavimbe, C., 96
Mavrogeni, Helen, 100
McCoy, Connie E., 106
McCrory, Mark A., 103
McDonnell, Barry J., 128
McEniery, Carmel M., 95, 128
McInnes, Gordon, 112
McIsaac, Warren, 132
McKie, Paul M., 47
McManus, Chris, 105
McManus, Richard J., 63, 150
McRae, Steven, 100
Medvegy, Mihaly, 134
Meier, Rhonda L., 142
Meijide, Luis, 98
Melander, Olle, 143
Melino, Michael, 109, 111
Mellen, Philip, 139
Mendelowitz, David, 142
Merchant, Nadya, 92, 110
Merenich, John, 81, 150
Mesas, Arthur E., 95
Mesirov, Claire, 140
Messerli, Franz, 66
Messerli, Franz H., 64, 65, 87, 93,
107, 110, 117, 150
Mestek, Michael L., 92
Mete, Mihriye, 90
Meyer, Peter M., 47, 113
Michaelides, A., 91
Miguel, Robinson, 142
Mijalkovic, Dragan, 116
Mikhailidis, Dimitri P., 100
Miliou, A., 124
Miskulin, Dana, 115
Mitsnefes, Mark, 106
Moffatt, Steven M., 133
Mohammad, Saklayen, 122
Mohyeldin, Yousri A., 142
Mojon, Artemio, 60, 97, 98, 99, 108,
110, 114, 121, 129, 131
Molitch, Mark E., 74, 150
Moñivas, Vanesa, 96
Monsalvo, M. L., 140
Monteiro, Agostinho, 138
Moore, Michael, 89
Moore, Michael A., 89
Mora, Carmen, 95
Moreira, Nadia, 135
Moreno, Carlos, 91
Moreno, Jennifer, 127
Moriguti, Julio C., 143
Moriguti, Júlio Cesar, 132
Morimoto, Ryo, 67
Morishita, Masako, 65
Morita, Kiyoshi, 122
Mori, Tatsuhiko, 59
Morris, Ken, 140
Morris, Martha Clare, 138
Moschouris, Panagiotis M., 119
Mota, Victoria, 129
Mounier‑Vehier, Claire, 92, 127
Mousa, Tarek M., 116
Moya, Ana, 97, 98, 99, 121
Mpafakis, I., 92, 102, 126
Mpekiari, Eleni, 99
Mugellini, Amedeo, 87, 88
Muiesan, Maria Lorenza, 91
Munnery, Iain, 128
Munnery, Margaret M., 128
Munroe, Patricia, 78
Munroe, Patricia B., 79
Munshi, Mohamed, 127
Myers, Martin, 136
Myshkina, Vera L., 108
N
Nadim, Mitra, 67
Nadkarni, Girish, 117
Nadkarni, Girish N., 93, 117
Nakamura, Yoshikazu, 117
Naqvi, Syed U., 117
Narkiewicz, Krzysztof, 75, 150
Nasothimiou, Efthimia G., 134
Nasser, Samar A., 93
Nastac, Iulian, 128
Natale, Francesco, 123
Nautiyal, Amit, 119
Navar, L. Gabriel, 52, 77, 151
Navarro‑Ibáñez, Vicente, 90
Naveen, Saxena, 102
Nelson, S. A. E., 89
Nelson, Sigrid A., 141
Nesbitt, Shawna D., 62, 151
Neumann, Claas L., 133
Neutel, Joel M., 54, 138, 151
Newton‑Cheh, Christopher, 78
Nguyen, Phuong‑son, 132
175
Author Index
Nicholas, Joyce S., 134
Nicholas, Susanne B., 47, 151
Nichols, Wilmer W., 115
Nieto, Javier, 95
Nobre, Fernando, 143
Nomura, Akikazu, 99
Norsk, Peter, 78
Notario, Patricia M., 123
Novack, Victor, 103
Nov, Ori, 103
Nuñez, Ana Galdamez, 88, 129
Nylen, Eric, 136
O
Obasare, Edinrin Rae, 127
O’Brien, Eoin, 56, 151
O’Connor, Patrick, 61
O’Connor, Patrick J., 89, 106
O’Donnell, Jennifer, 141
Odusan, Olatunde, 97
Oefelein, Michael, 139
Ogedegbe, Gbenga, 45, 49, 63, 90,
151
Ogihara, Toshio, 138
Ogunsemi, Olawale, 97
Ogura, Toshihiko, 130
Ohishi, Mitsuru, 95, 121
Okada, Yoshiyuki, 142
Okafor, H., 118
Okayama, Masanobu, 117
Okerson, Ted, 139
Oliva, Raymond, 99
Oliveras, Anna, 133
Onishi, Miyuki, 95, 121
Ono, Yoshikiyo, 67
Onuigbo, Nwamaka, 128
Oparil, Suzanne, 53, 65, 78, 88, 103,
105, 109, 111, 118, 126, 138, 144,
151
Orak, John K., 101
Oron, Yoram, 100
Orynchak, Mariya A., 116, 119
Osmond, Peter J., 111, 128
Otero, Alfonso, 97, 111, 121, 131
Owen, E. L., 97
P
Palaciao, Ryan, 116
Palermo, Lisa, 61
Paletas, Konstantinos, 99
Pandey, Kailash N., 117
Panjabi, Sumeet, 89, 141
Pan, Nan, 135
Pannu, Varinderpal, 100
Panza, Julio A., 65, 151
Papadakis, John A., 100
Papademetriou, V., 91, 92, 124
Papademetriou, Vasilios, 71, 94, 96,
105, 136, 151
Papagiannis, Nikolaos V., 119
Papaioannou, T., 102
Papapostolou, Vasileios, 132
Papst, Cheraz Cherif, 98, 112, 139
Paran, Esther, 103
Parati, Gianfranco, 63
Paredes‑Galan, Emilio, 120
Parikh, Neal S., 111
Parikh, Samip J., 47
Parisé, Hélène, 110, 131
Park, Chang‑Bum, 111, 116
Parker, Emily D., 106
Parker, Karen, 124
Park, Jae Hong, 119
Park, Jeong‑Euy, 94
Park, Jinhee, 122, 133
Patel, Rinkesh, 127
Patel, Seema, 116
Pavlidis, Athinodoros, 111
Pavlyuk, Evhenia A., 133
Pearson, Thomas A., 44, 151
Pedrinelli, Roberto, 116
Pego, Guilherme Augusto
Mariano, 135
Pego, João Bernardo, 135
Peixoto, Aldo J., 60, 73, 151
Pelazza, Bruno B., 123
Pemba, Senga, 141
Pencina, Michael, 96
Perez de Lis, Jesus, 111
Pérez, Javier, 129
Pérez, Miguel Palencia, 116
Perkins, Nancy, 136
Peroz, Julie, 99, 126, 128
Persson, Mats, 93
Peterson, Jessica A., 100
Petry, Nancy M., 136
Phillips, Robert A., 40, 61, 126, 151
Pickering, Thomas, 90
Pierce, Caleb, 103
Piñeiro, Luis, 121
Pinol, Ramon, 142
Pisoni, Roberto, 88, 108, 138
Pi‑Sunyer, F. Xavier, 58, 151
Pittaras, Andreas, 136
Pitt, Bertram, 71, 107, 151
Plavnik, Frida Liane, 102
Podjarny, Eduardo, 131
Pogue, Velvie A., 74, 151
Pollock, David M., 51, 151
Pollock, Norman K., 47
Polonia, Jorge, 96, 129, 134
Polonia, Jorge J., 137
Popov, E. G., 143
Potapova, Galina N., 143
Poulakis, M., 124, 126
Pousa, Lorenzo, 99, 111
Pratt, Howard J., 151
Pratt, J. Howard, 59
Pressler, Susan, 90, 115
Primak, Galina F., 133
Priore, Emanuela Lo, 123
Pritchard, Sheila L., 87
Protogerou, Athanase D., 126
Providência, Luis Augusto, 135
Pruden, James, 140
Pruette, Cozumel S., 101
Pstay, Bruce M., 79
Punzi, Henry A., 64, 96, 115, 152
Purakal, John, 141
Puri, Nitin, 66, 122
Purkayastha, Das, 109, 113, 114
Pyun, Wook Bum, 119
Pyun, Wook‑Bum, 118, 120
Q
Quéré, Stéphane, 92, 127, 140
R
176
Author Index
Rabelink, Ton J., 93
Raheja, Prafull, 59
Rahman, Mahboob, 60
Rahman, Mahbubur, 95, 102
Rahman, Syed T., 110
Raij, Leopoldo, 52, 152
Rajagopalan, Sanjay, 65
Rajagopal, Desikan, 92
Rajpal, Minesh, 111, 128
Rakugi, Hiromi, 95, 121, 138
Ramamurthy, Priyanka, 133
Ram, C. Venkata S., 40, 73, 152
Rana, Hamza, 117
Ranieri, Alessandro, 123
Rantamaula, Laura, 114
Rapoport, Jayson, 123
Rarra, Vagia, 134
Rasgon, Scott, 67
Rasgon, Scott A., 89, 108
Rash, Carla J., 136
Ratner, Robert E., 90
Ravussin, Eric, 137
Rebelo, Irene, 138
Rechtman, Ehud, 103
Reddy, Maithri, 90
Reddy, Podduturu S., 90
Reddy, Sushma, 90
Reid, David M., 137
Rekovets, Oksana L., 133
Reyes, Andres, 92, 98
Rey, Jose Manuel Del, 98
Reynolds, Kristi, 131, 140
Rezzani, Rita, 122
Rho, Tae‑Ho, 88
Rice, Kenneth, 78
Rice, Kenneth M., 79
Rich, Steven, 116
Rieken, Eike M., 133
Rim, Se‑Joong, 118, 119, 120
Rios, Maria T., 98, 111
Ríos, María T., 129
Rippe, James, 82, 152
Roberts, A., 115
Roberts, Andrew, 78, 112
Rocchini, Albert, 87
Rodriguez, Arantxa, 47, 91, 92, 98,
110
Rodriguez‑Artalejo, Fernando, 95
Rodríguez‑Artalejo, Fernando, 120
Rodriguez‑Pascual, Carlos, 120
Rogelio, Gregorio G., 139
Roig‑Espert, Belén, 90
Rojas, Jose M., 127
Rollins-Hairston, Aisha, 107
Roman, Mary J., 90
Romero, Jorge, 107, 110
Rosa, César S., 123
Rosenthal, Talma, 100, 105, 152
Rosman, Yosi, 103
Rossi, Filippo, 137
Rothwell, Peter M., 56
Rousos, D., 124, 128
Roussias, Leonidas, 106
Roussias, Leonidas G., 134
Routledge, Faye S., 131
Rudich, Assaf, 103
Rughani, Govind, 102
Ruilope, Luis M., 60, 67, 70, 93, 96,
105, 123, 133, 134, 152
Ruilope, Luis Maria, 101, 102
Ruiz, Santiago Garcia, 88, 109
Russell, Holly Ann, 123
Russell, Marie, 90
Russo, Andrea, 136
Russo, Kristen M., 123
Russo, Maria Giovanna, 123
Ryabikina, G. V., 143
Ryan, Michael J., 23, 76, 152
Ryu, Sung‑Kee, 118, 119, 120
S
Saban‑Ruiz, Jose, 47, 91, 92, 98, 110
Sabharwal, Manpreet S., 93, 117
Saelens, Brian E., 106
Saez, Ana Osa, 116
Safar, Michel E., 99, 112, 126, 128
Sakata, Koji, 96
Salciccioli, Louis, 127, 128
Saldaña, Manuel Aguilera, 88, 129
Saleh, Tarek M., 92
Salgado, Jose L., 99, 131
Salvi, Paolo, 128
Samad, Zahid, 118
Sampson, U., 118
Samuel, Rita, 109
Sanada, Hironobo, 123
Sanchez, Luis, 67
Sanchez, Olivia, 91, 98, 110
Sander, Gary E., 127
Sandu, Oana, 128
Sangaralingham, S. Jeson, 47
Sansone, Torry Mark, 140
Santos, Jose Nobre, 134
Santos, Rosa M., 138
Sanz, Antonio Salvador, 116
Sarafidis, Pantelis A., 99
Sarda, Sujata P., 133
Sarigianni, Maria, 99
Sarmento, Priscilla Lopes, 102
Sarzani, Riccardo, 107, 120, 133
Sas, David J., 101
Satoh, Fumitoshi, 67
Saul, Sara, 116
Saul, Sara M., 144
Saunders, Elijah, 40, 152
Sauter, Kathleen, 140
Sautin, Yuri Y., 100
Savopoulos, Christos, 111
Schiffrin, Ernesto L., 72, 152
Schmidlin, Olga, 98
Schmieder, Roland E., 67, 152
Schneider, Edward, 88
Schneider, Stephanie C., 90
Schoenthaler, Antoinette, 45, 152
Schreiner, Susan, 90
Schulz, Egbert G., 133
Schwartz, Ann, 61
Schwartz, Faina, 117
Schwartz, Joseph, 90
Schwartzman, Michal L., 66
Scisney‑Matlock, Margaret, 90, 115
Scott, Graham A., 141
Sebastian, Anthony, 98
Sechi, Leonardo A., 59, 88, 136
Secombes, Karen R., 137
177
Author Index
Segev, Shlomo, 103
Segura, Julian, 67, 93, 96, 101, 102,
105, 123, 134
Segura, Julián, 133
Selassie, Anbesaw, 130
Sen, Amanda, 90, 115
Seo, Hye‑Sun, 118, 120
Serdengecti, Kamil, 121
Seredyuk, Nestor M., 92, 119
Seredyuk, Vitaliy N., 92
Sergakova, L. M., 143
Serio, Ilaria, 95
Severin, Thomas, 98, 139
Seyoum, Berhane, 107
Sgourakis, Panagiotis D., 119
Shaftman, Stephanie, 110
Shah, Arpit, 110
Shahawy, Mahfouz El, 93, 94
Shah, Hardik K., 123, 132
Shah, Niren K., 115
Shanks, Amy M., 141
Shapiro, Joseph I., 142
Sharabi, Yehonatan, 103
Sharma, Abhishek, 128
Shatat, Ibrahim F., 101
Shea, J., 113
Sheremeta, Oleg M., 119
Sheriff, Helen, 136
Sherrill, Beth, 141
Sherwood, Andrew, 131
Sherwood, Nancy E., 106
Shibata, Shigeki, 142
Shi, Jiaxiao, 67
Shi, Jiaxiao M., 108
Shilova, Victoria Y., 142
Shimada, Kazuyuki, 102, 110, 118,
132
Shimaoka, Izumi, 121
Shimizu, Motohiro, 110
Shin, Hwashin H., 129
Shin, Sung‑Hee, 118, 120
Shi, Victor, 101
Shlyakhto, Evgeny V., 87
Shojaee, Ali, 96, 115, 138
Shoval, Ishay, 123
Shrabi, Yonatan, 124
Shull, Cyndi, 141
Shustov, Sergey B., 139
Sica, D., 115
Sica, Domenic, 67, 78, 112
Sica, Domenic A., 40, 67, 70, 152
Siciliano, Alessandro, 123
Silva, Jose A., 96, 137
Silverman, Angela, 90
Sim, John, 67
Sim, John J., 108
Simmons, Debra, 61, 89
Simonyi, Gabor, 134
Simpson, William G., 137
Sinaiko, Alan R., 106
Sindel, Sukru, 97
Sineiro, Elvira, 99, 121
Sion‑Vrdy, Netta, 103
Sirenko, Yuriy M., 133
Siu, Kin Lung, 122
Skoumas, I., 135
Skrypnyk, Nadiya V., 119
Slama, Gerard, 99
Smith, Albert V., 79
Smith, Jr., Sidney, 81
Smith, Rick, 88
Smith, Ronald D., 89
Smith, Steven M., 115
Smith, William, 139
Smyrnioudis, Nikolaos E., 119
Soboleva, Galina M., 108
Sodhi, Komal, 66
Sohn, Il‑Suk, 111, 116
Solari, D., 130
Solar‑Yohay, Susan, 101
Soldatos, N., 96
Sole, Ricardo M. Cabrera, 88, 109,
129
Soriano, Joaquin Rueda, 116
Sorrentino, Matthew, 40, 152
Sos, Thomas A., 56, 152
Sousa, Alexandra, 135
Sowers, James R., 74, 153
SperlHillen, JoAnn M., 89
Sridharan, Kanaka, 113, 114
Srikakarlapudi, Sirisha, 111, 128
Srinivasan, Sathanur R., 94
Staffileno, Beth A., 138
Stagni, Barbara, 95
Stallmann-Jorgensen, Inger, 47
Stasiv, Yuri, 107
Stauffer, Brian L., 92
Stefanadi, E., 66
Stefanadis, C., 61, 66, 91, 92, 94, 96,
102, 122, 124, 126, 128, 135
Steigerwalt, Susan, 90, 115
Stergiou, George S., 105, 106, 134
Sterling, Kevin A., 127
Stern, Naftali, 100
Steven, Bendel D., 109
Stevens, Lesley A., 68, 153
Strano, Talita R., 87
Strimike, Carolyn, 140
Struthers, Allan D., 66, 153
Sturgeon, Kathleen M., 136, 138, 144
Stylianou, Mario, 90
Suárez, Carmen, 133
Suleymanlar, Gultekin, 121
Sun, B., 97
Sun, Fengzhu, 117
Svetkey, Laura P., 49, 153
Symonides, Bartosz, 138
Syros, George, 93
Syrseloudis, D., 92, 102, 124, 128
Szalai, Alexander J., 103
Szendro, Gabriel, 103
T
Tabassome, Simon, 92, 127
Taddei, Stefano, 91
Takahashi, Toru, 122
Takechi, Shigeru, 99
Takeya, Yasushi, 95, 121
Taler, Sandra J., 73, 153
Tamarit‑García, Juan José, 90
Tangney, Christy, 138
Tao, Jun, 128
Tao, Ting, 53, 153
Tasic, Ivan, 116, 120
Tatara, Yuji, 95, 121
178
Author Index
Tatsis, I., 92, 124
Taylor, Addison A., 47, 64, 153
Taylor‑Zapata, Perdita, 101
Teixeira, Tiago, 134
Tejera, Eduardo, 138
Tello, Susana, 47, 91, 92, 98, 110
Terrone, Deborah, 140
Tewksbury, Duane A., 135
Thangaratnavel, Revathy, 127
Thies, Frank, 137
Thomopoulos, C., 92, 96, 122, 128
Thopy, Amanda, 106
Thrun, Jan‑Marc Schmidt, 133
Tiawana, Simrandeep K., 89
Tiktin, Margaret, 61
Tisler, Andras, 132
Titze, Jens, 77, 80, 153
Tobe, Sheldon W., 54, 136, 153
Tobin, Jonathan, 90
Tomiyama, Hirofumi, 130
Tong, Xin, 129
Tonne, Jason M., 116
Topouchian, Jirar, 128
Torrente‑Carballido, Marta, 120
Torro, Isabel, 101
Toto, Robert, 60, 121
Toto, Robert D., 74, 82, 122
Touyz, Rhian M., 43, 65, 153
Townsend, Raymond R., 46, 127,
139, 153
Tsapas, Apostolos, 99
Tsiachris, D., 92, 124, 128
Tsioufis, C., 66, 91, 92, 96, 102, 122,
124, 126, 128
Tsioufis, Costas, 96
Tsounis, Dimitrios, 100, 115
Turgan, Cetin, 97
Turk, Aquilla S., 102
Tutor, Elena, 91, 98
Tyszkiewicz, Jerzy T., 138
Tzamouranis, Dimitrios, 134
Tzamouranis, Dimitris, 105
Tziomalos, Konstantinos, 111
U
Uehara, Ritei, 117
Ugalde, Arturo, 98
Umans, Jason G., 90
Underwood, P., 97
Urbina, Elaine M., 106
Uribarri, Jaime, 128
Utas, Cengiz, 121
V
Vakalyuk, Igor P., 92, 116
Vakalyuk, Iryna I., 116, 119
Van Buren, Peter N., 121, 122
Vandervoort, Margaret K., 141
Vandervoort, M. K., 89
van Duijn, Cornelia M., 79
van Duin, Cornelia, 78
Vanella, Luca, 66, 122
VanGundy, Tiffany B., 142
van Pelt, Jos F., 135
Vansomphone, Southida S., 140
Varis, Juha, 114
Vasan, Ramachandran S., 117
Vasan, R. S., 96
Vaschilko, Alla S., 133
Vassalotti, Joseph A., 68, 153
Vecchione, Carmine, 134
Veerabhadrappa, Praveen, 136, 138,
144
Velhas, Moncho, 129
Venner-Jones, Kinda, 127
Veronesi, Maddalena, 93
Verri‑Junior, Waldiceu A., 143
Vette, Alan, 129
Victor, Ronald G., 40, 67, 153
Vigdorchik, Alexey V., 112
Vigil, Luis, 133
Vilches‑Moraga, Arturo, 120
Villafruela, Juanjo, 91
Villar, Van Anthony M., 122, 123
Vinereanu, Dragos, 143
Vinita, Srivastava, 102
Vittinghoff, Eric, 61
Vives, Miguel Angel Arnau, 116
Vongpatanasin, Wanpen, 59, 142
Vrentzos, George E., 100
Vyssoulis, Gregory, 61, 94, 135
W
Wagner, C., 110
Wagner, C. Shaun, 130, 134
Wang, Guijing, 137
Wang, Hongyu, 53, 153
Wang, Jackson, 94
Wang, Si‑Tien, 133
Wang, Zhijun, 59
Ward, Rachel, 124
Watkins, Shannon B., 144
Waverczak, William F., 96, 115, 138
Webb, David J., 65, 153
Webb, D. J., 97, 121
Webb, R. Clinton, 43, 153
Weber, M. A., 115
Weber, Michael, 78
Weber, Michael A., 40, 112, 153
Weder, Alan B., 42, 73, 141, 154
Weil, Brian R., 92
Weinberger, Myron H., 47, 154
Weir, Matthew R., 74, 90, 96, 115,
154
Wei, Robert, 133
Weitzman, Richard, 98, 113, 114
Welch, Robert, 141
Welch, W. Pete, 101
Wells, Ann M., 90
Wever‑Pinzon, Omar, 107
Whalen, J. J., 113
Whaley‑Connell, Adam, 68, 154
Whelton, Andrew, 66, 100, 154
White, W. B., 65, 115
White, William B., 56, 58, 63, 75, 78,
109, 112, 136, 154
Wilbur, JoEllen, 138
Wilcox, C., 91
Wilkinson, Ian B., 46, 95, 128, 154
Williams, Bryan, 56, 61, 74, 154
Williams, Eric, 141
Williams, G., 97
Williams, Gordon H., 40, 154
Williams, J., 97
Williams‑Johnson, Jean, 141
Williamson, Sheara, 136
Williamson, Sheara M., 144
179
Author Index
Williamson, Sheara T., 138
Williams, Ron, 129
Wilson, Peter F., 154
Wilson, Peter W. F., 44, 96
Winborne, Courtland, 124
Winkler, Amber, 141
Wohlgemuth, William K., 131
Wolak, Talya, 103
Wolf, Philip A., 96
Wong, Cindy J., 141
Wong, C. J., 89
Wong, Nathan D., 44, 154
Wood, Adrian D., 137
Wright, Richard F., 109
Wymer, David, 100
X
Xavier, Ana C., 100
Xing, Dongqi, 103, 118, 126, 144
Y
Yadao, Anthony, 139
Yakovlev, Sergey A., 108
Yamamoto‑Hanasaki, Hiroko, 121
Yamashina, Akira, 130
Yang, Qiong, 117
Yang, Wenya, 101
Yang, Yu, 47, 123
Yang, Zhen, 128
Yano, Yuichiro, 96, 102, 118
Yan, Shi Du, 135
Yatsyshyn, Natalya G., 97
Yatsyshyn, Roman I., 97
Yokota, Naoto, 114
Yoon, Esther, 87
Yoo, Sandra A., 90
Young, Joseph D., 61
Youn, Ho‑Joong, 88
Younis, Firas, 100
Yuan, Hong, 112
Yu‑Isenberg, Kristina, 110
Z
Zacker, Christopher, 141
Zager, Philip, 115
Zajicek, Anne, 101
Zamadio, Stacy, 142
Zand, Martin S., 60, 154
Zazulina, Antonina Y., 112
Zeniodi, Maria‑Helen, 100
Zhang, J., 140
Zhang, Jack, 112, 139
Zhang, Jie, 141
Zhang, Shiling, 107
Zhang, Wei, 103, 118
Zhang, Yanrong, 47, 97
Zhang, Yi, 112, 126, 128
Zhang, Ying, 101
Zhao, Yumin, 105, 130
Zhong, Wei, 144
Zhu, Haidong, 47
Zoppi, Annalisa, 87, 88
Zou, Guang Y., 141
Zou, G. Y., 89
180
Second Floor
Hilton New York Floor Plans
181
Thrid Floor
182
Fourth Floor
Concourse
183
Notes
184
Tekamlo (aliskiren and amlodipine) tablets
Initial U.S. Approval: 2010
BRIEF SUMMARY: Please see package insert for full prescribing information.
WARNING: AVOID USE IN PREGNANCY
When pregnancy is detected, discontinue Tekamlo as soon as possible. Drugs
that act directly on the renin-angiotensin-aldosterone system can cause injury
and even death to the developing fetus. [See Warnings and Precautions (5.1)
and Use in Specific Populations (8.1)].
1 INDICATIONS AND USAGE
Tekamlo is indicated for the treatment of hypertension, alone or with other antihypertensive agents.
Initial Therapy
Use Tekamlo as initial therapy in patients who are likely to need multiple drugs
to achieve their blood pressure goals.
Base the choice of Tekamlo as initial therapy on an assessment of potential benefits and risks.
Add-On Therapy
Switch a patient whose blood pressure is not adequately controlled with aliskiren
alone or amlodipine besylate (or another dihydropyridine calcium channel
blocker) to combination therapy with Tekamlo.
Replacement Therapy
Tekamlo may be substituted for its titrated components.
Patients with moderate or severe hypertension are at a relatively high risk for
cardiovascular events (such as strokes, heart attacks, and heart failure), kidney
failure, and vision problems, so prompt treatment is clinically relevant. Individualize the decision to use a combination as initial therapy by weighing factors
such as baseline blood pressure, the target goal, and the incremental likelihood
of achieving goal with a combination compared to monotherapy. Individual
blood pressure goals may vary based upon the patient’s risk.
Data from the high-dose multifactorial study [see Clinical Studies (14) in the full
prescribing information] provide estimates of the probability of reaching a target
blood pressure with Tekamlo compared to aliskiren or amlodipine monotherapy.
The figures below provide estimates of the likelihood of achieving systolic or
diastolic blood pressure control with Tekamlo 300 mg/10 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was
estimated by logistic regression modeling. The estimated likelihood at the right
tail of each curve is less reliable because of a small number of subjects with
high baseline blood pressures.
Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) <140 mmHg
Figure 2: Probability of Achieving Diastolic Blood Pressure (DBP) <90 mmHg
Figure 3: Probability of Achieving Systolic Blood Pressure (SBP) <130 mmHg
Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) <80 mmHg
The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal (e.g. SBP <140 mmHg or <130 mmHg) for the high
dose groups evaluated in the study. At all levels of baseline blood pressure, the
probability of achieving any given diastolic or systolic goal is greater with the
combination than for either monotherapy. For example, the mean baseline SBP/DBP
for patients participating in this multifactorial study was 157/100 mmHg. A
patient with a baseline blood pressure of 157/100 mmHg has about a 49% likelihood of achieving a goal of <140 mmHg (systolic) and 50% likelihood of achieving <90 mmHg (diastolic) on aliskiren alone, and the likelihood of achieving
these goals on amlodipine alone is about 62% (systolic) and 69% (diastolic).
The likelihood of achieving these goals on Tekamlo rises to about 74% (systolic)
and 83% (diastolic). The likelihood of achieving these goals on placebo is about
25% (systolic) and 27% (diastolic) [see Dosage and Administration (2) and
Clinical Studies (14) in the full prescribing information].
4 CONTRAINDICATIONS
None.
5 WARNINGS AND PRECAUTIONS
5.1 Fetal/Neonatal Morbidity and Mortality
The use of drugs that act directly on the renin-angiotensin-aldosterone system
during pregnancy can cause fetal and neonatal morbidity and death. No animal
studies were conducted with Tekamlo; however, decreased fetal birth weight was
observed in animal studies with aliskiren and intrauterine deaths were observed
in animal studies with amlodipine. Tekamlo can cause fetal harm when administered to a pregnant woman. When pregnancy is detected, discontinue Tekamlo as
soon as possible. If Tekamlo is used during pregnancy, or if a patient becomes
pregnant while taking this drug, apprise the patient of the potential hazard to the
fetus [see Use in Specific Populations (8.1)].
5.2 Head and Neck Angioedema
Aliskiren
Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been
reported in patients treated with aliskiren and has necessitated hospitalization
and intubation. This may occur at any time during treatment and has occurred
in patients with and without a history of angioedema with ACE inhibitors or
angiotensin receptor antagonists. If angioedema involves the throat, tongue,
glottis or larynx, or if the patient has a history of upper respiratory surgery, airway obstruction may occur and be fatal. Patients who experience these effects,
even without respiratory distress, require prolonged observation, since treatment with antihistamines and corticosteroids may not be sufficient to prevent
respiratory involvement. Prompt administration of subcutaneous epinephrine
solution 1:1000 (0.3 to 0.5 ml) and measures to ensure a patent airway may be
necessary.
Discontinue Tekamlo immediately in patients who develop angioedema and do
not readminister.
5.3 Hypotension
An excessive fall in blood pressure (hypotension) was rarely seen (0.2%) in
patients with uncomplicated hypertension treated with Tekamlo in controlled
trials.
In patients with an activated renin-angiotensin-aldosterone system, such as volumeand/or salt-depleted patients receiving high doses of diuretics, symptomatic
hypotension may occur in patients receiving renin-angiotensin-aldosterone
system (RAAS) blockers. Correct these conditions prior to administration of
Tekamlo, or start the treatment under close medical supervision.
If an excessive fall in blood pressure occurs with Tekamlo, place the patient in
the supine position and, if necessary, give an intravenous infusion of normal
saline. A transient hypotensive response is not a contraindication to further
treatment, which usually can be continued without difficulty once the blood
pressure has stabilized.
5.4 Risk of Myocardial Infarction or Increased Angina
Rarely, initiation or change to the dose of a calcium channel blocker has resulted
in the development of documented increased frequency, duration or severity
of angina or acute myocardial infarction, particularly in patients with severe
obstructive coronary artery disease. The mechanism of this effect has not been
elucidated.
5.5 Impaired Renal Function
Tekamlo
Clinical trials with Tekamlo in hypertension excluded patients with severe renal
impairment.
Aliskiren
Clinical trials of aliskiren in hypertension excluded patients with severe renal
dysfunction (creatinine 1.7 mg/dL for women and 2.0 mg/dL for men and/or
estimated GFR <30 ml/min), a history of dialysis, nephrotic syndrome, or renovascular hypertension. Consider periodic determinations of serum electrolytes to
detect possible electrolyte imbalances.
5.6 Patients with Hepatic Impairment
Amlodipine besylate
Amlodipine is extensively metabolized by the liver and the plasma elimination
half-life is 56 hours in patients with impaired hepatic function, therefore, caution
should be exercised when administering Tekamlo to patients with severe hepatic
impairment.
5.7 Patients with Congestive Heart Failure
Amlodipine besylate
Amlodipine (5-10 mg per day) has been studied in a placebo-controlled trial of
1153 patients with NYHA Class III or IV heart failure on stable doses of ACE
inhibitor, digoxin, and diuretics. Follow-up was at least 6 months, with a mean of
about 14 months. There was no overall adverse effect on survival or cardiac
morbidity (as defined by life-threatening arrhythmia, acute myocardial infarction,
or hospitalization for worsened heart failure). Amlodipine has been compared to
placebo in four 8-12 week studies of patients with NYHA Class II/III heart failure,
involving a total of 697 patients. In these studies, there was no evidence of
worsened heart failure based on measures of exercise tolerance, NYHA classification, symptoms, or left ventricular ejection fraction.
5.8 Renal Artery Stenosis
No data are available on the use of Tekamlo or aliskiren in patients with unilateral
or bilateral renal artery stenosis or stenosis of the artery to a solitary kidney.
However, in studies of ACE inhibitors in hypertensive patients with unilateral or
bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen have been reported.
5.9 Cyclosporine or Itraconazole
Aliskiren
When aliskiren was given with cyclosporine or itraconazole, the blood concentrations of aliskiren were significantly increased. Avoid concomitant use of
aliskiren with cyclosporine or itraconazole [see Drug Interactions (7)].
6 ADVERSE REACTIONS
6.1 Clinical Studies Experience
The following serious adverse reactions are discussed in greater detail in other
sections of the label:
• Risk of fetal/neonatal morbidity and mortality [see Warnings and Precautions
(5.1)]
• Head and neck angioedema [see Warnings and Precautions (5.2)]
• Hypotension [see Warnings and Precautions (5.3)]
Because clinical trials are conducted under widely varying conditions, adverse
reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates
observed in practice.
Tekamlo
Tekamlo has been evaluated for safety in more than 2800 patients, including 372
patients for 1 year or longer.
In a placebo-controlled study, there were 51% males, 62% Caucasians, 20%
Blacks, 18% Hispanics, and 17% who were over 65 years of age. In this study,
the overall incidence of adverse events on therapy with Tekamlo was similar to
the individual components. Discontinuation of therapy due to a clinical adverse
event in this study occurred in 1.7% of patients treated with Tekamlo (2.2% in
the highest dose group) versus 1.5% of patients given placebo.
Peripheral edema is a known, dose-dependent adverse effect of amlodipine. The
incidence of peripheral edema for Tekamlo in short-term double-blind placebocontrolled studies was lower than or equal to that of the corresponding amlodipine
doses.
The adverse event in a placebo-controlled trial that occurred in at least 2% of
patients treated with Tekamlo and at a higher incidence than placebo was peripheral edema (6.2% versus 1.0%). The incidence rate of peripheral edema at high
dose was 8.9%.
In a long-term safety trial, the safety profile of adverse events was similar to that
seen in the short-term controlled trials.
Aliskiren
Aliskiren has been evaluated for safety in 6460 patients, including 1740 treated
for longer than 6 months, and 1250 for longer than 1 year. In placebo-controlled
clinical trials, discontinuation of therapy because of a clinical adverse event,
including uncontrolled hypertension, occurred in 2.2% of patients treated with
aliskiren versus 3.5% of patients given placebo.
Two cases of angioedema with respiratory symptoms were reported with
aliskiren use in the clinical studies. Two other cases of periorbital edema without
respiratory symptoms were reported as possible angioedema and resulted in
discontinuation. The rate of these angioedema cases in the completed studies
was 0.06%.
In addition, 26 other cases of edema involving the face, hands, or whole body
were reported with aliskiren use, including 4 leading to discontinuation.
In the placebo-controlled studies, however, the incidence of edema involving the
face, hands, or whole body was 0.4% with aliskiren compared with 0.5% with
placebo. In a long-term active-controlled study with aliskiren and HCTZ arms,
the incidence of edema involving the face, hands, or whole body was 0.4% in
both treatment arms.
Aliskiren produces dose-related gastrointestinal (GI) adverse reactions. Diarrhea
was reported by 2.3% of patients at 300 mg, compared to 1.2% in placebo
patients. In women and the elderly (age ≥65) increases in diarrhea rates were
evident starting at a dose of 150 mg daily, with rates for these subgroups at
150 mg similar to those seen at 300 mg for men or younger patients (all rates
about 2%). Other GI symptoms included abdominal pain, dyspepsia, and gastroesophageal reflux, although increased rates for abdominal pain and dyspepsia
were distinguished from placebo only at 600 mg daily. Diarrhea and other
GI symptoms were typically mild and rarely led to discontinuation.
Aliskiren was associated with a slight increase in cough in the placebo-controlled
studies (1.1% for any aliskiren use versus 0.6% for placebo). In active-controlled
trials with ACE inhibitor (ramipril, lisinopril) arms, the rates of cough for the
aliskiren arms were about one-third to one-half the rates in the ACE inhibitor arms.
Other adverse reactions with increased rates for aliskiren compared to placebo
included rash (1% versus 0.3%), elevated uric acid (0.4% versus 0.1%), gout
(0.2% versus 0.1%), and renal stones (0.2% versus 0%).
Single episodes of tonic-clonic seizures with loss of consciousness were
reported in two patients treated with aliskiren in the clinical trials. One patient
had predisposing causes for seizures and had a negative electroencephalogram
(EEG) and cerebral imaging following the seizures; for the other patient, EEG and
imaging results were not reported. Aliskiren was discontinued and there was no
rechallenge in either case.
No clinically meaningful changes in vital signs or in ECG (including QTc interval)
were observed in patients treated with aliskiren.
Amlodipine besylate
Amlodipine (Norvasc®) has been evaluated for safety in more than 11,000
patients in U.S. and foreign clinical trials. Other adverse events that have been
reported <1% but >0.1% of patients in controlled clinical trials or under conditions of open trials or marketing experience where a causal relationship is
uncertain were:
Cardiovascular: arrhythmia (including ventricular tachycardia and atrial fibrillation), bradycardia, chest pain, peripheral ischemia, syncope, postural hypotension, vasculitis
Central and Peripheral Nervous System: neuropathy peripheral, paresthesia,
tremor, vertigo
Gastrointestinal: anorexia, constipation, dyspepsia,** dysphagia, diarrhea, flatulence, pancreatitis, vomiting, gingival hyperplasia
General: allergic reaction, asthenia,** back pain, hot flushes, malaise, pain, rigors, weight gain, weight decrease
Musculoskeletal System: arthralgia, arthrosis, muscle cramps,** myalgia
Psychiatric: sexual dysfunction (male** and female), insomnia, nervousness,
depression, abnormal dreams, anxiety, depersonalization
Respiratory System: dyspnea, epistaxis
Skin and Appendages: angioedema, erythema multiforme, pruritus,** rash,**
rash erythematous, rash maculopapular
**These events occurred in less than 1% in placebo-controlled trials, but the
incidence of these side effects was between 1% and 2% in all multiple dose studies.
Special Senses: abnormal vision, conjunctivitis, diplopia, eye pain, tinnitus
Urinary System: micturition frequency, micturition disorder, nocturia
Autonomic Nervous System: dry mouth, sweating increased
Metabolic and Nutritional: hyperglycemia, thirst
Hemopoietic: leukopenia, purpura, thrombocytopenia
Other events reported with amlodipine at a frequency of ≤0.1% of patients
include: cardiac failure, pulse irregularity, extrasystoles, skin discoloration,
urticaria, skin dryness, alopecia, dermatitis, muscle weakness, twitching, ataxia,
hypertonia, migraine, cold and clammy skin, apathy, agitation, amnesia, gastritis, increased appetite, loose stools, rhinitis, dysuria, polyuria, parosmia, taste
perversion, abnormal visual accommodation, and xerophthalmia. Other reactions
occurred sporadically and cannot be distinguished from medications or concurrent disease states such as myocardial infarction and angina.
6.2 Clinical Laboratory Test Abnormalities
RBC count, hemoglobin and hematocrit: Small mean changes from baseline
were seen in RBC count, hemoglobin and hematocrit in patients treated with
both Tekamlo and aliskiren monotherapy. This effect is also seen with other
agents acting on the renin angiotensin system. In aliskiren monotherapy trials
these decreases led to slight increases in rates of anemia compared to placebo
(0.1% for any aliskiren use, 0.3% for aliskiren 600 mg daily, vs. 0% for
placebo). No patients discontinued due to anemia.
Blood Urea Nitrogen (BUN)/Creatinine: Elevations in BUN (>40 mg/dL) and creatinine (>2.0 mg/dL) in patients treated with Tekamlo were <1.0%.
Serum Potassium: Increases in serum potassium >5.5 mEq/L were infrequent in
patients with essential hypertension treated with both Tekamlo and aliskiren
monotherapy (0.9% compared to 0.6% with placebo). However, when aliskiren
was used in combination with an angiotensin-converting enzyme inhibitor (ACEI)
in a diabetic population, increases in serum potassium were more frequent
(5.5%). Monitor electrolytes and renal function in this population.
6.3 Post-marketing Experience
The following adverse reactions have been identified during postapproval use of
either aliskiren or amlodipine. Because these reactions are reported voluntarily
from a population of uncertain size, it is not always possible to estimate their
frequency or establish a causal relationship to drug exposure:
Hypersensitivity: angioedema requiring airway management and hospitalization
Aliskiren: Peripheral edema, blood creatinine increased
Amlodipine: The following postmarketing event has been reported infrequently
where a causal relationship is uncertain: gynecomastia. In postmarketing experience, jaundice and hepatic enzyme elevations (mostly consistent with cholestasis or hepatitis), in some cases severe enough to require hospitalization, have
been reported in association with use of amlodipine.
7 DRUG INTERACTIONS
No drug interaction studies have been conducted with Tekamlo and other drugs,
although studies with the individual aliskiren and amlodipine besylate components are described below.
Aliskiren
Cyclosporine: Avoid co-administration of cyclosporine with aliskiren.
Itraconazole: Avoid co-administration of itraconazole with aliskiren.
[See Clinical Pharmacology (12.3) in the full prescribing information.]
Amlodipine besylate
In clinical trials, amlodipine has been safely administered with thiazide diuretics,
beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates,
sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory
drugs, antibiotics, and oral hypoglycemic drugs.
Cimetidine: Co-administration of amlodipine with cimetidine did not alter the
pharmacokinetics of amlodipine.
Grapefruit juice: Co-administration of 240 mL of grapefruit juice with a single
oral dose of amlodipine 10 mg in 20 healthy volunteers had no significant effect
on the pharmacokinetics of amlodipine.
Maalox® (antacid): Co-administration of the antacid Maalox with a single dose of
amlodipine had no significant effect on the pharmacokinetics of amlodipine.
Sildenafil: A single 100 mg dose of sildenafil in subjects with essential hypertension had no effect on the pharmacokinetic parameters of amlodipine. When
amlodipine and sildenafil were used in combination, each agent independently
exerted its own blood pressure lowering effect.
Atorvastatin: Co-administration of multiple 10 mg doses of amlodipine with 80 mg
of atorvastatin resulted in no significant change in the steady-state pharmacokinetic parameters of atorvastatin.
Digoxin: Co-administration of amlodipine with digoxin did not change serum
digoxin levels or digoxin renal clearance in normal volunteers.
Ethanol (alcohol): Single and multiple 10 mg doses of amlodipine had no significant effect on the pharmacokinetics of ethanol.
Warfarin: Co-administration of amlodipine with warfarin did not change the
warfarin prothrombin response time.
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Pregnancy Category D [See Warnings and Precautions Section]
The use of drugs that act directly on the renin-angiotensin-aldosterone system
during the second and third trimesters of pregnancy can cause fetal and neonatal morbidity and death. In addition, first trimester use of ACE inhibitors has
been associated with birth defects in retrospective data. No animal studies were
conducted with Tekamlo; however, decreased fetal birth weight was observed in
animal studies with aliskiren and intrauterine deaths were observed in animal
studies with amlodipine. Tekamlo can cause fetal harm when administered to a
pregnant woman. When pregnancy is detected, discontinue Tekamlo as soon as
possible. If Tekamlo is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
Human Data and Clinical Considerations
Maternal hypertension is associated with increased risks for preterm delivery,
intrauterine growth restriction, placental abruption, preeclampsia, and perinatal
mortality. Appropriate management of maternal hypertension during pregnancy
is important to optimize outcomes for both mother and fetus. Renin inhibitors
(like aliskiren), angiotensin II receptor antagonists and angiotensin converting
enzyme (ACE) inhibitors exert similar effects on the renin-angiotensin-aldosterone
system. Based on several dozen published cases, ACE inhibitor use during the
second and third trimesters of pregnancy is associated with fetal and neonatal
injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or
irreversible renal failure, and death. Decreased fetal renal function may result in
oligohydramnios and associated with fetal limb contractures, craniofacial deformation, and hypoplastic lung development. Prematurity, intrauterine growth
retardation, and patent ductus arteriosus have been reported in women using
these drugs, but it is not clear whether these occurrences were due to drug
exposure. Limited data are conflicting about whether first trimester use of ACE
inhibitors is associated with an increased risk of birth defects, but the drugs’
mechanism of action raises a theoretical concern.
When pregnancy occurs in a patient using Tekamlo, the physician should discontinue Tekamlo treatment as soon as possible. Inform the patient about potential risks to the fetus based on the time of gestational exposure to Tekamlo (first
trimester only or later). If exposure occurs beyond the first trimester, perform an
ultrasound examination.
In rare cases when another antihypertensive agent cannot be used to treat the
pregnant patient, serial ultrasound examinations should be used to assess the
intraamniotic environment. Routine fetal testing with non-stress tests, biophysical profiles, and/or contraction stress tests may be appropriate based on gestational age and standards of care in the community. If oligohydramnios occurs in
these situations, individualized decisions about continuing or discontinuing
Tekamlo treatment and about pregnancy management should be made by the
patient and her physicians. Patients and physicians should be aware that oligohydramnios may not appear until after the fetus has sustained irreversible injury.
Infants exposed to Tekamlo in-utero should be closely observed for hypotension,
oliguria, and hyperkalemia. If oliguria occurs, these infants may require blood
pressure and renal perfusion support. Exchange transfusion or dialysis may be
required to reverse hypotension and/or support decreased renal function.
Animal Data
No reproductive toxicity studies have been conducted with the combination of
aliskiren and amlodipine besylate. However, these studies have been conducted for aliskiren and amlodipine besylate alone.
Aliskiren
In developmental toxicity studies, pregnant rats and rabbits received oral
aliskiren hemifumarate during organogenesis at doses up to 20 and 7 times
the maximum recommended human dose (MRHD) based on body surface
area (mg/m2), respectively, in rats and rabbits. (Actual animal doses were up
to 600 mg/kg/day in rats and up to 100 mg/kg/day in rabbits.) No teratogenicity was observed; however, fetal birth weight was decreased in rabbits at
doses 3.2 times the MRHD based on body surface area (mg/m2). Aliskiren
was present in placentas, amniotic fluid and fetuses of pregnant rabbits.
Amlodipine
In developmental toxicity studies, pregnant rats and rabbits received oral
amlodipine maleate during organogenesis at doses approximately 10 and 20
times the maximum recommended human dose (MRHD) based on body surface area (mg/m2), respectively, in rats and rabbits. (Actual animal doses
were up to 10 mg/kg/day.) No evidence of teratogenicity or other embryofetal
toxicity was observed. However, litter size was decreased approximately 50%
and the number of intrauterine deaths was increased approximately 5-fold for
rats receiving amlodipine maleate at doses approximately 10 times the MRHD
based on body surface area (mg/m2) for 14 days before mating and throughout mating and gestation. Amlodipine maleate has been shown to prolong
both the gestation period and the duration of labor in rats at this dose.
8.3 Nursing Mothers
It is not known whether aliskiren or amlodipine is excreted in human milk.
Both aliskiren and amlodipine are secreted in the milk of lactating rats.
Because of the potential for serious adverse reactions in human milk-fed
infants from Tekamlo, a decision should be made whether to discontinue
nursing or discontinue Tekamlo, taking into account the importance of the
drug to the mother.
8.4 Pediatric Use
Safety and effectiveness of Tekamlo in pediatric patients have not been
established.
8.5 Geriatric Use
Tekamlo
In the short-term controlled clinical trials of Tekamlo, 17% of patients treated
with Tekamlo were ≥65 years. No overall differences in safety or effectiveness
were observed between these subjects and younger subjects. Other reported
clinical experience has not identified differences in responses between the
elderly and younger patients, but greater sensitivity of some older individuals
cannot be ruled out.
Aliskiren
Impact of aging on aliskiren pharmacokinetics has been assessed, when
compared to young adults (18-40 years), aliskiren mean AUC and Cmax in
elderly subjects (>65 years) are increased by 57% and 28%, respectively.
However, differences in efficacy and safety between the elderly and younger
populations were minor, indicating that differences in exposure due to age do
not significantly alter the clinical effect of the drug. Therefore, no starting
dose adjustment in geriatric population is required.
Amlodipine
Other reported clinical experience has not identified differences in responses
between the elderly and younger patients. However, elderly patients have
decreased clearance of amlodipine with a resulting increase of AUC of approximately 40-60%. In general dose selection for an elderly patient should be
cautious, usually starting at the low end of the dosing range, reflecting the
greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.
10 OVERDOSAGE
Aliskiren
Limited data are available related to overdosage in humans. The most likely
manifestation of overdosage would be hypotension. If symptomatic hypotension should occur, provide supportive treatment.
Amlodipine besylate
Single oral doses of amlodipine maleate equivalent to 40 mg amlodipine/kg
and 100 mg amlodipine/kg in mice and rats, respectively, caused deaths. Single oral amlodipine maleate doses equivalent to 4 or more mg amlodipine/kg
or higher in dogs (11 or more times the maximum recommended human
dose on a mg/m2 basis) caused a marked peripheral vasodilation and
hypotension.
Overdosage might be expected to cause excessive peripheral vasodilation
with marked hypotension and possibly a reflex tachycardia. In humans,
experience with intentional overdosage of amlodipine is limited. Reports of
intentional overdosage include a patient who ingested 250 mg and was
asymptomatic and was not hospitalized; another (120 mg) was hospitalized,
underwent gastric lavage and remained normotensive; the third (105 mg) was
hospitalized and had hypotension (90/50 mmHg) which normalized following
plasma expansion. A case of accidental drug overdose has been documented
in a 19-month-old male who ingested 30 mg amlodipine (about 2 mg/kg).
During the emergency room presentation, vital signs were stable with no evidence of hypotension, but a heart rate of 180 bpm. Ipecac was administered
3.5 hours after ingestion and on subsequent observation (overnight) no
sequelae were noted.
If massive overdose should occur, active cardiac and respiratory monitoring
should be instituted. Frequent blood pressure measurements are essential.
Should hypotension occur, cardiovascular support including elevation of the
extremities and the judicious administration of fluids should be initiated. If
hypotension remains unresponsive to these conservative measures, administration of vasopressors (such as phenylephrine) should be considered with
attention to circulating volume and urine output. Intravenous calcium gluconate may help to reverse the effects of calcium entry blockade. As amlodipine
is highly protein bound, hemodialysis is not likely to be of benefit.
Distributed by:
T2011-52
March 2011
©Novartis
Get to know TEKAMLO
at booth 1100
Ask our sales representative how to
obtain professional samples.*
150/5 mg
300/5 mg
300/10 mg
150/10 mg dose not shown.
*Samples are not available at booth 1100.
Please see brief summary of Prescribing Information,
including Boxed WARNING, on adjacent pages.
Tekamlo
™
(aliskiren and amlodipine)tablets
150/5mg • 150/10mg • 300/5mg • 300/10mg
East Hanover, New Jersey 07936-1080
© 2011 Novartis
Printed in USA
4/11
TKT-1053803

Program Book - American Society of Hypertension

Transcription

Similar documents

Hypertension

Medication Trouble Shooting in General Practice

PALACE MERANO ESPACE HENRI CHENOT

Postnatal recovery from pre-eclampsia - Action on Pre

COZAAR XQ Medical Slide Set: Disease

Journal of the Allentown Hospital - LVHN Scholarly Works

PHEOCHROMOCYTOMA DURING CHILDHOOD – A CASE REPORT

14th Annual Update in Pulmonary Hypertension

FEATURE - Philippine Heart Association